INDEX TO VOLUME XLI

Page numbers preceded by "(P)" refer to the summaries of symposia and papers at the meetings of the British Thoracic Society. "(E)" refers to editorials.

A

Abdominal and ribcage motion during external negative pressure ventilation using cuirass respirators (P), 710
binders, effect on breathing in tetraplegia (P), 244; 940
wall compliance, measurement in normal and tetraplegic subjects, 513
Abscess, pulmonary, in cystic fibrosis, case of, 221
Acetylcholine, bronchial responsiveness in asthma to, effects of thromboxane synthetase inhibitor (OKY-046) and lipoxygenase inhibitor (AA-861), 955
Acid test for gastro-oesophageal reflux in childhood asthma *(Letter)*, 160
ADAMS PC. *See* GILMARTIN JJ, VEALE D, *et al*
——. *See* KELLY CA, CORRIS PA, *et al*
ADDIS B. *See* MORGAN JM, MORGAN AD, *et al*
ADDISON J. *See* SEATON A, RUCKLEY VA, *et al*
ADEBO OA. *See* OSINOWO O, ADEBO OA, *et al*
Adenoidal tissue as aid to diagnosis of sarcoidosis in childhood, 2 cases, 66
Adenosine deaminase activity in tuberculous pericarditis, 888
monophosphate and allergen, bronchoconstriction induced by, inhibitory effect of terfenadine (P), 734
Adrenaline, circulating, concentrations during exercise in normal subjects and in exercise induced asthma (P), 718
α-Adrenoceptor agonists. *See* Alpha adrenoceptor agonists
Adrenoceptors, lymphocyte, and modulation by theophylline (P), 249
Aerosol challenge, increased tracheal permeability in sensitised rats after (P), 736
particle size, effect on bronchodilatation with nebulised terbutaline in asthma, 364
Aerosols, bronchodilator, particle size of, effect on lung distribution and pulmonary function (P), 721
nebulised, distribution of (P), 248
AFFORD SA. *See* CURRIE DC, AFFORD SA, *et al*
AFFORD SC. *See* BURNETT D, REYNOLDS JJ, *et al*
AGIUS RM, DAVISON AG, NEWMAN-TAYLOR AJ: Occupational asthma caused by salbutamol (P), 250
——, GODFREY RC, NEVILLE E, HERBERT A, BUCHANAN R, INMAN C, HOLGATE ST: Mast cells of bronchoalveolar lavage fluid in interstitial lung disease: comparison with transbronchial biopsy sections and ultrastructural appearance (P), 232
AGNEW JE, LOPEZ-VIDRIERO MT, PAVIA D, CLARKE SW: Functional small airways defence in symptomless cigarette smokers, 524
——. *See also* CURRIE DC, PAVIA D, *et al*
——. *See also* GEORGE RJD, PAVIA D, *et al*
——. *See also* GREENSTONE MA, CURRIE DC, *et al*
——. *See also* MILLAR AB, AGNEW JE, *et al*
——. *See also* PAVIA D, AGNEW JE, *et al*
——. *See also* PAVIA D, BATEMAN JRM, *et al*
——. *See also* SPITERI MA, PAVIA D, *et al*
——. *See also* TAYLOR RG, AGNEW JE, *et al*
——. *See also* TAYLOR RG, PAVIA D, *et al*
AGOSTI J. *See* LEKUONA I, CABRERA A, *et al*
AGUSTI-VIDAL A. *See* BALLESTER E, ROCA J, *et al*
AHMAD F. *See* MCLEOD DT, CROUGHAN MJ, *et al*
AHMEDZAI S. *See* DORWARD AJ, BANHAM SW, *et al*
AIDS, differentiation of pulmonary infection and Kaposi's sarcoma by fibreoptic bronchoscopy in (P), 715
pneumonia related to, comparison of clinical and bronchoscopic diagnosis in (P), 228
pulmonary complications of, review of 90 English cases (P), 730
pulmonary infection in, diagnosis of, value of bronchoalveolar lavage in, 345
Air disaster, Manchester, pulmonary complications associated with (P), 234
Airflow limitation, chronic, or fibrosing alveolitis, regional gas and tissue volume of lung in supine subjects with, computed tomography based estimates of, 932
limitation, chronic, treatment response in, value of serial peak expiratory flow measurements in assessment of, 606
limitation, effect on gas diffusion in lungs (P), 242
nasal, stimulant effect on ventilation during sleep (P), 243
obstruction, chronic, breathlessness in, short burst oxygen treatment for, 611
obstruction, chronic, bronchial reactivity following prednisolone in (P), 240
obstruction, chronic, corticosteroid trials in, placebo responses in (P), 723
obstruction, chronic, corticosteroids in, comparison of PEF and spirometric response to (P), 234
obstruction, chronic, effect of captopril on pulmonary haemodynamics and lung function in (P), 225
obstruction, chronic, hypoxaemic, effects of theophylline on cardiac rhythm in (P), 722
obstruction, chronic, in smokers, pathogenesis of, and detection of "early" lung disease (E), 81
obstruction, chronic, nebuliser or Nebuhaler for? (P), 722
obstruction, chronic, neuropathy in patients treated or not treated with almitrine (P), 224
obstruction, chronic, physiological emphysema and corticosteroid responsiveness in (P), 723
obstruction, chronic, severe, changes in FEV_1 and disturbances of cardiac rhythm in, nebuliser compared with Nebuhaler for (P), 722
obstruction, chronic, severe, long term almitrine treatment in, which patients benefit? (P), 224
obstruction, chronic, supplementary oxygen during exercise in, dose response study (P), 725
obstruction, chronic, surgery in, assessment of fitness for (P), 720
obstruction, chronic, with excessive tracheobronchial secretion, effect of manual percussion on tracheobronchial clearance in, 448
obstruction, hypercapnia during oxygen therapy in, reappraisal of (E), 897
obstruction in adults with cystic fibrosis, prednisolone in treatment of, 34
obstruction, spontaneous and induced, effect of volume history on maximal airflow in bronchial asthma during (P), 724
Airway, asthmatic, mechanism of action of phenylephrine and methoxamine in (P), 718
calibre and bronchial reactivity, drug induced changes interdependent? (P), 239
disease, obstructive. *See* Airflow obstruction
function in normal subjects, effect of infused VIP, 663
hyperreactivity in asthma, role of inflammation in (E), 657
in asthma, terfenadine as H_1 histamine receptor antagonist for (P), 247

obstruction. *See* Airflow obstruction
physiology, effect of fibreoptic bronchoscopy (P), 712
response to methacholine during exercise induced refractoriness in asthma, 667
response to salbutamol in wheezy infants, evidence for beta-adrenergic responsiveness (P), 240
responsiveness to leukotriene D_4, effect of verapamil *in vitro* and *in vivo*, 12
Airways, small, functional defence and mucociliary clearance in symptomless cigarette smokers, 524
AL-ALUSI FA: Pleural effusion in Iraq: a prospective study of 100 cases, 492
ALBAZZAZ MK, HARVEY JE: Influenza vaccination in asthmatic subjects (P), 239
Alcoholics, chronic, pulmonary dysfunction in, contribution of ethanol and cigarette smoking to, 197
ALI NJ. *See* HARRISON BDW, STOKES TC, *et al*
AL-KADHIMI A. *See* RASHID A, SENDI A, *et al*
ALLAN A, SETHIA B, TURNER MA: Recent experience of the treatment of aspergilloma with a surgical stapling device, 483
ALLEN J. *See* HADFIELD JW, ALLEN J
ALLEN MB, CHANDRASEKERA C, PROWSE K: Peripheral neuropathy with almitrine (P), 723
——, GROCCOT L, CHIPPING P, PROWSE K: Sleep and oxygen saturation in erythrocytosis (P), 711
——, PROWSE K: *Haemophilus* pneumonia in hospitalised patients (P), 731
——, PUGH E, WILSON RSE: Nebuliser or Nebuhaler for COAD? (P), 722
——, WARD AM, PERKS WH: $Alpha_1$ antitrypsin deficiency due to $M^{Malton}Z$ phenotype: case report and family study, 568
Allergen and adenosine monophosphate, bronchoconstriction induced by, inhibitory effect of terfenadine (P), 734
and exercise, bronchoconstriction in asthma induced by, effect of inhaled piriprost (U-60, 257), 746
nasal, effect of nedocromil sodium (P), 246
Allergic alveolitis, extrinsic, prevalence of, effect of cigarette smoking (P), 252
Allergy to locusts (*S gregaria* and *L migratoria*) (P), 251
Almitrine, neuropathy in COAD patients treated or not treated with (P), 224
oral, in chronic bronchitis, rest and exercise pulmonary haemodynamics and right ventricular ejection fraction after (P), 224
peripheral neuropathy with (P), 723
treatment, long term, in severe COAD, which patients benefit? 224
Alpha adrenoceptor agonists, circulating, influence on lung function in healthy subjects and patients with exercise induced asthma, 552
$Alpha_1$-antitrypsin. *See* α_1-Antitrypsin
ALSTRUP P. *See* SØRENSEN HR, LUND C, *et al*
AL-SUHALI A-R. *See* ORPHANIDOU D, HUGHES JMB, *et al*
Altitude, high, effect on pulmonary haemodynamics of yak, cattle, and cross breeds, 696
ALTON EW, JOHNSON M, TURNER-WARWICK M: Fibrosing alveolitis: treatment with cyclosporin (P), 715
——, KWAN S, TURNER-WARWICK M: Pulmonary involvement in scleroderma: comparison with cryptogenic fibrosing alveolitis (P), 714
Alveolar macrophages, function, alteration of, and pulmonary cellular defence after inhalation injury (P), 728
macrophages obtained by BAL in pulmonary sarcoidosis, density of HLA-DR antigen on (P), 231
macrophages, phenotypic analysis in normal subjects and in interstitial lung disease, 429
surface measurement, new technique for, and assessment of microscopic emphysema (P), 716
Alveolar-capillary permeability, changed, and serum angiotensin converting enzyme activity in sarcoidosis, relationship between, 629
Alveolitis, allergic, extrinsic, prevalence of, effect of cigarette smoking (P), 252
fibrosing, cryptogenic, cyclosporin treatment of (P), 715
fibrosing, cryptogenic, increased bronchoalveolar elastase burden in (P), 728
fibrosing, cryptogenic, pulmonary involvement in, comparison with scleroderma (P), 714
fibrosing, or chronic airflow limitation, regional gas and tissue volume of lung in supine subjects with, computed tomography based estimates of, 932
of T suppressor lymphocyte type, acute pulmonary toxoplasmosis with, case of, 972
Aminophylline, effect on sternomastoid muscle fatigue, 122
intravenous, in patients already taking oral theophylline, effect on calculated dose of knowledge of serum theophylline concentration on admission, 759
intravenous, measurement of serum theophylline concentration on admission before, essential? (P), 248
Amiodarone pulmonary toxicity, functional and structural evaluation, 100
Amoxycillin in bronchiectasis given in standard or high doses orally or by inhalation, short term response to, 559
ANAND IS, HARRIS E, FERRARI R, PEARCE P, HARRIS P: Pulmonary haemodynamics of the yak, cattle, and cross breeds at high altitude, 696
ANDERSON F. *See* BRITTON JR, BURNEY PGJ, *et al*
——. *See* BURNEY PGJ, BRITTON JR, *et al*
ANDERSON K, LUK A, MCLEOD J, MORAN F: The application of pattern recognition and signal processing techniques in the diagnosis of asbestosis (P), 715
——, MCSHARRY C, BOYD G: The effect of cigarette smoking on the prevalence of extrinsic allergic alveolitis (P), 252
ANDERSON LE. *See* FERGUSSON RJ, ANDERSON LE, *et al*
ANDREESEN R. *See* COSTABEL U, BROSS KJ, *et al*
ANDREY S. *See* STRADLING JR, KOZAR L, *et al*
Aneurysm, aortic, caused by schistosomiasis, case of, 890
left ventricular, staphylococcal infection of, 154
Aneurysms, mycotic, of pulmonary artery, fatal haemorrhage from, case of, 70
Angelchik prosthesis, new complication associated with, case of *(Letter)*, 655
Angiotensin converting enzyme activity and protein, distribution in rat lung, effect of monocrotaline ingestion, 914
converting enzyme activity in serum and changed alveolar-capillary permeability in sarcoidosis, relationship between, 629
converting enzyme, serum measurements, serial lavage lymphocyte counts, and gallium-67 scans for monitoring of corticosteroid treatment in pulmonary sarcoidosis, evaluation of, 903
Antibiotic prophylaxis in cardiothoracic surgery, current practice in UK, 396; *(Letters)*, 816
Antibiotics, short and long term response to, effect on lung function in bronchiectasis, 798
Antibodies, food, in asthma (P), 735
monoclonal. *See* Monoclonal antibodies
Anticholinergic blockade of propranolol induced bronchoconstriction (P), 718
Anti-elastases in bronchoalveolar lavage fluid from patients with α_1-proteinase inhibitor deficiency or chronic obstructive bronchitis (P), 254
Antihistamines. *See* Terfenadine and astemizole
Antileucoprotease and elastase activity in polymorphonuclear leucocytes, *in vitro* effect of mercapto-ethanesulphonate, 840
α_1-Antitrypsin deficiency due to $M^{Malton}Z$ phenotype, case report and family study, 568
gene in chronic lung disease, restriction fragment length polymorphism of (P), 719
ANTTI-POIKA M, NORDMAN H, NICKELS J, KESKINEN H, VILJANEN A: Lung disease after exposure to polyvinyl chloride dust, 566
Aortic aneurysm caused by schistosomiasis, case of, 890
arch, interrupted, associated with Pourfour du Petit syndrome, case of, 217

Apnoea, obstructive, during sleep, and snoring, palatopharyngoplasty in treatment of (P), 719
APPERLEY JF. *See* SUTEDJA T, APPERLEY JF, *et al*
APPS MCP. *See* WALLIS PJW, APPS MCP, *et al*
ARBAB OA. *See* WIGGINS J, ARBAB OA, *et al*
ARM JP, SETHI TJ, EISER NM, WALPORT MJ, LEE TH: Comparative activities of leukotriene B_4 and LTB_5 in enhancing complement receptors (CR1 and CR3) in human neutrophils (P), 734
ARNOLD AG. *See* SIMPSON FG, ARNOLD AG, *et al*
Arterial filtration, effect on cerebral blood flow during cardiopulmonary bypass, 386
hypoxaemia occurring after methacholine challenge in asthma, effect of nifedipine, 468
Arthritis, rheumatoid, and silicosis, relationship between, in South African gold miners, 596
rheumatoid, low dose methotrexate pneumonitis in, case of, 703
Asbestosis, diagnosis of, pattern recognition and signal processing techniques in (P), 715
ASHOUR M: Recurrence of tracheo-oesophageal fistula 32 years after primary repair, 76
ASHRAF J, DUSSEK JE, MOORE BP: Late results of plombage *(Letter)*, 494
ASHWORTH M. *See* GOULD GA, ASHWORTH M, *et al*
Asian subjects, asthma in, effect of oesophageal stimulation (P), 225
ASKONAS BA. *See* OPENSHAW PJM, CANNON MJ, *et al*
Aspergilloma, pulmonary, preoperative embolisation of bronchial circulation in, case of, 324
treatment with surgical stapling device, recent experience of, 483
Aspergillosis, invasive, Pancoast's syndrome associated with, case of, 156
Aspergillus fumigatus, action on respiratory burst of neutrophils (P), 256
Aspiration biopsy, fine needle, of discrete pulmonary lesions, interpretation of negative results in, 875
needle, transbronchial, diagnostis and treatment of case of bronchogenic cyst using, 326
simple, of pneumothorax (P), 711
transbronchial, of subcarinal lymph nodes in carcinoma of lung (P), 711
ASSOUFI BK, DALLY M, LOZEWICZ S, NEWMAN-TAYLOR AJ, DENISON DM: Absence of refractory period or cumulative effect of cold air hyperventilation (P), 238
——, STEAD RJ, ROBERTS CM, HODSON ME, BATTEN JC: Response to salbutamol in adult patients with cystic fibrosis related to recovery from acute exacerbations of pulmonary infection (P), 732
Astemizole and terfenadine as non-sedative H_1 antihistamines for hay fever, comparative trial of *(Letters)*, 654, 976
Asthma, acute, non-respiratory symptoms of, 701
acute, plasma histamine concentration in (P), 241
airway in, mechanism of action of phenylephrine and methoxamine in (P), 718
airway reactivity in, role of inflammation in (E), 657
and eczema, house dust mite antigens sensitizing children with, differences in source of (P), 707
and hay fever, trends in general practice in UK (1976–83), 111
arterial hypoxaemia occurring after methacholine challenge in, effect of nifedipine, 468
bronchial, maximal airflow in, effect of volume history during spontaneous and induced airflow obstruction (P), 724
bronchial responsiveness to acetylcholine in, effects of thromboxane synthetase inhibitor (OKY-046) and lipoxygenase inhibitor (AA-861), 955
bronchoconstriction induced by allergen and exercise in, effect of inhaled piriprost (U-60, 257), 746
bronchoconstriction induced by leukotriene D_4 in, effect of sodium cromoglycate (P), 246
bronchoconstriction induced by leukotriene D_4 in, effect of verapamil and sodium cromoglycate, 753
bronchodilatation with nebulised terbutaline in, effect of aerosol particle size, 364
Charcot-Leyden crystals and Curschmann spirals in sputum in *(Historical review)*, 503
childhood, gastro-oesophageal reflux in, acid test for *(Letter)*, 160
childhood, mild, beclomethasone dipropionate for, twice versus four times daily treatment, 602
childhood, supervision of, role of primary school teachers in (P), 707
children with one parent with, respiratory symptoms, atopy and non-specific bronchial responsiveness in (P), 226
chronic, high dose corticosteroid aerosol treatments for, comparison of beclomethasone dipropionate (1500 μg/day) and budesonide (1600 μg/day), 869
chronic, influenza vaccination in, trial of (P), 239
chronic, severe and moderately severe, domiciliary comparison of terbutaline treatment by metered dose inhaler with and without conical spacer in, 766
deaths from, case-control study (Auckland, New Zealand, 1981–82), 833
Edinburgh emergency admission service for, 15 years' experience (P), 232
effect of oesophageal stimulation in Asian subjects (P), 225
eosinophilic pleuropneumonia, and pericarditis, combined, without vasculitis, 2 cases of, 571
food antibodies in (P), 735
in Bristol children, interrelationships of physical disability, family knowledge of asthma and psychological stress (P), 707
in pregnancy (P), 707
in pre-school children, clinical and immunological characteristics (P), 225
induced by exercise, and endogenous opioids, 350
induced by exercise, circulating adrenaline concentrations during exercise in (P), 718
induced by exercise, effect of H_1-receptor blockade (P), 735
induced by exercise, hypertonicity as initiating stimulus for (P), 239
induced by exercise, lung function in patients with, influence of α adrenoceptor agonists, 552
induced by exercise, platelet activation during, effect of prophylaxis with cromoglycate and salbutamol, 290
induced by exercise, refractory period in, circulating mediator and catecholamine concentrations during (P), 718
mild, eosinophils and mast cells in bronchoalveolar lavage in, relationship to bronchial hyperreactivity (P), 735
nocturnal, overnight bronchoconstriction in, effect of sleep deprivation, 676
nocturnal, sodium cromoglycate in, 39
occupational, due to maleic anhydride, bronchial provocation testing and immunological data (P), 251
occupational, due to oil mists (P), 250
occupational, due to salbutamol (P), 250
occupational, due to unheated colophony (P), 708
occupational, in bathtub resurfacer due to pentamethylene diethylene triamine (P), 251
occupational, in hairdressing salon, 42
patient compliance with inhaled therapy in, importance of (P), 721
refractoriness in, absence after exercise with warm, humid inspirate *(Letters)*, 415
refractoriness induced by exercise in, airway response to methacholine during, 667
regional ventilation, perfusion and ventilation-perfusion ratios in, tomography using krypton 81 m of, 542
self assessment of, influence of knowledge of peak flow, evidence from studies with coded peak flow meter, 671
severe, acute, acute hydrocortisone myopathy in, case of, 411
severe, acute, clinical trials in, importance of type II errors in, 824
severe, acute, mechanical ventilation in, experience of (1973–85), 464
severe, acute, neutrophil chemotactic activity in (P), 735
severe, acute, treatment by mechanical (intermittent positive pressure) ventilation, 10 years' experience (1974–83) from district

general hospital, 459
severe, patients admitted with (but not in ventilatory failure), effect of intravenous hydrocortisone added to oral prednisolone (P), 248
stable, beclomethasone dipropionate twice daily from concentrated aerosol inhaler in, efficacy and patient compliance, 960
steroid dependent, chronic, no steroid sparing effect with hydroxychloroquine in (P), 721
symptoms, airway calibre and histamine reactivity following blind food challenge in, assessment of (P), 240
terfenadine as H_1 histamine receptor antagonist for airways in (P), 247
treatment outside hospital in UK, relative usage of newer therapies (1975–83) (P), 249
trials, analysis of power of (P), 248
Atelectasis, shrinking pleuritis with, exogenous particles in lymph nodes in *(Letters)*, 655
ATHERTON ST. *See* LUKSZA AR, SMITH P, *et al*
Atrophy and respiratory tract infection, role in autumnal exacerbation of bronchial reactivity in rural population (P), 239
Atrium, left, and right pulmonary artery, direct communication between, case of, 78
AUMANN JLTM, BOSCH JMM VAN DEN, ELBERS JRJ, WAGENAAR SJ SC: Metastatic meningioma of the lung, 487
AYRES JG: Seasonal pattern of acute bronchitis in general practice in the United Kingdom 1976–83, 106
———: Trends in asthma and hay fever in general practice in the United Kingdom 1976–83, 111
——. *See also* PACKE GE, AYRES JG, *et al*
——. *See also* WIGGINS J, ARBAB OA, *et al*
AZARIADES M. *See* KAY PH, AZARIADES M, *et al*

B

BACCI E. *See* PAGGIARO PL, INNOCENTI A, *et al*
BACH MK. *See* MANN JS, ROBINSON C, *et al*
BACHMAN M. *See* GAILLARD RC, BACHMAN M, *et al*
Bacterial growth in sputum and contamination free endobronchial samples from patients with cystic fibrosis, conformity of, 641
products, effect on ferret tracheal ciliated epithelium (P), 729
BALDWIN DL. *See* CORRADO OJ, GOMEZ E, *et al*
BALL SG. *See* BERKIN KE, WALKER G, *et al*
BALLESTER E, ROCA J, RODRIGUEZ-ROISIN R, AGUSTI-VIDAL A: Effect of nifedipine on arterial hypoxaemia occurring after methacholine challenge in asthma, 468
BANHAM SW, MCKILLOP J, CARLYLE D, BOYD G: Lung permeability in pigeon fanciers (P), 227
——, MCSHARRY C, LYNCH PP, BOYD G: Relationships between avian exposure, humoral immune response, and pigeon breeders' disease among Scottish pigeon fanciers, 274
——. *See also* DORWARD AJ, BANHAM SW, *et al*
——. *See also* MILROY R, SMITH ML, *et al*
BANNER NR, HAIGH A, BUSHNELL T, GOVAN JR: Problems with staphylococcal infection in patients with transtracheal micro-catheters (P), 235
——, LLOYD MH, LOCKWOOD P, GOVAN JR: Portable oxygen therapy via a transtracheal catheter during exercise (P), 245
BARBER PV. *See* CERNY T, BARNES D, *et al*
BARER GR. *See* WILKINSON M, LANGHORNE CA, *et al*
Barium miners, silicosis in, 591
BARKER A, RUTMAN A, WILSON R, TAYLOR G, COLE PJ: Effect of bacterial products on ferret tracheal ciliated epithelium (P), 729
BARNES D. *See* CERNY T, BARNES D, *et al*
BARNES NC. *See* GRAY B, BARNES NC, *et al*
——. *See* JENKINS SC, BARNES NC, *et al*
BARNES PJ. *See* DIXON CMS, FULLER RW, *et al*
——. *See* IND PW, BARNES PJ, *et al*
——. *See* IND PW, DIXON CMS, *et al*
——. *See* PALMER JBD, CUSS FMC, *et al*
——. *See* WARRENS AN, BARNES PJ, *et al*
BARNES RMR. *See* CHURCH SE, FINN R, *et al*
BARROWCLIFFE MP, MORICE AH, JONES JG, SEVER PS: Pulmonary clearance of vasoactive intestinal peptide, 88
Basophils of blood and smoking *(Letter)*, 335
BATEMAN ED. *See* WILLCOX PA, POTGIETER PD, *et al*
BATEMAN JRM. *See* PAVIA D, BATEMAN JRM, *et al*
BATEMAN NT. *See* O'DOHERTY MJ, VAN DE PETTE J, *et al*
Bathtub resurfacer, occupational asthma due to pentamethylene diethylene triamine in (P), 251
BATTEN JC. *See* ASSOUFI BK, STEAD RJ, *et al*
——. *See* PANTIN CFA, STEAD RJ, *et al*
——. *See* STEAD RJ, DUNCAN FR, *et al*
——. *See* STEAD RJ, HODSON ME, *et al*
BAXTER P. *See* BENNETT J, BAXTER P, *et al*
BCG vaccination, neonatal, tuberculin sensitivity after (P), 226
BEAGLEHOLE R. *See* REA HH, SCRAGG R, *et al*
BEASLEY CR. *See* RAFFERTY P, BEASLEY CR, *et al*
Beclomethasone dipropionate for mild childhood asthma, twice versus four times daily treatment, 602
dipropionate twice daily from concentrated aerosol inhaler in stable asthma, efficacy and patient compliance, 960
BÉLANGER J. *See* CORMIER Y, BÉLANGER J, *et al*
BELCHER M. *See* JARVIS MJ, BELCHER M, *et al*
BELCHER NG, MURDOCH R, DALTON N, REES PJ, CLARK TJH, LEE TH: Circulating mediator and catecholamine concentrations during the refractory period in exercise induced asthma (P), 718
——, REES PJ: Changes in pulmonary clearance of technetium labelled DTPA during haemodialysis, 381
——, ——: Effects of pholcodine and salbutamol on citric acid induced cough in normal subjects, 74
——, ——, CLARKE TJH, LEE TH: Hypertonicity as an initiating stimulus for exercise induced asthma (P), 239
BELFIELD PW. *See* JOHNSON CE, BELFIELD PW, *et al*
——. *See* SIMPSON FG, ARNOLD AG, *et al*
BELLONE A. *See* BIERNACKI W, WHYTE KF, *et al*
BENATAR SR. *See* WILLCOX PA, POTGIETER PD, *et al*
BENFIELD G, CULLEN M, MATTHEWS HR, WATSON D, COLLINS F, WOODROFFE C, STUART N, PERREN T, EDWARDS C: Intensive chemotherapy plus adjuvant surgery in operable small cell carcinoma of the bronchus: a phase II study (P), 230
BENNETT J, BAXTER P, DAVIES RJ: Respiratory symptoms in coffee process workers and their relationship to bronchial hyperresponsiveness, atopy and sensitization to the green coffee bean (P), 708
BENSON-MITCHELL R. *See* PEACOCK A, BENSON-MITCHELL R, *et al*
BERKIN KE, WALKER G, INGLIS GC, BALL SG, THOMSON NC: Circulating adrenaline concentrations during exercise in normal subjects and patients with exercise induced asthma (P), 718
BEST JJK. *See* GOULD GA, MCLEAN A, *et al*
Beta blockade, selective and non-selective, effect on lung function and tracheobronchial mucociliary clearance in healthy subjects, 301
Beta-adrenergic responsiveness in wheezy infants, evidence from airway response to salbutamol for (P), 240
Beta-adrenoceptor number in peripheral tissue after chronic hypoxia in rats, effect of isoprenaline (P), 249
BEVERLEY PCL. *See* MOSS FM, BOBROW LG, *et al*
BIERNACKI W, WHYTE KF, GOULD GA, BELLONE A, FLENLEY DC: The extent of pulmonary emphysema as assessed non-invasively by CT scan in life does not relate to pulmonary haemodynamics during rest or exercise (P), 726
BIRD G. *See* KELLY CA, WARD C, *et al*
Bird breeder's disease, skin tests in, 538
BISCHLER PJE. *See* SACKS SH, HARRISON M, *et al*
Björk-Shiley valve prostheses, failed, metallurgical analysis of, 142
BLAINLEY AD, CURLING M, GREEN M: Transbronchial aspiration of subcarinal lymph nodes in carcinoma of the lung (P), 711

——, OLLIER S, CUNDELL D, SMITH RE, DAVIES RJ: Occupational asthma in a hairdressing salon, 42
——, TOPPING MD, OLLIER S, DAVIES RJ: Specific IgE to storage mites in Essex farmworkers (P), 251
BLAIR B. *See* HASLETON PS, GOMM S, *et al*
BLANK M. *See* PALMER JBD, CUSS FMC, *et al*
BLASCHKE E. *See* EKLUND A, BLASCHKE E
BLATSIOS V. *See* BOUROS DE, GASIS A, *et al*
BLAUROCK M. *See* LINK H, REINHARD U, *et al*
BLEEHEN NM, GIRLING DJ: Survival in small cell lung carcinoma after surgery *(Letter)*, 896
BLESOVSKY A. *See* LAU YL, RADHI JM, *et al*
Blood basophils and smoking *(Letter)*, 335
flow and oxygen carriage, calf, after reversal of polycythaemia secondary to hypoxic lung disease, 306
flow, bronchial, distribution during histamine infusion in unanaesthetised sheep (P), 245
flow, cerebral, during cardiopulmonary bypass, effect of arterial filtration, 386
flow, pulmonary, effective, measured by inert gas rebreathing method in ventilated patients, effect of inspired oxygen concentration (P), 725
platelet. *See* Platelet
BLOOM SR. *See* PALMER JBD, CUSS FMC, *et al*
BOBROW LG. *See* MOSS FM, BOBROW LG, *et al*
BODNER G. *See* SCARLAT A, BODNER G, *et al*
Bone marrow transplantation, allogeneic, lung function changes after, 508
marrow transplantation and lung (E), 497
marrow transplantation, lung function after, effect of preconditioning regimens (P), 726
marrow transplants, high dose total body irradiation and subsequent cytomegalovirus pneumonitis in recipients of (P), 730
Book notices, 69, 153, 336, 412, 495, 570, 576, 648, 706, 815, 885, 976
BORLAND C: Lung function in the elderly *(Letter)*, 335
BOSCH JMM VAN DEN, WAGENAAR SJ SC, WESTERMANN CJJ: Asthma, eosinophilic pleuropneumonia, and pericarditis without vasculitis, 571
——. *See also* AUMANN JLTM, BOSCH JMM VAN DEN, *et al*
BOUROS DE, GASIS A, MELISSINOS CH, BLATSIOS V, EMMANOUEL A: Leiomyomas of the lower respiratory tract *(Letter)*, 976
BOWLER S, WOODCOCK A, DA COSTA P, TURNER-WARWICK M: Chronic pulmonary paracoccidioidomycosis masquerading as lymphangitis carcinomatosa, 72
BOYD G. *See* ANDERSON K, MCSHARRY C, *et al*
——. *See* BANHAM SW, MCKILLOP J, *et al*
——. *See* BANHAM SW, MCSHARRY C, *et al*
BOYLE T. *See* MCNICHOLAS WT, COFFEY M, *et al*
BRADLEY RD. *See* TREACHER DF, COWELL TK, *et al*
BRADLEY GW. *See* MORGAN JM, MORGAN AD, *et al*
Brainstem pathology, diaphragm dysfunction associated with (P), 710
BRANDENHOFF P, HØIER-MADSEN K, STRUVE-CHRISTENSEN E: Pneumopericardium after pneumonectomy and lobectomy, 55
Branhamella catarrhalis, pathogenic mechanisms and lack of IgA1 protease production (P), 253
BRANTHWAITE MA. *See* SIMONDS AK, PARKER RA, *et al*
BRAUDE S. *See* NOLOP KB, MAXWELL DL, *et al*
Breathing disturbances related to sleep in restrictive chest wall disease, effects of protriptyline, 586
during sleep in myotonic dystrophy and non-myotonic respiratory muscle weakness (P), 710
in tetraplegia, effect of abdominal binders (P), 244; 940
nose and mouth, effects on 2 oxygen conserving nasal prong systems, 808
See also Ventilation
Breathlessness after surgery for carcinoma of bronchus (P), 230
in chronic obstructive airways disease, short burst oxygen treatment for, 611
BRETTLE R. *See* MCLEOD DT, CROUGHAN MJ, *et al*
British Thoracic Society: Summer Meeting, 707
Thoracic Society: Winter Meeting, 224
BRITTEN A. *See* TURNER-WARWICK M, MCALLISTER W, *et al*
BRITTON JR, BURNEY PGJ, CHINN S, PAPACOSTA AO, ANDERSON F, TATTERSFIELD AE: The role of respiratory tract infection and atopy in autumnal exacerbation of bronchial reactivity in a rural population (P), 239
——, ——, ——, ——, TATTERSFIELD AE: The relationship between change in bronchial reactivity and change in respiratory symptoms in a community survey (P), 713
——, MORTAGY A, TATTERSFIELD AE: Histamine challenge testing: comparison of three methods, 128
——. *See also* BURNEY PGJ, BRITTON JR, *et al*
——. *See also* CROSSLEY J, BRITTON JR, *et al*
——. *See also* GARRETT H, BRITTON JR, *et al*
——. *See also* GARRETT H, VATHENEN S, *et al*
BOEK WVD. *See* HENGSTUM MV, FESTEN J, *et al*
Bromocriptine, pleuropulmonary fibrosis induced by, case of, 328
Bronchi of subjects dead from chronic bronchitis or bronchiectasis, IgA subclass bearing cells in (P), 256
Bronchial asthma, maximal airflow in, effect of volume history during spontaneous and induced airflow obstruction (P), 724
blood flow distribution during histamine infusion in unanaesthetised sheep (P), 245
brushing and bronchial biopsy in lung cancer, comparison of diagnostic accuracy and cell typing reliability, 475
carcinoids, clinicopathological study (P), 229
carcinoma, cardiovascular reflexes more commonly impaired in patients with?, 372
carcinoma, chemotherapeutic agents in, assessment of, human tumour xenografts growing in immunodeficient mice as model for, 376
carcinoma, non-small cell, chemotherapy in *(Letter)*, 335
carcinoma, occult cardiac invasion in, detection by two dimensional echocardiography, 138
carcinoma, small cell, operable, intensive chemotherapy plus adjuvant surgery in, phase II study (P), 230
carcinoma, surgery for, breathlessness after (P), 230
challenge tests in humidifier related lung diseases (P), 252
challenge with histamine, changes in transcutaneous oxygen and carbon dioxide in response to (P), 246
circulation, preoperative embolisation of, in case of pulmonary aspergilloma, 324
hyperreactivity, relationship to eosinophils and mast cells in bronchoalveolar lavage in mild asthma (P), 733
hyperresponsiveness, atopy and sensitization to green coffee bean, relationship to respiratory symptoms in coffee process workers (P), 708
hyperresponsiveness symptoms in schoolchildren (P), 735
reactivity and airway calibre, drug induced changes interdependent? (P), 239
reactivity and peripheral blood eosinophil counts (P), 241
reactivity, autumnal exacerbation in rural population, role of respiratory tract infection and atopy in (P), 239
reactivity changes and respiratory symptom changes, relationship between, in community survey (P), 713
reactivity following prednisolone in chronic obstructive airways disease (P), 240
reactivity, specific, to toluene diisocyanate, relationship with baseline clinical findings, 279
reactivity to histamine, distribution in adult population (P), 233
reactivity to inhaled methacholine, prevalence in New Zealand children, 283; *(Letters)*, 705
response to inhaled histamine, relationship to 24 hour sodium excretion (P), 240
responsiveness to acetylcholine in asthma, effects of thromboxane synthetase inhibitor (OKY-046) and lipoxygenase inhibitor (AA-861), 955
sepsis, chronic, cilioinhibitory factors in sputum in (P), 253
sepsis, chronic, *Pseudomonas aeruginosa* phenazine pigments in

sputum in, inhibition of human ciliary beat frequency *in vitro* by (P), 729
smooth muscle, human, *in vitro* responses to leukotriene D_4 in relation to quantity of muscle (P), 734
Bronchiectasis and oligospermia in 2 families *(Letters)*, 80
lung function in, effect of short and long term antibiotic response, 798
migration of ^{111}indium-labelled neutrophils to lungs in (P), 256
or chronic bronchitis, IgA subclass bearing cells in bronchi of subjects dead from (P), 256
purulent, serum acute phase proteins in (P), 254
short term response to amoxycillin given in standard or high dose orally or by inhalation in, 559
tracheobronchial clearance in (P), 255
Bronchiolitis, obliterative, adult, histocompatibility antigens in (P), 237
Bronchitis, acute, seasonal pattern in general practice in UK (1976–83), 106
chronic, acute effects of oral theophylline on trapped gas volume in (P), 722
chronic, comparison of 6 and 12 minute walk distance with 100 metre walk times in (P), 245
chronic, hypoxic, symptomatic oxygen therapy in (P), 245
chronic, or bronchiectasis, IgA subclass bearing cells in bronchi of subjects dead from (P), 256
chronic, oral almitrine in, rest and exercise pulmonary haemodynamics and right ventricular ejection fraction after (P), 224
chronic, peak flow rate variability in, interpretation of, 771
obstructive, chronic, or α_1-proteinase inhibitor deficiency, anti-elastases in bronchoalveolar lavage fluid from patients with (P), 254
obstructive, chronic, tissue inhibitor of metalloproteinases and collagenase inhibitory activity in lung secretions in, effect of corticosteroid treatment, 740
Bronchoalveolar elastase burden, increased, in cryptogenic fibrosing alveolitis (P), 728
lavage eosinophils and mast cells in mild asthma, relationship to bronchial hyperreactivity (P), 733
lavage fluid, absolute and differential cell counts in, effect of filtration (P), 727
lavage fluid from patients with α_1-proteinase inhibitor deficiency or chronic obstructive bronchitis, anti-elastases in (P), 254
lavage fluid from patients with sarcoidosis, fibronectin and collagenase in (P), 230
lavage fluid, HLA-DR antigens on human macrophages from, 261
lavage fluid, inhibition of T cell function by (P), 231
lavage fluid lymphocytes in farmer's lung disease, relationship to radiographic changes and lung function, 28
lavage fluid mast cells in interstitial lung disease, comparison with transbronchial biopsy sections and ultrastructural appearance (P), 232
lavage fluid of healthy granite workers, raised immunoglobulin concentrations in, 266
lavage in case of Waldenström's macroglobulinaemia with pulmonary infiltrates, 409
lavage in pulmonary mycotoxicosis (organic dust toxic syndrome), 924
lavage in rapid diagnosis of cytomegalovirus pneumonitis (P), 234
lavage lymphocyte counts, serial, serum angiotensin converting enzyme measurements, and gallium-67 scans for monitoring of corticosteroid treatment in pulmonary sarcoidosis, evaluation of, 903
lavage samples, sequential, comparison of concentrations of proteinase inhibitors (antileucoprotease and α_1 proteinase inhibitor), porcine pancreatic elastase inhibitory capacity, and cell profiles in, 435
lavage, value in diagnosis of pulmonary infection in AIDS, 345
mast cells in sarcoidosis, increased numbers and accentuation of mediator release, 94
Bronchoconstriction in asthma induced by allergen and exercise, effect of inhaled piriprost (U-60, 257), 746
in asthma induced by leukotriene D_4, effect of sodium cromoglycate (P), 246
in asthma induced by leukotriene D_4, effect of verapamil and sodium cromoglycate, 753
induced by adenosine monophosphate and allergen, inhibitory effect of terfenadine (P), 734
induced by "fog", sodium cromoglycate pretreatment and clearance of ^{99m}Tc-DTPA in (P), 227
induced by propranolol, anticholinergic blockade of (P), 718
induced by sulphur dioxide, action of nedocromil sodium on (P), 246
overnight, in nocturnal asthma, effect of sleep deprivation, 676
Bronchodilatation with nebulised terbutaline in asthma, effect of aerosol particle size, 364
Bronchodilator aerosols, particle size of, effect on lung distribution and pulmonary function (P), 721
Bronchogenic cyst, diagnosis and treatment, using transbronchial needle aspiration, of case of, 326
Broncho-oesophageal fistula, oesophageal intubation for (P), 712
Bronchopleural fistula after pneumonectomy *(Letter)*, 896
Bronchoscope, fibreoptic, flexible, rapid diagnosis of sputum-negative miliary tuberculosis with, 681
Bronchoscopic practice by physicians in UK, postal survey, 311
Bronchoscopy, fibreoptic, effect on airway physiology (P), 712
fibreoptic, in differentiation of pulmonary infection and Kaposi's sarcoma in AIDS (P), 715
set, new, for laser therapy, 485
Bronchus, tumour of, granular cell, bronchoscopic and clinical features, with 2 cases, 927
BROPHY C. *See* MIER A, BROPHY C, *et al*
BROSS KJ. *See* COSTABEL U, BROSS KJ, *et al*
BROSTOFF J. *See* FLINT KC, LEUNG KBP, *et al*
——. *See* HIND CRK, FLINT KC, *et al*
BROWN WR. *See* SEATON A, RUCKLEY VA, *et al*
BUCHANAN DR, CROMWELL O, KAY AB: Neutrophil chemotactic activity in acute severe asthma (P), 735
BUCHANAN R. *See* AGIUS RM, GODFREY RC, *et al*
BUIJS W. *See* HENGSTUM MV, FESTEN J, *et al*
Bullae, large, in lung in sarcoidosis, 3 cases of, 792
Bullous emphysematous lung, intracavity drainage of (P), 233
lung disease, selection for surgery in, value of computed tomography for, 855
BURGE PS, WIELAND GA, ROBERTSON AS, WEIR D: Occupational asthma due to unheated colophony (P), 708
——. *See also* GOVE RI, ROBERTSON AS, *et al*
——. *See also* ROBERTSON AS, WIELAND GA, *et al*
BURNETT D: Immunoglobulins in the lung (E), 337
——, CROCKER J, STOCKLEY RA: IgA subclass bearing cells in the bronchi of subjects who have died with chronic bronchitis or bronchiectasis (P), 256
——, REYNOLDS JJ, WARD RV, AFFORD SC, STOCKLEY RA: Tissue inhibitor of metalloproteinases and collagenase inhibitory activity in lung secretions from patients with chronic obstructive bronchitis: effect of corticosteroid treatment, 740
——. *See also* CURRIE DC, AFFORD SA, *et al*
——. *See also* HILL SL, MORRISON HM, *et al*
——. *See also* HILL SL, SHAW JC, *et al*
——. *See also* MORRISON HM, KRAMPS JA, *et al*
——. *See also* STOCKLEY RA, MORRISON HM, *et al*
——. *See also* STOCKLEY RA, SHAW JC, *et al*
BURNEY PGJ, BRITTON JR, CHINN S, TATTERSFIELD AE, PAPACOSTA AO, KELSON M, ANDERSON F, CORFIELD D: Distribution of bronchial reactivity to histamine in an adult population (P), 233
——, ——, ——, ——, PLATT H, PAPACOSTA AO, KELSON M: The relationship between the bronchial response to inhaled histamine and 24 hour sodium excretion (P), 240
——. *See also* BRITTON JR, BURNEY PGJ, *et al*
BURR ML: Lung function in the elderly *(Letter)*, 335
BUSH A, DENISON DM: Use of different magnification factors to calcu-

late radiological lung volumes, 158
BUSHNELL T. *See* BANNER NR, HAIGH A, *et al*
BUTANY JW. *See* LIU FL-W, COHEN RD, *et al*
BUTCHER RG. *See* CAMPBELL DA, DU BOIS RM, *et al*
Byssinosis and respiratory disability (E), 1
emphysema due to cigarette smoking in, physiological evidence, 6

C

CA-50 radioimmunoassay inhibition test in diagnosis of lung cancer (P), 716
CABRERA A. *See* LEKUONA I, CABRERA A, *et al*
Cadmium inhalation and emphysema (P), 714
Calcium ionophore (A23187) and unopsonised zymosan, human eosinophils stimulated by, generation of prostaglandins, thromboxane and leukotriene C_4 by (P), 733
CALDER MA. *See* DOUGLAS JG, CALDER MA, *et al*
——. *See* FRANCE AJ, MCLEOD DT, *et al*
——. *See* MCLEOD DT, CROUGHAN MJ, *et al*
CALHOUN WJ, CHRISTMAN JW, ERSHLER WB, GRAHAM WGB, DAVIS GS: Raised immunoglobulin concentrations in bronchoalveolar lavage fluid of healthy granite workers, 266
CAMPBELL D. *See* POLLOK AJ, GEMMELL CG, *et al*
CAMPBELL DA, DU BOIS RM, BUTCHER RG, POULTER LW: Density of HLA-DR antigen on alveolar macrophages obtained by BAL in pulmonary sarcoidosis (P), 231
——, POULTER LW, DU BOIS RM: Phenotypic analysis of alveolar macrophages in normal subjects and in patients with interstitial lung disease, 429
——. *See also* MUNRO CS, CAMPBELL DA, *et al*
——. *See also* POULTER LW, CAMPBELL DA, *et al*
CAMPBELL IA (for BTS RESEARCH COMMITTEE): BTS study of nine months' treatment with rifampicin and ethambutol in *Mycobacterium kansasii* pulmonary infection (P), 709
——, HANSFORD M, PRESCOTT RJ: Effect of a "stop smoking" booklet on smokers attending for chest radiography: a controlled study, 369
CANNON MJ. *See* OPENSHAW PJM, CANNON MJ, *et al*
CANNY GJ, MARCOTTE JE, LEVISON H: Lung abscess in cystic fibrosis, 221
CAPEWELL SJ, LEAKER AR, LEITCH AG: Tuberculosis in NHS staff: is it a problem? (P), 708
——, WEBB JN, CROMPTON GK: Primary leiomyosarcoma of the lung presenting with a persistent pneumothorax, 649
——. *See also* ELLIS DA, CAPEWELL SJ
Captopril, effect on pulmonary haemodynamics and lung function in chronic airflow obstruction (P), 225
Carbenicillin aerosol therapy, which nebuliser and compressor for? (P), 236
Carbon dioxide and oxygen, transcutaneous, changes in response to histamine bronchial challenge (P), 246
monoxide, end expired, concentration of, time course of, importance in cigarette smoking studies (P), 727
monoxide monitors, low cost, in smoking assessment, 886
monoxide transfer and quantitative CT scan for estimation of size of distal airspaces defining emphysema in smokers (P), 717
monoxide transfer coefficient changes over 10 years in middle aged men, influence of smoking habit (P), 726
Carboxyhaemoglobin concentrations, distribution in smokers and non-smokers, 25
Carcinoembryonic antigen concentrations in serum and secretions, effect of cigarette smoking, pulmonary inflammation, and lung disease, 17
Carcinoids, bronchial, clinicopathological study (P), 229
Carcinoma, bronchial, cardiovascular reflexes more commonly impaired in patients with?, 372
bronchial, chemotherapeutic agents in, assessment of, human tumour xenografts growing in immunodeficient mice as model for, 376
bronchial, non-small cell, chemotherapy in (*Letter*), 335
bronchial, occult cardiac invasion in, detection by two dimensional echocardiography, 138
bronchial, small cell, operable, intensive chemotherapy plus adjuvant surgery in, phase II study (P), 230
bronchial, surgery for, breathlessness after (P), 230
of lung, bronchial brushing and bronchial biopsy in, comparison of diagnostic accuracy and cell typing reliability, 475
of lung, diagnosis by CA-50 radioimmunoassay inhibition test (P), 716
of lung presenting with digital ischaemia, case of, 573
of lung, prognosis after surgery with and without preoperative CT scans of thorax, abdomen and head (P), 229
of lung, small cell, chemotherapy for, quality of life during (P), 719
of lung, small cell, detection in pleural effusions with monoclonal antibodies (P), 238
of lung, small cell, gallium scanning in (P), 229
of lung, small cell, short duration combination chemotherapy in treatment of, 688
of lung, small cell, survival after surgery in, 479; (*Letter*), 896
of lung, transbronchial aspiration of subcarinal lymph nodes in (P), 711
of oesophagus, oat cell, primary, 318
pulmonary, xenografts, human, activity of cytotoxic agents in, effect of interferon (P), 233
Carcinomatous pleural effusions, paracentesis through fine silastic catheter (P), 711
Cardiac effects of salbutamol given by air driven nebuliser at home, 331
invasion, occult, in bronchial carcinoma, detection by two dimensional echocardiography, 138
rhythm in hypozaemic chronic airways obstruction, effects of theophylline (P), 722
See also Heart
Cardiopulmonary bypass, cerebral blood flow during, effect of arterial filtration, 386
bypass priming fluid, chalk in, 148
Cardiothoracic surgery, antibiotic prophylaxis in, current practice in UK, 396; (*Letters*), 816
Cardiovascular reflexes, more commonly impaired in patients with bronchial carcinoma?, 372
CARLYLE D. *See* BANHAM SW, MCKILLOP J, *et al*
CARMICHAEL J. *See* FERGUSSON RJ, CARMICHAEL J, *et al*
CARSWELL F, HEK G, ROBINSON E: Interrelationships of physical disability, family knowledge of asthma and psychological stress in Bristol children (P), 707
——, MUKHERJEE S, HEAP P: Increased permeability of the trachea in sensitised rats after aerosol challenge (P), 736
——, THOMPSON SJ: Differences in the source of the house dust mite antigens sensitising asthmatic and eczematous children (P), 707
CARTER A. *See* EVANS TW, WATERHOUSE JC, *et al*
CARTER R. *See* WINTER, JH, CARTER R, *et al*
CARTY H. *See* O'HALLORAN SM, GILBERT J, *et al*
CASH M. *See* ORENSTEIN M, WEBBER CA, *et al*
Catecholamines and mediators, circulating, concentrations during refractory period in exercise induced asthma (P), 718
CATTERALL JR, RHIND GB, STEWART IC, WHYTE KF, SHAPIRO CM, DOUGLAS NJ: Effect of sleep deprivation on overnight bronchoconstriction in nocturnal asthma, 676
——. *See also* MORGAN AD, CONNAUGHTON JJ, *et al*
CAVAROCCHI N. *See* JONES DK, CAVAROCCHI N, *et al*
CAYTON RM. *See* LAMB RK, REDDY A, *et al*
——. *See* SUGGETT AJ, PROCTOR A, *et al*
Cerebral blood flow during cardiopulmonary bypass, effect of arterial filtration, 386
CERNY T, BARNES D, HASLETON PS, BARBER PV, HEALY K, THATCHER N: Monoclonal antibodies against the epidermal growth factor receptor (P), 238
Cervical mediastinoscopy, role in patients with superior vena caval obstruction (P), 712

CHADWICK GA. *See* HIGGINS RM, COOKSON WOCM, *et al*
CHANINIAN AP: Diffuse pulmonary mesothelioma presenting as bilateral lymphangitis *(Letter)*, 223
Chalk in priming fluid for cardiopulmonary bypass, 148
CHANDRASEKERA C. *See* ALLEN MB, CHANDRASEKERA C, *et al*
CHAPELA R. *See* SELMAN M, MONTAÑO M, *et al*
CHAPMAN BJ. *See* CROMPTON GK, GRANT IWB, *et al*
Charcot, Jean-Martin (1825–93), Charcot-Leyden crystals and Curschmann spirals in asthmatic sputum *(Historical review)*, 503
CHARLES PJ. *See* SWEATMAN MC, MARKWICK JR, *et al*
Chemotherapeutic agents in bronchial carcinoma, assessment of, human tumour xenografts growing in immunodeficient mice as model for, 376
CHEN D. *See* NUNN JF, MILLEDGE JS, *et al*
CHERNIACK RM. *See* HASLETT C, SHEN AS, *et al*
Chest physiotherapy in cystic fibrosis, oral high frequency oscillation as adjunct to (P), 235
physiotherapy in cystic fibrosis, positive expiratory pressure as adjunct to, evaluation of, 951
physiotherapy, nebulised saline and terbutaline as adjunct to, assessment of (P), 235
physiotherapy. *See also* Postural drainage
radiography, miniature, static, GP referrals for, indications and diagnostic yield (P), 717
radiography, smokers attending for, effect of "stop smoking" booklet, study of, 369
wall disease, restrictive, breathing disturbances related to sleep in, effects of protriptyline, 586
wall disease, restrictive, intermittent positive pressure hyperinflation in (P), 244
wall tumours, primary, wide surgical resection as main treatment modality in (P), 713
Chickenpox, haemothorax in course of, case of, 491
CHIH-HSIUNG W. *See* LINDSEY DC, CHIH-HSIUNG W, *et al*
China stone and china clay dusts, inhalation and relationship between mineralogy of dust retained in lungs and pathological changes, 190
CHINN DJ, NARUSE Y, COTES JE: Accuracy of gas analysis in lung function laboratories, 133
CHINN S. *See* BRITTON JR, BURNEY PGJ, *et al*
——. *See* BURNEY PGJ, BRITTON JR, *et al*
CHIPPING P. *See* ALLEN MB, GROCCOT L, *et al*
Chlorine exposure, acute, respiratory health after (P), 249
CHOO-KANG YFJ. *See* DOUGLAS JG, CALDER MA, *et al*
——. *See* DOUGLAS JG, MIDDLETON WG, *et al*
CHOW JSF. *See* LEE PK, SO SY, *et al*
CHRISTMAN JW. *See* CALHOUN WJ, CHRISTMAN JW, *et al*
CHRYSTYN H, MULLEY BA, PEAKE MD: Acute effects of oral theophylline on trapped gas volume in chronic bronchitis (P), 722
CHUDRY N. *See* WILSON NM, CHUDRY N, *et al*
CHUNG KF: Role of inflammation in the hyperreactivity of the airways in asthma (E), 657
CHURCH SE, FINN R, BARNES RMR, WILLIAMS AJ: Food antibodies in asthma (P), 735
——, WILLIAMS AJ: Finger clubbing—a survey of patient awareness (P), 237
CHURCHILL AR. *See* SLUIS-CREMER GK, HESSEL PA, *et al*
Chylothorax, review of 18 cases, 880
CID C. *See* LEKUONA I, CABRERA A, *et al*
Cilia from sites of purulent infection, beat frequency of, 453
human, beating of, *in vitro*, effect of heat stable factor produced by *Haemophilus influenzae* (P), 253
Ciliary beat frequency and mucociliary clearance, nasal, effect of cigarette smoking, 519
beat frequency, human, inhibition *in vitro* by *Pseudomonas aeruginosa* phenazine pigments in sputum in chronic bronchial sepsis (P), 729
function, human, *in vitro*, effect of *Streptococcus pneumoniae* (P), 253
Ciliated tracheal epithelium, ferret, effect of bacterial products (P), 729
Cilioinhibitory factors in sputum in chronic bronchial sepsis (P), 253
Citric acid, cough induced by, effects of pholcodine and salbutamol in normal subjects, 74
CITRON KM, THOMAS GO: Ocular toxicity from ethambutol (E), 737
——. *See also* PACKE GE, AYRES JG, *et al*
CLANCY L, KELLY P, O'REILLY L, HEALY T: Pathogenicity of *Mycobacterium tuberculosis* during anti-tuberculosis therapy (P), 228
——. *See also* HOWELL F, O'LAOIDE R, *et al*
CLARK B. *See* TITINCHI SJ, CLARK B, *et al*
CLARK CJ. *See* POLLOK AJ, GEMMELL CG, *et al*
CLARK TJH. *See* BELCHER NG, MURDOCH R, *et al*
——. *See* BELCHER NG, REES PJ, *et al*
——. *See* MAHAUTHAMAN R, YOULTEN LJF, *et al*
CLARKE CA. *See* STOCKLEY RA, SHAW JC, *et al*
CLARKE SW. *See* AGNEW JE, LOPEZ-VIDRIERO MT, *et al*
——. *See* CLAY MM, PAVIA D, *et al*
——. *See* CURRIE DC, PAVIA D, *et al*
——. *See* GEORGE RJD, PAVIA D, *et al*
——. *See* GREENSTONE MA, CURRIE DC, *et al*
——. *See* LOPEZ-VIDRIERO MT, PAVIA D, *et al*
——. *See* MILLAR AB, AGNEW JE, *et al*
——. *See* NEWMAN SP, PELLOW PGD, *et al*
——. *See* PAVIA D, AGNEW JE, *et al*
——. *See* PAVIA D, BATEMAN JRM, *et al*
——. *See* SPITERI MA, COOK D, *et al*
——. *See* SPITERI MA, PAVIA D, *et al*
——. *See* TAYLOR RG, AGNEW JE, *et al*
——. *See* TAYLOR RG, PAVIA D, *et al*
——. *See* TAYLOR RG, WOODMAN G, *et al*
——. *See* WINTONIUK DM, WOODMAN G, *et al*
——. *See* WOODMAN G, NEWMAN SP, *et al*
CLAY MM, PAVIA D, CLARKE SW: Effect of aerosol particle size on bronchodilatation with nebulised terbutaline in asthmatic subjects, 364
——, ——, ——: Nebulised aerosols (P), 248
CLEMENT P. *See* MANN JS, ROBINSON C, *et al*
CLIFFORD RD, HOLGATE ST: Prevalence of bronchial reactivity to inhaled methacholine in New Zealand children *(Letter)*, 705
——, ——, RADFORD M: The symptoms of bronchial hyperresponsiveness in schoolchildren (P), 735
——, PUGSLEY A, RADFORD M, HOLGATE ST: Respiratory symptoms, atopy and non-specific bronchial responsiveness in children with one asthmatic parent (P), 226
COAKLEY J. *See* LUKSZA AR, SMITH P, *et al*
Coalworkers, central lymph node changes and progressive massive fibrosis in, 531
COCHRANE GM. *See* HORN CP, HILL P, *et al*
——. *See* O'DRISCOLL BRC, KING M, *et al*
COCKROFT A. *See* SEAL RME, COCKCROFT A, *et al*
COE CI, JOYCE H, WATSON A, PRIDE NB: Frequency dependence of respiratory resistance in smokers (P), 242
Coeliac disease, lung cavities as complication of (P), 237
Coffee process workers, respiratory symptoms in, relationship to bronchial hyperresponsiveness, atopy and sensitization to green coffee bean (P), 708
COFFEY M. *See* MCNICHOLAS WT, COFFEY M, *et al*
COHEN RD. *See* LIU FL-W, COHEN RD, *et al*
Cold air hyperventilation, absence of refractory period or cumulative effect with (P), 238
COLE PJ. *See* BARKER A, RUTMAN A, *et al*
——. *See* CURRIE DC, AFFORD SA, *et al*
——. *See* CURRIE DC, NEEDHAM S, *et al*
——. *See* CURRIE DC, PAVIA D, *et al*
——. *See* GARBETT ND, CURRIE DC, *et al*
——. *See* GREENSTONE MA, CURRIE DC, *et al*
——. *See* GREENSTONE MA, NEWMAN-TAYLOR AJ, *et al*
——. *See* MUNRO CS, CAMPBELL DA, *et al*

——. *See* PAVIA D, AGNEW JE, *et al*
——. *See* STANLEY PJ, WILSON R, *et al*
——. *See* STEINFORT C, WILSON R, *et al*
——. *See* SYKES DA, WILSON R, *et al*
——. *See* WARRENS AN, BARNES PJ, *et al*
——. *See* WILSON R, PITT T, *et al*
——. *See* WILSON R, RUTMAN A, *et al*
——. *See* WILSON R, SYKES DA, *et al*
COLEBATCH HJH. *See* GREAVES IA, COLEBATCH HJH
Collagen concentration, biosynthesis and degradation in idiopathic pulmonary fibrosis, 355
in lung *(Review article)*, 418
Collagenase and fibronectin in bronchoalveolar lavage fluid from patients with sarcoidosis (P), 230
inhibitory activity and tissue inhibitor of metalloproteinases in lung secretions in chronic obstructive bronchitis, effect of corticosteroid treatment, 740
COLLINS F. *See* BENFIELD G, CULLEN M, *et al*
COLLINS JV. *See* HANSON PJV, COLLINS JV
——. *See* MITCHELL DM, GILDEH P, *et al*
——. *See* WARDLAW AJ, DUNNETTE S, *et al*
Colophony, unheated, occupational asthma due to (P), 708
Complement receptors (CR1 and CR3) in human neutrophils, comparative activities of leukotriene B_4 and B_5 in enhancement of (P), 734
Computed tomography, estimates of regional gas and tissue volume of lung in supine subjects with chronic airflow limitation or fibrosing alveolitis based on, 932
tomography in estimation of regional gas and tissue volumes of lung in supine man, 620
tomography, narrow section, in diffuse lung disease (P), 717
tomography, quantitative scan, and CO transfer for estimation of size of distal airspaces defining emphysema in smokers (P), 717
tomography scans, preoperative, of thorax, abdomen and head, prognosis after surgery for lung cancer with and without (P), 229
tomography, value in selection for surgery in bullous lung disease, 855
CONNAUGHTON JJ, MACNEE W, RHIND GB, HAYHURST MD, MUIR AL, FLENLEY DC: Rest and exercise pulmonary haemodynamics and right ventricular ejection fraction after oral almitrine in chronic bronchitis (P), 224
——. *See also* MORGAN AD, CONNAUGHTON JJ, *et al*
CONNELLAN SJ, ROCCHICCIOLI K, PICKERING CAC: Assessment of symptoms, airway calibre and histamine reactivity in asthmatics following blind food challenge (P), 240
CONNOLLY CE. *See* STEVENS FM, CONNOLLY CE, *et al*
CONNOLLY CK: Absence of refractoriness in asthmatic subjects after exercise with warm, humid inspirate *(Letter)*, 415
——, FARR B, HARRISON BDW (for BTS RESEARCH COMMITTEE): Radiological clearing after pneumonia (P), 731
COOK D. *See* SPITERI MA, COOK D, *et al*
COOKE NJ. *See* JOHNSON CE, BELFIELD PW, *et al*
——. *See* SIMPSON FG, ARNOLD AG, *et al*
——. *See* SIMPSON FG, MORGAN M, *et al*
——. *See* SIMPSON FG, MORRISON JFJ, *et al*
COOKSON WOCM. *See* HIGGINS RM, COOKSON WOCM, *et al*
——. *See* SHALE DJ, WISEMAN MS, *et al*
COOPER BG. *See* CORRIS PA, COOPER BG, *et al*
——. *See* VEALE D, COOPER BG, *et al*
COOPER CB, WATERHOUSE JC, NICHOLL JP, SUGGETT AJ, HOWARD P: Survival of patients with hypoxic cor pulmonale given domiciliary oxygen therapy (P), 235
Cor pulmonale, hypoxic, domiciliary oxygen therapy in, survival after (P), 235
CORFIELD D. *See* BURNEY PGJ, BRITTON JR, *et al*
CORMICK W, OLSON LG, HENSLEY MJ, SAUNDERS NA: Nocturnal hypoxaemia and quality of sleep in patients with chronic obstructive lung disease, 846
CORMIER Y, BÉLANGER J, TARDIF A, LEBLANC P, LAVIOLETTE M: Relationships between radiographic change, pulmonary function, and bronchoalveolar lavage fluid lymphocytes in farmer's lung disease, 28
——. *See also* LECOURS R, LAVIOLETTE M, *et al*
Coronary artery surgery, revisional, use of lateral thoracotomy to avoid injury to patent anterior grafts in, 692
CORRADO OJ, GOMEZ E, BALDWIN DL, DAVIES RJ: The effect of nedocromil sodium on nasal allergen (P), 246
——, GOULD CAL, KASSAB JY, DAVIES RJ: Nasal response of rhinitic and non-rhinitic subjects to histamine and methacholine: a comparative study, 863
Corrections, 223, 496
CORRIN B. *See* WESTERMANN CJJ, OOSTVEEN ACM, *et al*
CORRIS PA, COOPER BG, KELLY CA, GIBSON GJ: Breathlessness after surgery for carcinoma of the bronchus (P), 230
——, KERTES PJ, JENNINGS K, MORRITT GN, NEVILLE E, GIBSON GJ: Detection of occult cardiac invasion by two dimensional echocardiography in patients with bronchial carcinoma, 138
——. *See also* KELLY CA, CORRIS PA, *et al*
Corticosteroid aerosol treatments, high dose, for chronic asthma, comparison of beclomethasome dipropionate (1500 μg/day) and budesonide (1600 μg/day), 869
responsiveness and physiological emphysema in chronic airways obstruction (P), 723
treatment, effect on elastase inhibitors of sputum sol phase (α_1 proteinase inhibitor, antileucoprotease, and α_2 macroglobulin), 442
treatment, effect on tissue inhibitor of metalloproteinases and collagenase inhibitory activity in lung secretions in chronic obstructive bronchitis, 740
treatment in pulmonary sarcoidosis, monitoring of, evaluation of serial lavage lymphocyte counts, serum angiotensin converting enzyme measurements, and gallium-67 scans for, 903
treatment of sarcoidosis, tuberculous pleural effusion occurring during, case of, 651
treatment, rate of improvement of lung function in sarcoidosis during, 473
trials in chronic airflow obstruction, placebo responses in (P), 723
Corticosteroids in chronic airflow obstruction, comparison of PEF and spirometric response to (P), 234
COSTABEL U, BROSS KJ, ANDREESEN R, MATTHYS H: HLA-DR antigens on human macrophages from bronchoalveolar lavage fluid, 261
COTES JE. *See* CHINN DJ, NARUSE Y, *et al*
——. *See* POSNER V, COTES JE
COTTER FE. *See* WEDZICHA JA, COTTER FE, *et al*
Cough induced by citric acid, effects of pholcodine and salbutamol in normal subjects, 74
COULSHED N. *See* GAUTAM PC, COULSHED N, *et al*
COURIEL J. *See* MACFARLANE P, MILLER V, *et al*
COUTTS I. *See* WHITE RJ, COUTTS I, *et al*
COWELL TK. *See* TREACHER DF, COWELL TK, *et al*
Coxiella burnetii infection (Q fever), person to person transmission within family, 974
CRICHTON NJ. *See* RUSSELL NJ, CRICHTON NJ, *et al*
CROCKER J. *See* BURNETT D, CROCKER J, *et al*
CROMPTON GK, GRANT IWB, CHAPMAN BJ, THOMSON SA, MCDONALD CF: Edinburgh emergency admission service: report on 15 years' experience (P), 232
——. *See also* CAPEWELL SJ, WEBB JN, *et al*
——. *See also* DOUGLAS JG, MIDDLETON WG, *et al*
——. *See also* HIGGINS B, GREENING AP, *et al*
CROMWELL O. *See* BUCHANAN DR, CROMWELL O, *et al*
CROOK SJ. *See* SHEINMAN BD, DEVALIA JL, *et al*
CROSS CE. *See* LINDSEY DC, CHIH-HSIUNG W, *et al*
CROSSLEY J, BRITTON JR, TATTERSFIELD AE: Investigation of the mechanism of action of phenylephrine and methoxamine in asthmatic airways (P), 718
CROUGHAN MJ. *See* MCLEOD DT, CROUGHAN MJ, *et al*
CROWNE E. *See* O'HICKEY S, CROWNE E, *et al*
Cryoanalgesia, role in control of postthoracotomy pain (P), 233
Cuirass respirators, external negative pressure ventilation using, rib-

cage and abdominal motion during (P), 710
CULLEN M. *See* BENFIELD G, CULLEN M, *et al*
CUNDELL D. *See* BLAINEY AD, OLLIER S, *et al*
CUNNINGHAM D. *See* DORWARD AJ, BANHAM SW, *et al*
CURLING M. *See* BLAINEY AD, CURLING M, *et al*
CURRIE DC, AFFORD SA, BURNETT D, STOCKLEY RA, COLE PJ: A more sensitive method for quantitation of elastolytic activity in purulent sputum (P), 729
——, NEEDHAM S, PETERS AM, COLE PJ, LAVENDER JP: ^{111}Indium labelled neutrophils migrate to the lungs in bronchiectasis (P), 256
——, PAVIA D, AGNEW JE, LOPEZ-VIDRIERO MT, DIAMOND PD, COLE PJ, CLARKE SW: Tracheobronchial clearance in bronchiectasis (P), 255
——. *See also* GARBETT ND, CURRIE DC, *et al*
——. *See also* GREENSTONE MA, CURRIE DC, *et al*
——. *See also* PAVIA D, AGNEW JE, *et al*
——. *See also* SYKES DA, WILSON R, *et al*
——. *See also* WILSON R, SYKES DA, *et al*
Curschmann, Heinrich (1846–1910), Curschmann spirals and Charcot-Leyden crystals in asthmatic sputum *(Historical review)*, 503
CURULL V. *See* MORELL F, CURULL V, *et al*
CUSS FMC. *See* PALMER JBD, CUSS FMC, *et al*
Cyanosis, central, in patient with rheumatic heart disease, unusual cause of, 333
Cyclosporin treatment of fibrosing alveolitis (P), 715
Cyprus, mesothelioma in, role of tremolite in (P), 250
Cyst, bronchogenic, diagnosis and treatment, using transbronchial needle aspiration, of case of, 326
Cystic fibrosis, airflow obstruction in adults with, prednisolone in treatment of, 34
fibrosis, bacterial growth in sputum and contamination free endobronchial samples in patients with, conformity of, 641
fibrosis, distal intestinal obstuction syndrome in, treatment of (P), 732
fibrosis, health care of adult patients in Wessex—consultant's view (P), 236
fibrosis, health care of adult patients in Wessex—patient's view (P), 236
fibrosis, lung abscess in, case of, 221
fibrosis, lung function in, effect of postural drainage with forced expiration technique (P), 236
fibrosis, meconium ileus equivalent in, oral gastrograffin in treatment of (P), 733
fibrosis, oral high frequency oscillation as adjunct to physiotherapy in (P), 235
fibrosis, pregnancy in (P), 732
fibrosis, positive expiratory pressure as adjunct to chest physiotherapy in treatment of, evaluation of, 951
fibrosis, response to salbutamol related to recovery from acute exacerbations of pulmonary infection in adults with (P), 732
fibrosis, venous access in, use of totally implantable system for (P), 732
Cytomegalovirus pneumonitis after high dose total body irradiation in bone marrow transplant recipients (P), 730
pneumonitis, alpha interferon in, local production of (P), 730
pneumonitis, rapid diagnosis by bronchoalveolar lavage (P), 234
Cytotoxic agents, activity in human lung cancer xenografts, effect of interferon (P), 233
agents, lung permeability in patients with haematological malignancies treated with (P), 227

D

DA COSTA P. *See* BOWLER S, WOODSTOCK A, *et al*
DALLY M. *See* ASSOUFI BK, DALLY M, *et al*
DALTON N. *See* BELCHER NG, MURDOCH R, *et al*
DARBYSHIRE JH. *See* DAVIDSON AG, FAYERS PM, *et al*
DARROW D. *See* MAY JJ, STALLONES L, *et al*
DAVIDSON AC, HARRISON NK, GEDDES DM: Treatment of distal intestinal obstruction syndrome in patients with cystic fibrosis (P), 732
——, JONES BJM, MASKELL G, GEDDES DM, HATTFIELD ARW: Oesophageal intubation for broncho-oesophageal fistula—how effective is it? (P), 712
——. *See also* LEACH R, GEORGE RJD, *et al*
DAVIDSON J. *See* SUTTON PP, GEMMELL HG, *et al*
DAVIDSON TI. *See* KAPLAN J, DAVIDSON TI
——. *See* STEAD RJ, DUNCAN FR, *et al*
DAVIES BH. *See* EBDEN P, JENKINS A, *et al*
——. *See* JONES KP, DAVIES BH
DAVIES JA. *See* JOHNSON CE, BELFIELD PW, *et al*
DAVIES RJ. *See* BENNETT J, BAXTER P, *et al*
——. *See* BLAINEY AD, OLLIER S, *et al*
——. *See* BLAINEY AD, TOPPING MD, *et al*
——. *See* CORRADO OJ, GOMEZ E, *et al*
——. *See* CORRADO OJ, GOULD CAL, *et al*
——. *See* OSMAN J, DAVIES RJ
——. *See* SHEINMAN BD, DEVALIA JL, *et al*
DAVIES S. *See* DURHAM SR, DAVIES S, *et al*
DAVIS GS. *See* CALHOUN WJ, CHRISTMAN JW, *et al*
DAVIS JMG, GYLSETH B, MORGAN A: Assessment of mineral fibres from human lung tissue *(Review article)*, 167
DAVIS PB: Bronchiectasis and oligospermia: two families *(Letter)*, 80
DAVIS S. *See* JOHNSON CE, BELFIELD PW, *et al*
DAVISON AG, FAYERS PM, NEWMAN-TAYLOR AJ, VENABLES KM, DARBYSHIRE JH, PICKERING CAC, HOLDEN H, SMITH NJ, MASON H, SCOTT M: Cadmium inhalation and emphysema (P), 714
——, ——, NUNN AJ, VENABLES KM, NEWMAN-TAYLOR AJ: Number of patients required in lung function studies, 830
——, LEWIS P, NEWMAN-TAYLOR AJ: Validation of smoking histories in a study of occupational lung disease (P), 252
——. *See also* AGIUS RM, DAVISON AG, *et al*
——. *See also* MILBURN HJ, STIRK PR, *et al*
DENCH M. *See* MOGHISSI K, JESSOP T, *et al*
DENISON DM, MORGAN MDL, MILLAR AB: Estimation of regional gas and tissue volumes of the lung in supine man using computed tomography, 620
——. *See also* ASSOURI BK, DALLY M, *et al*
——. *See also* BUSH A, DENISON DM
——. *See also* GOLDMAN JM, ROSE LS, *et al*
——. *See also* GOLDMAN JM, WILLIAMS SJ, *et al*
——. *See also* MILLAR AB, FROMSON B, *et al*
——. *See also* MORGAN MDL, DENISON DM, *et al*
DERNEVIK L: Exogenous particles in lymph nodes in patients with shrinking pleuritis with atelectasis *(Letter)*, 655
Desmoids, intrathoracic, 2 cases of, 894
DEVALIA JL. *See* SHEINMAN BD, DEVALIA JL, *et al*
DIAMOND PD. *See* CURRIE DC, PAVIA D, *et al*
Diaphragm dysfunction associated with brainstem pathology (P), 710
weakness, new symptom revealed by swimming (P), 244
DICKINSON KEJ. *See* WINTER RJD, RUDD RM, *et al*
DICKSON CR. *See* RICHARDS R, RENWICK AG, *et al*
Diethylene triamine pentacetate (pentacetic acid). *See* DTPA
Digital ischaemia, carcinoma of lung presenting with, case of, 573
DIJKMAN JH. *See* MORRISON HM, KRAMPS JA, *et al*
——. *See* STOCKLEY RA, MORRISON HM, *et al*
——. *See* STOLK J, KRAMPS JA, *et al*
DIMOND AH. *See* MITCHELL DM, GILDEH P, *et al*
DIXON AK. *See* MOORE NR, PHILLIPS MS, *et al*
DIXON CMS, FULLER RW, BARNES PJ: The action of nedocromil sodium on sulphur dioxide induced bronchoconstriction (P), 246
——. *See also* IND PW, DIXON CMS, *et al*
DOLLERY CT. *See* IND PW, BARNES PJ, *et al*
DONNELLY RJ. *See* RASHID A, SENDI A, *et al*
DORE C. *See* NUNN JF, MILLEDGE JS, *et al*
DORWARD AJ, BANHAM SW, HUTCHEON AW, AHMEDZAI S, CUNNINGHAM D, GREGOR A, SOUKOP M, STACK BHR, MACKAY NSD, KAYE SB: Short

duration combination chemotherapy in the treatment of small cell lung cancer, 688
DOUGLAS JG, CALDER MA, CHOO-KANG YFJ, LEITCH AG: *Myobacterium gordonae*: a new pathogen?, 152
——, MIDDLETON WG, GADDIE J, PETRIE GR, CHOO-KANG YFJ, PRESCOTT RJ, CROMPTON GK: Sarcoidosis: a disorder commoner in non-smokers?, 787
——. *See also* MANN JS, DOUGLAS JG, *et al*
DOUGLAS NJ. *See* CATTERALL JR, RHIND GB, *et al*
——. *See* MORGAN AD, CONNAUGHTON JJ, *et al*
DOWNAR E. *See* LIU FL-W, COHEN RD, *et al*
DOWNING I, SCOTT W, FLENLEY DC, GREENING AP: Patients with cryptogenic fibrosing alveolitis have an increased bronchoalveolar elastase burden (P), 728
DOYLE T. *See* YEO H, DOYLE T, *et al*
Drug resistance in *Mycobacterium tuberculosis*, survey in native and immigrant groups over 25 years in Blackburn, 946
DRURY JK. *See* WINTER JH, MCCARTNEY AC, *et al*
DTPA clearance slower with ^{113}indium than with ^{99m}Tc as radiolabel (P), 227
^{99m}Tc labelled, clearance of, and sodium cromoglycate pretreatment in "fog" induced bronchoconstriction (P), 227
^{99m}Tc labelled, pulmonary clearance of, changes during haemodialysis, 381
DU BOIS RM. *See* CAMPBELL DA, DU BOIS RM, *et al*
——. *See* CAMPBELL DA, POULTER LW, *et al*
——. *See* LEVER AML, MILBURN HJ, *et al*
——. *See* MILBURN HJ, GROB JP, *et al*
——. *See* MILBURN HJ, STIRK PR, *et al*
——. *See* MUNRO CS, CAMPBELL DA, *et al*
——. *See* POULTER LW, CAMPBELL DA, *et al*
DUNCAN FR. *See* STEAD RJ, DUNCAN FR, *et al*
DUNNETTE S. *See* WARDLAW AJ, DUNNETTE S, *et al*
DURHAM SR, DAVIES S, VENABLES KM, GRANEEK BJ, NEWMAN-TAYLOR AJ: Occupational asthma in a bathtub resurfacer due to pentamethylene diethylene triamine (P), 251
——. *See also* GRANEEK BJ, DURHAM SR, *et al*
DUSSEK JE. *See* ASHRAF J, DUSSEK JE, *et al*
Dust, organic, potentially tissue damaging enzymes in (P), 250
toxic syndrome, organic, associated with silo unloading, 919
toxic syndrome, organic, bronchoalveolar lavage in, 924
Dyspnoea during and after exercise, perception of (P), 725
Dystrophy, myotonic, and non-myotonic respiratory muscle weakness, breathing during sleep in (P), 710

E

EBDEN P, JENKINS A, HOUSTON G, DAVIES BH: Comparison of two high dose corticosteroid aerosol treatments, beclomethasone dipropionate (1500 μg/day) and budesonide (1600 μg/day), for chronic asthma, 869
——. *See* GARRETT H, VATHENEN S, *et al*
Echocardiography, two dimensional, in detection of occult cardiac invasion in bronchial carcinoma, 138
Eczema and asthma, house dust mite antigens sensitizing children with, differences in source of (P), 707
EDELSON JD. *See* LIU FL-W, COHEN RD, *et al*
Edinburgh emergency admission service for asthma, 15 years' experience (P), 232
Editorials:
Bone marrow transplantation and the lung, 497
Byssinosis: a diagnosis or a symptom?, 1
Hypercapnia during oxygen therapy in airways obstruction: a reappraisal, 897
Immunoglobulins in the lung, 337
Improving the chances of successful research funding, 817
Industrial benefits and respiratory diseases, 257; *Erratum*, 496
Mineral fibres and mesothelioma, 161
Observations on the pathogenesis of chronic airflow obstruction in smokers: implications for the detection of "early" lung disease, 81
Ocular toxicity from ethambutol (E), 737
Regional thoracic medical centres, 417
Role of inflammation in the hyperreactivity of the airways in asthma, 657
The small clinical trial: is there a better way?, 822
EDWARDS C. *See* BENFIELD G, CULLEN M, *et al*
EDWARDS JH, TROTMAN DM: Potentially tissue damaging enzymes in organic dust (P), 250
EDWARDS RHT. *See* EFTHIMIOU J, FLEMING J, *et al*
EFTHIMIOU J, FLEMING J, EDWARDS RHT, SPIRO SG: Effect of aminophylline on fatigue of the sternomastoid muscle in man, 122
EGGER D. *See* GAILLARD RC, BACHMAN M, *et al*
EISER NM. *See* ARM JP, SETHI TJ, *et al*
EKLUND A, BLASCHKE E: Relationship between changed alveolar-capillary permeability and angiotensin converting enzyme activity in serum in sarcoidosis, 629
Elastase and antileucoprotease activity in polymorphonuclear leucocytes, *in vitro* effect of mercapto-ethanesulphonate, 840
bronchoalveolar, increased burden of, in cryptogenic fibrosing alveolitis (P), 728
inhibitors of sputum sol phase (α_1 proteinase inhibitor, antileucoprotease, and α_2 macroglobulin), variability, relationship to neutrophil elastase inhibition, and effect of corticosteroid treatment, 442
inhibitors. *See also* Proteinase inhibitors
pancreatic. *See* Pancreatic elastase
Elastin and lung *(Review article)*, 577
Elastolytic activity in purulent sputum, quantitation of, more sensitive method for (P), 729
ELBERS JRJ. *See* AUMANN JLTM, BOSCH JMM VAN DEN, *et al*
Elderly, lung function in *(Letters)*, 335
ELLIOT JA. *See* ROBERTS JA, ELLIOT JA, *et al*
ELLIS DA, CAPEWELL SJ: Pulmonary veno-occlusive disease after chemotherapy *(Letter)*, 415
EMANUEL MB: Comparative trial of two non-sedative H_1 antihistamines, terfenadine and astemizole, for hay fever *(Letters)*, 654, 976
EMERSON PA. *See* RUSSELL NJ, CRICHTON NJ, *et al*
EMMANOUEL A. *See* BOUROS DE, GASIS A, *et al*
EMPEY DW. *See* WALLIS PJW, APPS MCP, *et al*
——. *See* WEDZICHA JA, COTTER FE, *et al*
Emphysema and cadmium inhalation (P), 714
in byssinosis due to cigarette smoking, physiological evidence, 6
in smokers, size of distal airspaces defining, estimation by quantitative CT scan and CO transfer (P), 717
microscopic, assessment of, and new technique for measuring alveolar surface (P), 716
physiological, and corticosteroid responsiveness in chronic airways obstruction (P), 723
pulmonary, extent as assessed by CT scan in life, not related to pulmonary haemodynamics during rest or exercise (P), 726
Emphysematous lung, bullous, intracavity drainage of (P), 233
Endobronchial samples, contamination free, and sputum from patients with cystic fibrosis, conformity of bacterial growth in, 641
ENGLISH TAH. *See* HAKIM M, STOVIN PGI, *et al*
Enzymes, potentially tissue damaging, in organic dust (P), 250
Eosinophilic pleuropneumonia, asthma, and pericarditis, combined, without vasculitis, 2 cases of, 571
pneumonia, chronic, long term follow up (P), 715
Eosinophils and mast cells in bronchoalveolar lavage in mild asthma, relationship to bronchial hyperreactivity (P), 733
counts in peripheral blood and bronchial reactivity (P), 241
human, stimulated by calcium ionophore (A23187) and unopsonised zymosan, generation of prostaglandins, thromboxane and leukotriene C_4 by (P), 733
Epidermal growth factor receptor, monoclonal antibodies against (P), 238

EPSTEIN EJ. *See* GAUTAM PC, COULSHED N, *et al*
ERSHLER WB. *See* CALHOUN WJ, CHRISTMAN JW, *et al*
Erythrocytosis, sleep and oxygen saturation in (P), 711
ESSEX E. *See* HORN CP, HILL P, *et al*
Essex farmworkers, specific IgE to storage mites in (P), 251
Ethambutol and rifampicin, 9 months' treatment with, in *Mycobacterium kansasii* pulmonary infection, BTS study (P), 709
ocular toxicity due to (E), 737
Ethanol and cigarette smoking, contribution to pulmonary dysfunction in chronic alcoholics, 197
EVANS TW, WATERHOUSE JC, CARTER A, NICHOLL JF, HOWARD P: Short burst oxygen treatment for breathlessness in chronic obstructive airways disease, 611
EWAN PW. *See* MORICE AH, SNAPE C, *et al*
Exercise and allergen, bronchoconstriction in asthma induced by, effe. of inhaled piriprost (U-60, 257), 746
asthma induced by, and endogenous opioids, 350
asthma induced by, effect of H_1-receptor blockade (P), 735
asthma induced by, hypertonicity as initiating stimulus for (P), 239
asthma induced by, lung function in patients with, influence of α adrenoceptor agonists, 552
asthma induced by, platelet activation during, effect of prophylaxis with cromoglycate and salbutamol, 290
asthma induced by, refractory period in, circulating mediator and catecholamine concentrations during (P), 718
dyspnoea during and after, perception of (P), 725
in asthma with warm, humid inspirate, absence of refractoriness after *(Letters)*, 415
in COAD patients, supplementary oxygen during, dose response study (P), 725
in normal subjects and in exercise induced asthma, circulating adrenaline concentrations during (P), 718
portable oxygen therapy via transtracheal catheter during (P), 245
refractoriness in asthma induced by, airway response to methacholine during, 667
Expiratory flow, peak, knowledge of, influence on self assessment of asthma, evidence from studies with coded peak flow meter, 671
flow, peak, serial measurements of, value in assessment of treatment response in chronic airflow limitation, 606
flow, peak, serial records of, to be plotted on logarithmic scale? (P), 233
flow rates, peak, variability in chronic bronchitis, interpretation of, 771
pressure, positive, as adjunct to chest physiotherapy in treatment of cystic fibrosis, evaluation of, 951
Eye. *See* Ocular

F

FAIRFAX AJ, MCNABB WR, SPIRO SG: Chylothorax: a review of 18 cases, 880
FALLON RJ. *See* WINTER JH, MCCARTNEY AC, *et al*
FAREBROTHER MTB. *See* HELLER RF, HAYWARD DM, *et al*
Farmers and farmworkers, lung function of, in England and Wales, 117
Farmer's lung after *Mycoplasma pneumoniae* infection, 2 cases of, 68
lung disease, relationships between radiographic changes, lung function, and bronchoalveolar lavage fluid lymphoctyes in, 28
Farmworkers in Essex, specific IgE to storage mites in (P), 251
FARR B. *See* CONNOLLY CK, FARR B, *et al*
FAYERS PM. *See* DAVISON AG, FAYERS PM, *et al*
FELDMAN C. *See* LEVY H, KALLENBACH JM, *et al*
FELMINGHAM D. *See* HIND CRK, FLINT KC, *et al*
FENWICK J. *See* REA HH, SCRAGG R, *et al*
FERGUSSON RJ, ANDERSON LE, SMYTH JF: Effect of interferon on the activity of cytotoxic agents in human lung cancer xenografts (P), 233
——, CARMICHAEL J, SMYTH JF: Human tumour xenografts growing in immunodeficient mice: a useful model for assessing chemotherapeutic agents in bronchial carcinoma, 376
FERRARI R. *See* ANAND IS, HARRIS E, *et al*
FESTEN J. *See* HENGSTUM MV, FESTEN J, *et al*
Fibreoptic bronchoscopy, effect on airway physiology (P), 712
bronchoscopy, flexible, in rapid diagnosis of sputum-negative miliary tuberculosis, 681
bronchoscopy in differentiation of pulmonary infection and Kaposi's sarcoma in AIDS (P), 715
Fibronectin and collagenase in bronchoalveolar lavage fluid from patients with sarcoidosis (P), 230
Fibrosis, cystic. *See* Cystic fibrosis
massive, progressive, and central lymph node changes in coalworkers, 531
mediastinal, idiopathic, surgical treatment of 5 cases, 210
pleuropulmonary, induced by bromocriptine, case of, 328
pulmonary, anatomical lung shunting in, 208
pulmonary, idiopathic, collagen concentration, biosynthesis and degradation in, 355
Fibrous dysplasia, symptomatic, of right first rib excised via posterolateral thoractomy, case of, 575
FIELD J, LANE IF: Carcinoma of the lung presenting with digital ischaemia, 573
FILUK RB, WARREN PW: Bronchoalveolar lavage in Waldenström's macroglobulinaemia with pulmonary infiltrates, 409
FINCH RG. *See* WOODHEAD MA, MACFARLANE JT, *et al*
Finger clubbing, survey of patient awareness (P), 237
FINN R. *See* CHURCH SE, FINN R, *et al*
FISHMAN EK. *See* SCHWARTZ AR, FISHMAN EK, *et al*
Fistula, broncho-oesophageal; oesophageal intubation for (P), 712
bronchopleural, after pneumonectomy *(Letter)*, 896
tracheo-oesophageal, recurrence 32 years after primary repair, case of, 76
FITZGERALD MX. *See* MCNICHOLAS WT, COFFEY M, *et al*
——. *See* NOLAN MT, FITZGERALD MX
——. *See* O'CONNOR CM, POWER C, *et al*
FITZPATRICK M, HIGENBOTTAM TW: Sodium cromoglycate pretreatment and clearance of ^{99m}Tc-DTPA in "fog" induced bronchoconstriction (P), 227
——. *See also* JONES DK, FITZPATRICK M, *et al*
FLANNERY EM. *See* SEARS MR, JONES DT, *et al*
FLEMING J. *See* EFTHIMIOU J, FLEMING J, *et al*
FLENLEY DC. *See* BIERNACKI W, WHYTE KF, *et al*
——. *See* CONNAUGHTON JJ, MACNEE W, *et al*
——. *See* DOWNING I, SCOTT W, *et al*
——. *See* FRANCE AJ, STEWART IC, *et al*
——. *See* GOULD GA, FORSYTH IS, *et al*
——. *See* GOULD GA, MCLEAN A, *et al*
——. *See* LAMB D, MACLEAN A, *et al*
——. *See* MORGAN AD, CONNAUGHTON JJ, *et al*
——. *See* RHIND GB, PRINCE KL, *et al*
FLINT KC, LEUNG KBP, HUDSPITH BN, BROSTOFF J, PEARCE FL, GERAINT-JAMES D, JOHNSON N MCI: Bronchoalveolar mast cells in sarcoidosis: increased numbers and accentuation of mediator release, 94
——. *See also* HIND CRK, FLINT KC, *et al*
FLOWER CDR. *See* MOORE NR, PHILLIPS MS, *et al*
Food antibodies in asthma (P), 735
challenge, blind, in asthma, assessment of symptoms, airway calibre and histamine reactivity following (P), 240
Forskolin, potentiating effect on isoprenaline in isolated trachea (P), 242
FORSYTH IS. *See* GOULD GA, FORSYTH IS, *et al*
FOSTER S. *See* SHAW RJ, ROWLAND-HILL CA, *et al*
FOX B: Henry Hyde Salter (1827–71): a biographical sketch *(Letter)*, 416
FRANCE AJ, MCLEOD DT, CALDER MA, SEATON A: The clinical and radiological features of *Mycobacterium malmoense* infections in Scotland (P), 709
——, STEWART IC, WATHEN CG, WIGHTMAN AJ, FLENLEY DC: Gallium

67 lung scans in pulmonary tuberculosis (P), 228
——. *See also* SHAUNAK S, FRANCE AJ, *et al*
FRANCIS RA. *See* GEORGE RJD, PAVIA D, *et al*
——. *See* TAYLOR RG, AGNEW JE, *et al*
FREEMAN JG. *See* LINDSAY DC, FREEMAN JG, *et al*
FREEMAN R, GOULD FK: Antibiotic prophylaxis in cardiothoracic surgery in the United Kingdom: current practice *(Letter)*, 816
FRIEND JAR. *See* SUTTON PP, GEMMELL HG, *et al*
FROMSON B. *See* MILLAR AB, FROMSON B, *et al*
FUJIMURA M, SASAKI F, NAKATSUMI Y, TAKAHASHI Y, HIFUMI S, TAGA K, MIFUNE J-I, TANAKA T, MATSUDA T: Effects of a thromboxane synthetase inhibitor (OKY-046) and lipoxygenase inhibitor (AA-861) on bronchial responsiveness to acetylcholine in asthmatic subjects, 955
FULLER J. *See* HIGENBOTTAM TW, FULLER J
FULER RW. *See* DIXON CMS, FULLER RW, *et al*
——. *See* IND PW, DIXON CMS, *et al*

G

GADDIE J. *See* DOUGLAS JG, MIDDLETON WG, *et al*
GAILLARD RC, BACHMAN M, ROCHAT T, EGGER D, HALLER R DE, JUNOD AF: Exercise induced asthma and endogenous opioids, 350
Gallium scanning in small cell lung cancer (P), 229
Gallium-67 lung scans in pulmonary tuberculosis (P), 228
scans, serial lavage lymphocyte counts, and serum angiotensin converting enzyme measurements for monitoring of corticosteroid treatment in pulmonary sarcoidosis, evaluation of, 903
GARBETT ND, CURRIE DC, COLE PJ: Daily purulent sputum production without bronchiectasis (P), 720
GARRETT CPO. *See* GEORGE PJM, GARRETT CPO, *et al*
GARRETT H, BRITTON JR, HANLEY SP, HADFIELD JW, TATTERSFIELD AE: Are drug induced changes in bronchial reactivity and airway calibre interdependent? (P), 239
——, VATHENEN S, HILL RA, EBDEN P, BRITTON JR, TATTERSFIELD AE: A comparison of six and twelve minute walk distance with 100 metre walk times in subjects with chronic bronchitis (P), 245
Gas analysis in lung function laboratories, accuracy of, 133
and tissue volumes of lung, regional, in supine man, estimation with computed tomography, 620
and tissue volumes of lung, regional, in supine subjects with chronic airflow limitation or fibrosing alveolitis, computed tomography based estimates of, 932
diffusion in lungs, effect of airflow limitation (P), 242
exchange abnormalities following oesophageal surgery (P), 230
exchange and ventilation during sleep in interstitial lung disease, 777
GASIS A. *See* BOUROS DE, GASIS A, *et al*
Gastric tube, reversed, oesophagoplasty with, late complications of, 61
Gastrografin, oral, in treatment of meconium ileus equivalent in cystic fibrosis (P), 733
Gastro-oesophageal reflux during sexual intercourse (reflux dyspareunia), 215
reflux in childhood asthma, acid test for *(Letter)*, 160
GAUTAM PC, COULSHED N, EPSTEIN EJ, LLEWELLYN MJ, VARGAS E, TALLIS RC: Preoperative clinical predictors of long term survival in mitral stenosis: analysis of 200 cases followed for up to 27 years after closed mitral valvotomy, 401
GEDDES DM, SPIRO SG, SOUHAMI RH, HARPER P, TOBIAS J: Quality of life during chemotherapy for small cell carcinoma of the lung (P), 719
——. *See also* DAVIDSON AC, HARRISON NK, *et al*
——. *See also* DAVIDSON AC, JONES BJM, *et al*
——. *See also* GEORGE RJD, PAVIA D, *et al*
——. *See also* LEACH R, GEORGE RJD, *et al*
——. *See also* MOORE-GILLON J, GEORGE RJD, *et al*
GEMMELL CG. *See* POLLOK AJ, GEMMELL CG, *et al*
GEMMELL HG. *See* SUTTON PP, GEMMELL HG, *et al*
GEORGE PJM, GARRETT CPO, GOLDSTRAW P, HETZEL MR, RAMSAY AD: Resuscitative laser photoresection of a tracheal tumour before elective surgery, 812
——, ——, HETZEL MR: Is the Nd YAG laser ideal first line treatment for obstructing tracheal tumours? (P), 712
GEORGE RJD, PAVIA D, WOODMAN G, LOPEZ-VIDRIERO MT, FRANCIS RA, AGNEW JE, CLARKE SW, GEDDES DM: Oral high frequency oscillation as an adjunct to physiotherapy in cystic fibrosis (P), 235
——. *See also* LEACH R, GEORGE RJD, *et al*
——. *See also* MOORE-GILLON J, GEORGE RJD, *et al*
GERAINT-JAMES D. *See* FLINT KC, LEUNG KBP, *et al*
GIBBS A. *See* WAGNER JC, POOLEY FD, *et al*
GIBBS C. *See* WHITE RJ, COUTTS I, *et al*
GIBSON GJ. *See* CORRIS PA, COOPER BG, *et al*
——. *See* CORRIS PA, KERTES PJ, *et al*
——. *See* GILMARTIN JJ, VEALE D, *et al*
——. *See* KELLY CA, CORRIS PA, *et al*
——. *See* VEALE D, COOPER BG, *et al*
GIEMBYCZ MA. *See* ROBERTS JA, GIEMBYCZ MA, *et al*
GILBERT J. *See* O'HALLORAN SM, GILBERT J, *et al*
GILDEH P. *See* MITCHELL DM, GILDEH P, *et al*
GILLJAM H, MALMBORG A-S, STRANDVIK B: Conformity of bacterial growth in sputum and contamination free endobronchial samples in patients with cystic fibrosis, 641
GILMARTIN JJ, VEALE D, MURRAY A, ADAMS PC, GIBSON GJ: Cardiac effects of salbutamol given by air driven nebuliser at home, 331
——. *See also* VEALE D, COOPER BG, *et al*
GIRLING DJ. *See* BLEEHEN NM, GIRLING DJ
GLEESON MJ. *See* REES PJ, KING M, *et al*
GLEICH GJ. *See* WARDLAW AJ, DUNNETTE S, *et al*
GLINDMEYER HW. *See* WEILL H, JONES RN, *et al*
GODFREY RC. *See* AGIUS RM, GODFREY RC, *et al*
——. *See* PEACOCK A, BENSON-MITCHELL R, *et al*
Gold miners, South African, relationship between silicosis and rheumatoid arthritis in, 596
GOLDMAN AL. *See* MORRISON DA, GOLDMAN AL
GOLDMAN JM, ROSE LS, MORGAN MDL, DENISON DM: Measurement of abdominal wall compliance in normal subjects and tetraplegic patients, 513
——, ——, WILLIAMS SJ, SILVER JR, DENISON DM: Effect of abdominal binders on breathing in tetraplegic patients, 940
——, WILLIAMS SJ, DENISON DM, SILVER JR: The effect of abdominal binders on breathing in tetraplegic patients (P), 244
——. *See also* SUTEDJA T, APPERLEY JF, *et al*
GOLDSTEIN DS, WILLIAMS MH: Rate of improvement of pulmonary function in sarcoidosis during treatment with corticosteroids, 473
GOLDSTRAW P. *See* GEORGE PJM, GARRETT CPO, *et al*
——. *See* KAY PH, AZARIADES M, *et al*
——. *See* VENN GE, WILLIAMS PR, *et al*
GOMEZ E. *See* CORRADO OJ, GOMEZ E, *et al*
GOMM S. *See* HASLETON PS, GOMM S, *et al*
GORDAN IJ. *See* LUKSZA AR, SMITH P, *et al*
GORDON DJ. *See* TEE RD, GORDON DJ, *et al*
GOULD CAL. *See* CORRADO OJ, GOULD CAL, *et al*
GOULD FK. *See* FREEMAN R, GOULD FK
GOULD G. *See* O'REILLY JF, GOULD G, *et al*
GOULD GA, ASHWORTH M, LEWIS GTR: Are cardiovascular reflexes more commonly impaired in patients with bronchial carcinoma?, 372
——, FORSYTH IS, FLENLEY DC: Comparison of two oxygen conserving nasal prong systems and the effects of nose and mouth breathing, 808
——, MCLEAN A, MACNEE W, HAYHURST MD, REDPATH AT, WARREN PM, BEST JJK, LAMB D, FLENLEY DC: Quantitative CT scan and CO transfer can estimate the size of directly measured distal airspaces which defines emphysema in smokers (P), 717
——. *See also* BIERNACKI W, WHYTE KF, *et al*
GOVAN JR. *See* BANNER NR, HAIGH A, *et al*
——. *See* BANNER NR, LLOYD MH, *et al*

GOVE RJ, ROBERTSON AS, BURGE PS: Physiological emphysema and corticosteroid responsiveness in chronic airways obstruction (P), 723
——, ——, ——: Placebo responses in corticosteroid trials in chronic airflow obstruction (P), 723
——, ——, WIELAND GA, BURGE PS: Comparison of the PEF and spirometric response to corticosteroids in chronic airflow obstruction (P), 234
GRACIA J DE. *See* MORELL F, CURULL V, *et al*
GRACIA X DE. *See* MONSÓ E, VIDAL R, *et al*
GRAHAM GP. *See* SABANATHAN S, GRAHAM GP, *et al*
GRAHAM WGB. *See* CALHOUN WJ, CHRISTMAN JW, *et al*
GRANEEK BJ, DURHAM SR, TOPPING M, TEE RD, HAWKINS R, NEWMAN-TAYLOR AJ: Occupational asthma caused by maleic anhydride: bronchial provocation testing and immunological data (P), 251
——. *See also* DURHAM SR, DAVIES S, *et al*
Granite workers, healthy, raised immunoglobulin concentrations in bronchoalveolar lavage fluid of, 266
GRANT IWB. *See* CROMPTON GK, GRANT IWB, *et al*
Granular cell tumour of bronchus, bronchoscopic and clinical features, with 2 cases, 927
Granulomatosis, Wegener's, tuberculosis of nasopharynx misdiagnosed as, case of, 219
GRAY B, BARNES NC, NYEKO C, MARQUIS A: Changes in transcutaneous oxygen and carbon dioxide in response to histamine bronchial challenge (P), 246
GREAVES IA, COLEBATCH HJH: Observations on the pathogenesis of chronic airflow obstruction in smokers: implications for the detection of "early" lung disease (E), 81
GREEN M. *See* BLAINEY AD, CURLING M, *et al*
——. *See* MIER A, BROPHY C, *et al*
GREEN S. *See* PRENDIVILLE A, GREEN S, *et al*
GREENING AP. *See* DOWNING I, SCOTT W, *et al*
——. *See* HIGGINS B, GREENING AP, *et al*
GREENOUGH A, STOCKS J, NOTHEN U, HELMS P, LOFTRUS J, PRICE JF: Respiratory compliance and functional residual capacity in young children (P), 226
GREENSTONE MA, CURRIE DC, PAVIA D, AGNEW JE, PELLOW PGD, HENDRY WF, CLARKE SW, COLE PJ: Effect of "mucolytic" agents in Young's syndrome (P), 724
——, NEWMAN-TAYLOR AJ, COLE PJ: Bronchiectasis and oligospermia: two families *(Letter)*, 80
——. *See also* LOPEZ-VIDRIERO MT, PAVIA D, *et al*
——. *See also* STANLEY PJ, WILSON R, *et al*
GREGOR A. *See* DORWARD AJ, BANHAM SW, *et al*
GRIFFITHS CG. *See* VEALE D, COOPER BG, *et al*
GRIFFITHS PD. *See* LEVER AML, MILBURN HJ, *et al*
GRIFFITHS RJ. *See* WILKINS EGL, GRIFFITHS RJ, *et al*
GROB JP. *See* MILBURN HJ, GROB JP, *et al*
GROCCOT L. *See* ALLEN MB, GROCCOT L, *et al*
GRUNDY JE. *See* LEVER AML, MILBURN HJ, *et al*
——. *See* MILBURN HJ, GROB JP, *et al*
GRÜNEBERG RN. *See* WILSON APR, TREASURE T, *et al*
GUNNEBERG A. *See* ROBERTS JA, ELLIOT JA, *et al*
GUNNING A. *See* SACKS SH, HARRISON M, *et al*
GYLSETH B. *See* DAVIS JMG, GYLSETH B, *et al*

H

HABIB NA. *See* HERSHMAN MJ, HABIB NA, *et al*
HADFIELD JW, ALLEN J: Tuberculin sensitivity after neonatal BCG (P), 226
——, TATTERSFIELD AE: Domiciliary nebuliser therapy: a double blind dose-response assessment (P), 247
——. *See also* GARRETT H, BRITTON JR, *et al*
Haematological malignancies, lung permeability in patients treated with cytotoxic drugs for (P), 227
Haemodialysis, changes in pulmonary clearance of ^{99m}Tc DTPA during, 381
Haemodynamics, pulmonary, during rest or exercise, not related to extent of pulmonary emphysema as assessed by CT scan in life (P), 726
pulmonary, of yak, cattle, and cross breeds at high altitude, 696
Haemophilus influenzae as cause of community-acquired pneumonia in previously fit adults (P), 228
influenzae, heat stable factor produced by, effect on beating of human cilia *in vitro* (P), 253
influenzae lipopolysaccharide, effect on human respiratory epithelium *in vitro* (P), 728
influenzae pneumonia in hospitalised patients (P), 731
influenzae, potential role in sputum histamine rises in infective lung disease (P), 241
Haemoptysis, massive, as presenting symptom in case of mitral stenosis, 413
Haemorrhage, fatal, from mycotic aneurysms of pulmonary artery, case of, 70
Haemothorax in course of chickenpox, case of, 491
HAIGH A. *See* BANNER NR, HAIGH A, *et al*
Hairdressing salon, occupational asthma in, 42
HAKIM M, STOVIN PGI, ENGLISH TAH, WALLWORK J: Transvenous lung biopsy in the pig, 964
HALLER R DE. *See* GAILLARD RC, BACHMAN M, *et al*
HAMILTON PJ, PEARSON ADJ: Bone marrow transplantation and the lung (E), 497
HANLEY SP. *See* GARRETT H, BRITTON JR, *et al*
HANSFORD M. *See* CAMPBELL IA, HANSFORD M, *et al*
HANSON PJV, COLLINS JV: Pulmonary infection or Kaposi sarcoma? A diagnostic role for fibreoptic bronchoscopy in the acquired immunodeficiency syndrome (P), 715
HAPONIK EF. *See* HERNANDEZ OG, HAPONIK EF, *et al*
HARGREAVE FE. *See* RAMSDALE EH, MORRIS MM, *et al*
HARPER P. *See* GEDDES DM, SPIRO SG, *et al*
HARRIS E. *See* ANAND IS, HARRIS E, *et al*
HARRIS P. *See* ANAND IS, HARRIS E, *et al*
HARRISON BDW, STOKES TC, HART GJ, VAUGHAN DA, ALI NJ, ROBINSON AA: Effect of intravenous hydrocortisone in addition to oral prednisolone in the treatment of patients admitted to hospital with severe asthma but not in ventilatory failure (P), 248
——. *See also* CONNOLLY CK, FARR B, *et al*
HARRISON JM. *See* ORMEROD LP, HARRISON JM, *et al*
HARRISON M. *See* SACKS SH, HARRISON M, *et al*
HARRISON NK, KNIGHT RK: Tuberculosis of the nasopharynx misdiagnosed as Wegener's granulomatosis, 219
——. *See also* DAVIDSON AC, HARRISON NK, *et al*
HART GJ. *See* HARRISON BDW, STOKES TC, *et al*
HARVEY JE. *See* ALBAZZAZ MK, HARVEY JE
HASLAM PL. *See* TURNER-WARWICK M, MCALLISTER W, *et al*
HASLETON PS, GOMM S, BLAIR B, THATCHER N: A clinicopathological study of bronchial carcinoids (P), 229
——. *See also* CERNY T, BARNES D, *et al*
HASLETT C, SHEN AS, WORTHEN GS, CHERNIACK RM, HENSON PM: Patterns of ^{111}In-neutrophil traffic in lung injury (P), 232
HATTFIELD ARW. *See* DAVIDSON AC, JONES BJM, *et al*
HAWKINS R. *See* GRANEEK BJ, DURHAM SR, *et al*
——. *See* TEE RD, GORDON DJ, *et al*
Hay fever and asthma, trends in general practice in UK (1976–83), 111
fever, terfenadine and astemizole as non-sedative H_1 antihistamines for, comparative trial of *(Letters)*, 654, 976
HAYHURST MD. *See* CONNAUGHTON JJ, MACNEE W, *et al*
——. *See* GOULD GA, MCLEAN A, *et al*
HAYWARD DM. *See* HELLER RF, HAYWARD DM, *et al*
HEAF D. *See* O'HALLORAN SM, GILBERT J, *et al*
HEALY K. *See* CERNY T, BARNES D, *et al*
HEALY T. *See* CLANCY L, KELLY P, *et al*
——. *See* HOWELL F, O'LAOIDE R, *et al*
HEAP P. *See* CARSWELL F, MUKHERJEE S, *et al*

HEARD JG. *See* MILLER WC, HEARD JG, *et al*
Heart disease, rheumatic, central cyanosis in patient with, unusual cause of, 333
valve. *See* Valve
See also Cardiac
Heart-lung transplantation, distant organ procurement for, single flush preservation technique for (P), 713
HEATH D. *See* WILKINSON M, LANGHORNE CA, *et al*
HEK G. *See* CARSWELL F, HEK, *et al*
HELLER RF, HAYWARD DM, FAREBROTHER MTB: Lung function of farmers in England and Wales, 117
HELMS P. *See* GREENHOUGH A, STOCKS J, *et al*
HENDERSON B. *See* ORPHANIDOU D, HUGHES JMB, *et al*
HENDRICK DJ. *See* KELLY CA, WARD C, *et al*
HENDRY WF. *See* GREENSTONE MA, CURRIE DC, *et al*
——. *See* LOPEZ-VIDRIERO MT, PAVIA D, *et al*
HENGSTUM MV, FESTEN J, BUIJS W, BROEK WVD: Reproducibility of tracheobronchial clearance measured by means of a radioaerosol technique (P), 255
HENRIKSEN L, HJELMS E: Cerebral blood flow during cardiopulmonary bypass in man: effect of arterial filtration, 386
HENSLEY MJ. *See* CORMICK W, OLSON LG, *et al*
HENSON PM. *See* HASLETT C, SHEN AS, *et al*
HERBERT A: Pathogenesis of pleurisy, pleural fibrosis, and mesothelial proliferation, 176
——. *See also* AGIUS RM, GODFREY RC, *et al*
HERBISON GP. *See* SEARS MR, JONES DT, *et al*
HERNANDEZ OG, HAPONIK EF, SUMMER WR: Granular cell tumour of the bronchus: bronchoscopic and clinical features, 927
HERSHMAN MJ, HABIB NA, STEIN R, WOOD CB: Diagnosis of lung cancer by a CA-50 radioimmunoassay inhibition test (I_4^5), 716
HESSEL PA. *See* SLUIS-CREMER GK, HESSEL PA, *et al*
HETZEL MR. *See* GEORGE PJM, GARRETT CPO, *et al*
HEURICH AE. *See* ORENSTEIN M, WEBBER CA, *et al*
HEWITT CJ. *See* SEARS MR, JONES DT, *et al*
HIFUMI S. *See* FUJIMURA M, SASAKI F, *et al*
HIGENBOTTAM TW, FULLER J: Annual asthma treatment outside hospital in the UK 1975–1983 (P), 249
——. *See also* FITZPATRICK M, HIGENBOTTAM TW
——. *See also* JONES DK, CAVAROCCHI N, *et al*
——. *See also* JONES DK, FITZPATRICK M, *et al*
——. *See also* MILLER MR, SHAW D, *et al*
HIGGINS B, GREENING AP, CROMPTON GK: Assisted ventilation in severe acute asthma, 464
HIGGINS P. *See* WILSON R, RUTMAN A, *et al*
HIGGINS RM, COOKSON WOCM, CHADWICK GA, MCCARTHY G, JOHN S, LANE DJ: Changes in FEV_1 and disturbances of cardiac rhythm in severe airways obstruction: a comparison of nebuliser and Nebuhaler (P), 722
——, LANE DJ: Simple aspiration of pneumothorax (P), 711
HIGGS CMB, RICHARDSON RB, LEA DA, LEWIS GTR, LASZLO G: Influence of knowledge of peak flow on self assessment of asthma: studies with a coded peak flow meter, 671
HILL P. *See* HORN CP, HILL P, *et al*
HILL RA, TATTERSFIELD AE: The role of primary school teachers in the supervision of childhood asthma (P), 707
——. *See also* GARRETT H, VATHENEN S, *et al*
HILL SL, MORRISON HM, BURNETT D, STOCKLEY RA: Short term response of patients with bronchiectasis to treatment with amoxycillin given in standard or high doses orally or by inhalation, 559
——, SHAW JC, SMITH SR, BURNETT D, STOCKLEY RA: Serum acute phase proteins in purulent bronchiectasis (P), 254
——, STOCKLEY RA: Effect of short and long term antibiotic response on lung function in bronchiectasis, 798
HILVERING C. *See* WESTERMANN CJJ, OOSTVEEN ACM, *et al*
HIND CRK, FLINT KC, FELMINGHAM D, HUDSPITH BN, BROSTOFF J, JOHNSON N MCI: Absence of acute phase response in patients with active pulmonary sarcoidosis (P), 231
Histamine and methacholine, nasal response of rhinitic and non-rhinitic subjects to, comparative study, 863
bronchial challenge, changes in transcutaneous oxygen and carbon dioxide in response to (P), 246
bronchial reactivity to, distribution in adult population (P), 233
challenge testing, comparison of 3 methods, 128
H_1 receptor antagonist (terfenadine) for airways in asthma (P), 247
H_1 receptor blockade, effect on exercise induced asthma (P), 735
infusion, bronchial blood flow distribution in unanaesthetised sheep during (P), 245
inhaled, bronchial response to, relationship to 24 hour sodium excretion (P), 240
plasma concentration in acute asthma (P), 241
rises in sputum in infective lung disease, potential role of *Haemophilus influenzae* in (P), 241
Histiocytoma, fibrous, malignant, xanthogranulomatous, arising from posterior mediastinum, case of, 322
Histocompatibility antigens in adult obliterative bronchiolitis (P), 237
HITCHCOCK H. *See* STEVENS FM, CONNOLLY CE, *et al*
HJELMS E. *See* HENRIKSEN L, HJELMS E
HJEMDAHL P. *See* LARSSON K, MARTINSSON A, *et al*
HLA-DR antigen density on alveolar macrophages obtained by BAL in pulmonary sarcoidosis (P), 231
antigens on human macrophages from bronchoalveolar lavage fluid, 261
HNIZDO E. *See* SLUIS-CREMER GK, HESSEL PA, *et al*
HODGSON I. *See* KALSHEKER NA, HODGSON I, *et al*
HODSON ME, WEBBER BA, HOFMEYR JL, MORGAN MDL: The effects of postural drainage incorporating the forced expiration technique on pulmonary function in cystic fibrosis (P), 236
——. *See also* ASSOUFI BK, STEAD RJ, *et al*
——. *See also* HOFMEYR JL, WEBBER BA, *et al*
——. *See also* PANTIN CFA, STEAD RJ, *et al*
——. *See also* SMITH MJ, HODSON ME
——. *See also* STEAD RJ, DUNCAN FR, *et al*
——. *See also* STEAD RJ, HODSON ME, *et al*
HOEFNAGEL CA. *See* ZANDWIJK N VAN, ZWIJNENBURG A, *et al*
HOFMEYR JL, WEBBER BA, HODSON ME: Evaluation of positive expiratory pressure as an adjunct to chest physiotherapy in the treatment of cystic fibrosis, 951
——. *See also* HODSON ME, WEBBER BA, *et al*
HØIER-MADSEN K. *See* BRANDENHOFF P, HØIER-MADSEN K, *et al*
HOLDAWAY MD. *See* SEARS MR, JONES DT, *et al*
HOLDEN H. *See* DAVISON AG, FAYERS PM, *et al*
HOLGATE ST. *See* AGIUS RM, GODFREY RC, *et al*
——. *See* CLIFFORD RD, HOLGATE ST
——. *See* CLIFFORD RD, HOLGATE ST, *et al*
——. *See* CLIFFORD RD, PUGSLEY A, *et al*
——. *See* MANN JS, ROBINSON C, *et al*
——. *See* PARKER SE, ROLLES CJ, *et al*
——. *See* RAFFERTY P, BEASLEY CR, *et al*
——. *See* RAFFERTY P, HOLGATE ST, *et al*
——. *See* RICHARDS R, RENWICK AG, *et al*
——. *See* TWENTYMAN OP, HOLGATE ST, *et al*
HONEYBOURNE D, PICKERING CAC: Physiological evidence that emphysema is not a feature of byssinosis, 6
HOPPER L. *See* SUTEDJA T, APPERLEY JF, *et al*
——. *See* WATSON A, JOYCE H, *et al*
HORAI T. *See* MARSUDA M, HORAI T, *et al*
HORN CP, HILL P, ESSEX E, COCHRANE GM: Does compliance with inhaled therapy by asthmatic patients matter? (P), 721
House dust mite antigens sensitizing asthmatic and eczematous children, differences in source of (P), 707
HOUSTON G. *See* EBDEN P, JENKINS A, *et al*
HOWARD P. *See* COOPER CB, WATERHOUSE JC, *et al*
——. *See* EVANS TW, WATERHOUSE JC, *et al*
——. *See* SUGGETT AJ, JARRETT JA, *et al*
——. *See* SUGGETT AJ, PROCTOR A, *et al*
——. *See* WILKINSON M, LANGHORNE CA, *et al*
HOWARD SV. *See* LYONS DJ, HOWARD SV, *et al*
HOWARTH P. *See* TWENTYMAN OP, HOLGATE ST, *et al*

HOWELL F, O'LAOIDE R, KELLY P, HEALY T, CLANCY L: Mortality from bacteriologically proved cases of tuberculosis as seen in a single hospital unit 1973–1984 (P), 709
HUDGSON P. *See* VEALE D, COOPER BG, *et al*
HUDSPITH BN. *See* FLINT KC, LEUNG KBP, *et al*
——. *See* HIND CRK, FLINT KC, *et al*
HUGHES A. *See* LEYS K, MORICE AH, *et al*
——. *See* MARTIN G, HUGHES A, *et al*
HUGHES CF, WAUGH R, LINDSAY D: Surgery for pulmonary aspergilloma: preoperative embolisation of the bronchial circulation, 324
HUGHES J. *See* WEILL H, JONES RN, *et al*
HUGHES JMB. *See* NOLOP KB, MAXWELL DL, *et al*
——. *See* ORPHANIDOU D, HUGHES JMB, *et al*
——. *See* SUTEDJA T, APPERLEY JF, *et al*
Humidifier, lung diseases related to, bronchial challenge tests in (P), 252
HUNTER AS. *See* LAU YL, RADHI JM, *et al*
HURT R: Chemotherapy in non-small cell bronchial carcinoma *(Letter)*, 335
HURWITZ M. *See* LEVY H, KALLENBACH JM, *et al*
HUSAIN OAN. *See* WINNING AJ, MCIVOR J, *et al*
HUTCHEON AW. *See* DORWARD AJ, BANHAM SW, *et al*
HUTCHISON DCS. *See* JARVIS MJ, BELCHER M, *et al*
Hydrocortisone, intravenous, added to oral prednisolone, effect on patients admitted with severe asthma but not in ventilatory failure (P), 248
  myopathy, acute, in acute severe asthma, case of, 411
Hydroxychloroquine in chronic steroid dependent asthma, no steroid sparing effect with (P), 721
Hypercapnia and added deadspace, steady state responses to, in awake and sleeping dogs (P), 724
  during oxygen therapy in airways obstruction, reappraisal of (E), 897
Hyperhidrosis, unilateral, associated with underlying intrathoracic neoplasia, 2 cases of, 814
Hyperinflation, intermittent positive pressure, in restrictive chest wall disease (P), 244
Hypertension, pulmonary, due to pulmonary vascular disease and chronic obstructive lung disease, effect of prostacyclin (P), 723
Hyperthroidism, lung function before and after treatment in (P), 243
  respiratory muscle function before and after treatment in (P), 710
Hypertonicity as initiating stimulus for exercise induced asthma (P), 239
Hyperventilation, cold air, absence of refractory period or cumulative effect with (P), 238
  voluntary, in chronic obstructive lung disease, failure to predict response to oral progesterone treatment, 616
Hypoxaemia, arterial, occurring after methacholine challenge in asthma, effect of nifedipine, 468
  nocturnal, and quality of sleep in chronic obstructive lung disease, 846
Hypoxia, chronic, β-adrenoceptor number in peripheral tissue after, effect of isoprenaline in rats (P), 249
  effect on platelet size (P), 725
Hypoxic chronic bronchitis, symptomatic oxygen therapy in (P), 245
  cor pulmonale, domiciliary oxygen therapy in, survival after (P), 235
  lung disease, polycythaemia secondary to, reversal of, calf blood flow and oxygen carriage after, 306

I

IKEGAMI H. *See* MATSUDA M, HORAI T, *et al*
Immune deficiency syndrome, acquired. *See* AIDS
Immunoglobulin A subclass bearing cells in bronchi of subjects dead from chronic bronchitis or bronchiectasis (P), 256
  A1 protease production, lack of, and pathogenic mechanisms of *Branhamella catarrhalis* (P), 253
  concentrations, raised, in bronchoalveolar lavage fluid of healthy granite workers, 266
  E, specific, to storage mites in Essex farmworkers (P), 251
Immunoglobulins in lung (E), 337
IND PW, BARNES PJ, DOLLERY CT: Plasma histamine concentration in acute asthma (P), 241
——, DIXON CMS, FULLER RW, BARNES PJ: Anticholinergic blockade of propranolol induced bronchoconstriction (P), 718
^{111}Indium-labelled neutrophils, migration to lungs in bronchiectasis (P), 256
Industrial benefits and respiratory diseases (E), 257; *Erratum*, 496
Inflammation, role in airway hyperreactivity in asthma (E), 657
Influenza vaccination in chronic asthma, trial of (P), 239
INGLIS GC. *See* BERKIN KE, WALKER G, *et al*
INGLIS JM. *See* MANN JS, DOUGLAS JG, *et al*
INGRAM RH, JT. *See* LIM TK, INGRAM RH, JT, *et al*
INGUANZO R. *See* LEKUONA I, CABRERA A, *et al*
INMAN C. *See* AGIUS RM, GODFREY RC, *et al*
INNOCENTI A. *See* PAGGIARO PL, INNOCENTI A, *et al*
Inspiratory muscle function after thoracoplasty (P), 244
Interferon, alpha, in cytomegalovirus penumonitis, local production of (P), 730
  effect on activity of cytotoxic agents in human lung cancer xenografts (P), 233
Interleukin-1 augmentation of leukotriene B_4 generation by human neutrophils stimulated by unopsonised zymosan (P), 733
Intestinal obstruction syndrome, distal, in cystic fibrosis, treatment of (P), 732
Intrathoracic desmoids, 2 cases of, 894
  neoplasia, underlying, unilateral hyperhidrosis associated with, 2 cases of, 814
^{123}I-Iodoamphetamine for lung imaging studies, 801
Ipratropium bromide and salbutamol, nebulised, to be used sequentially or as mixture? (P), 247
  bromide, high dose, effect of 4 weeks' treatment on lung mucociliary clearance, 295
Iraq, pleural effusion in, prospective study of 100 cases, 492
Irradiation, total body, high dose, and subsequent cytomegalovirus pneumonitis in bone marrow transplant recipients (P), 730
IRVINE E. *See* LEE TH, IRVINE E
Isoprenaline, effect on β-adrenoceptor number in peripheral tissue after chronic hypoxia in rats (P), 249
  potentiating effect of forskolin in isolated trachea (P), 242
N-Isopropyl-*p*[^{123}I]iodoamphetamine. *See* ^{123}I-Iodoamphetamine
ITOH T. *See* NATSUAKI M, YOSHIKAWA Y, *et al*

J

JACKSON R. *See* REA HH, SCRAGG R, *et al*
JARRETT JA. *See* SUGGETT AJ, JARRETT JA, *et al*
JARVIS MJ, BELCHER M, VESEY C, HUTCHISON DCS: Low cost carbon monoxide monitors in smoking assessment, 886
JAVALOYAS M. *See* RODRIGUEZ E, MARTINEZ J, *et al*
JENKINS A. *See* EBDEN P, JENKINS A, *et al*
JENKINS PA, WILLIAMS R: What is the true incidence of disease due to opportunist mycobacteria? (P), 709
JENKINS SC, BARNES NC, MOXHAM J: The Respiradyne: a pocket size pulmonary function monitor (P), 243
JENNINGS K. *See* CORRIS PA, KERTES PJ, *et al*
JESSOP T. *See* MOGHISSI K, JESSOP T, *et al*
JEYASINGHAM KJ. *See* MERDAD A, JEYASINGHAM KJ
——. *See* MORIN JF, JEYASINGHAM KJ
JOHN S. *See* HIGGINS RM, COOKSON WOCM, *et al*
JOHNSON CE, BELFIELD PW, DAVIS S, COOKE NJ, SPENCER A, DAVIES JA: Platelet activation during exercise induced asthma: effect of prophylaxis with cromoglycate and salbutamol, 290
JOHNSON M. *See* ALTON EW, JOHNSON M, *et al*
JOHNSON N MCI. *See* FLINT KC, LEUNG KBP, *et al*
——. *See* HIND CRK, FLINT KC, *et al*
——. *See* POZNIAK AL, SWINBURN CR, *et al*

JONES BJM. *See* DAVIDSON AC, JONES BJM, *et al*
JONES DK, CAVAROCCHI N, HIGENBOTTAM TW, WALLWORK J: A single flush preservation technique for distant organ procurement for heart-lung transplantation (P), 713
——, FITZPATRICK M, HIGENBOTTAM TW: Effects of prostacyclin on pulmonary hypertension due to pulmonary vascular disease and chronic obstructive lung disease (P), 723
JONES DT. *See* SEARS MR, JONES DT, *et al*
JONES JG. *See* BARROWCLIFFE MP, MORICE AH, *et al*
JONES KP, DAVIES BH: Inhibition of T cell function by bronchoalveolar lavage fluid (P), 231
JONES L. *See* SUTEDJA T, APPERLEY JF, *et al*
JONES RN. *See* WEILL H, JONES RN, *et al*
JONES SE. *See* SWEATMAN MC, MARKWICK JR, *et al*
JÖRRES R. *See* MAGNUSSEN H, REUSS G, *et al*
JOYCE H. *See* COE CI, JOYCE H, *et al*
——. *See* WATSON A, JOYCE H, *et al*
JUNOD AF. *See* GAILLARD RC, BACHMAN M, *et al*

K

KALLENBACH JM. *See* LEVY H, KALLENBACH JM, *et al*
KALSHEKER NA, HODGSON I, WATKINS GL, WHITE JP, MORRISON HM, STOCKLEY RA: Restriction fragment length polymorphism of the alpha$_1$-antitrypsin gene in chronic lung disease (P), 719
KAPLAN DK. *See* STARKEY IR, KAPLAN DK, *et al*
KAPLAN J, DAVIDSON TI: Intrathoracic desmoids: report of two cases, 894
Kaposi's sarcoma and pulmonary infection, differentation by fibreoptic bronchoscopy in AIDS (P), 715
Kartagener's syndrome, pulmonary mucociliary clearance in, how badly impaired? (P), 255
KASSAB JY. *See* CORRADO OJ, GOULD CAL, *et al*
KAY AB. *See* BUCHANAN DR, CROMWELL O, *et al*
——. *See* WARDLAW AJ, DUNNETTE S, *et al*
KAY PH, AZARIADES M, GOLDSTRAW P: The role of cervical mediastinoscopy in patients with superior vena caval obstruction (P), 712
KAYE SB. *See* DORWARD AJ, BANHAM SW, *et al*
KEAL EE. *See* SHAW RJ, ROWLAND-HILL CA, *et al*
KELLY CA, CORRIS PA, ADAMS PC, MURRAY A, GIBSON GJ: Effects of theophylline on cardiac rhythm in patients with hypoxaemic chronic airways obstruction (P), 722
——, WARD C, BIRD G, HENDRICK DJ, WALTERS EH: The effect of filtration on absolute and differential cell counts in fluid obtained at bronchoalveolar lavage (P), 727
——. *See also* CORRIS PA, COOPER BG, *et al*
KELLY P. *See* CLANCY L, KELLY P, *et al*
——. *See* HOWELL F, O'LAOIDE R, *et al*
KELSON M. *See* BURNEY PGJ, BRITTON JR, *et al*
KENDRICK AH, O'REILLY JF, LASZLO G: Lung function in hyperthyroidism before and after treatment (P), 243
——. *See also* O'REILLY JF, GOULD G, *et al*
KENNEDY HG. *See* SUTEDJA T, APPERLEY JF, *et al*
KERR WF. *See* ROXBURGH JC, MARKLAND CG, *et al*
KERTES PJ. *See* CORRIS PA, KERTES PJ, *et al*
KESKINEN H. *See* ANTTI-POIKA M, NORDMAN H, *et al*
KING M. *See* O'DRISCOLL BRC, KING M, *et al*
——. *See* REES PJ, KING M, *et al*
KINNEAR WJM, PHILLIPS MS, SHNEERSON JM: Inspiratory muscle function after thoracoplasty (P), 244
——, SHNEERSON JM: Ribcage and abdominal motion during external negative pressure ventilation using cuirass respirators (P), 710
——. *See also* PHILLIPS MS, KINNEAR WJM, *et al*
KIRK AJB: Reflux dyspareunia, 215
KNIGHT RK. *See* HARRISON NK, KNIGHT RK
KNOX AJ, MASCIE-TAYLOR BH, MUERS MF: Acute hydrocortisone myopathy in acute severe asthma, 411
——, WARDMAN AG, PAGE RL: Tuberculous pleural effusion occurring during corticosteroid treatment of sarcoidosis, 651
KOZAR L. *See* STRADLING JR, KOZAR L, *et al*
KRAMER GC. *See* LINDSEY DC, CHIH-HSIUNG W, *et al*
KRAMPS JA. *See* MORRISON HM, KRAMPS JA, *et al*
——. *See* STOCKLEY RA, MORRISON HM, *et al*
——. *See* STOLK J, KRAMPS JA, *et al*
Krypton 81m, use for tomography of regional ventilation, perfusion and ventilation-perfusion ratios in normal subjects and asthmatics, 542
KUNG I. *See* SEAL RME, COCKCROFT A, *et al*
KWAN S. *See* ALTON EW, KWAN S, *et al*

L

Laboratories for lung function, gas analysis in, accuracy of, 133
LACEY J. *See* TEE RD, GORDON DJ, *et al*
LAMB D, MACLEAN A, FLENLEY DC: A new technique for measuring alveolar surface and the assessment of microscopic emphysema (P), 716
——. *See also* GOULD GA, MCLEAN A, *et al*
LAMB RK, REDDY A, CAYTON RM, MATTHEWS HR: Abnormalities in gas exchange following oesophageal surgery (P), 230
LANE DJ. *See* HIGGINS RM, COOKSON WOCM, *et al*
——. *See* HIGGINS RM, LANE DJ
LANE IF. *See* FIELD J, LANE IF
LANGHORNE CA. *See* WILKINSON M, LANGHORNE CA, *et al*
LARGE SR, SHNEERSON JM, STOVIN PGI, WALLWORK J: Surgical pathology of the thymus: 20 years' experience, 51; *Errata*, 706
LARSSON K, MARTINSSON A, HJEMDAHL P: Influence of circulating α adrenoceptor agonists on lung function in patients with exercise induced asthma and healthy subjects, 552
Laser, Nd YAG, as first line treatment for obstructing tracheal tumours (P), 712
photoresection, Nd YAG, resuscitative, of tracheal tumour before elective surgery, case of, 812
therapy, new bronchoscopy set for, 485
LASZLO G. *See* HIGGS CMB, RICHARDSON RB, *et al*
——. *See* KENDRICK AH, O'REILLY JF, *et al*
——. *See* O'REILLY JF, GOULD G, *et al*
LAU YL, RADHI JM, BLESOVSKY A, HUNTER AS: A case of middle lobe pulmonary sequestration, 810
LAURENT GJ: Lung collagen: more than scaffolding (*Review article*), 418
LAVENDER JP. *See* CURRIE DC, NEEDHAM S, *et al*
LAVIOLETTE M. *See* CORMIER Y, BÉLANGER J, *et al*
——. *See* LECOURS R, LAVIOLETTE M, *et al*
LAWFORD PV. *See* ROBERTS KM, LAWFORD PV
LAWRENCE R. *See* TURNER-WARWICK M, MCALLISTER W, *et al*
LAWTIE N. *See* SUTTON PP, GEMMELL HG, *et al*
LEA DA. *See* HIGGS CMB, RICHARDSON RB, *et al*
LEACH R, GEORGE RJD, DAVIDSON AC, GEDDES DM: Supplementary oxygen during exercise in COAD patients—a dose response study (P), 725
LEAKER AR. *See* CAPEWELL SJ, LEAKER AR, *et al*
LEBLANC P. *See* CORMIER Y, BÉLANGER J, *et al*
LECOURS R, LAVIOLETTE M, CORMIER Y: Bronchoalveolar lavage in pulmonary mycotoxicosis (organic dust toxic syndrome), 924
LEE PK, SO SY, CHOW JSF: An unusual cause of central cyanosis in a patient with rheumatic heart disease, 333
LEE TH, IRVINE E: The monokine interleukin-1 augments leukotriene B_4 generation by human neutrophils stimulated by unopsonised zymosan (P), 733
——. *See also* ARM JP, SETHI TJ, *et al*
——. *See also* BELCHER NG, MURDOCH R, *et al*
——. *See also* BELCHER NG, REES PJ, *et al*
——. *See also* MAHAUTHAMAN R, YOULTEN LJF, *et al*
LEE WR, STRETTON TB: Byssinosis: a disease or a symptom? (E), 1
LEGGE JS. *See* SUTTON PP, GEMMELL HG, *et al*

Legionella, pneumococcal and mycoplasma pneumonias, comparative clinical and laboratory features (P), 228
Legionnaires' disease outbreak at Glasgow Royal Infirmary, early containment by rapid diagnosis (P), 731
disease, review of 79 community acquired cases in Nottingham, 635
Leiomyomas of lower respiratory tract *(Letter)*, 976
Leiomyosarcoma of lung, primary, presenting with persistent pneumothorax, case of, 649
LEITCH AG. *See* CAPEWELL SJ, LEAKER AR, *et al*
——. *See* DOUGLAS JG, CALDER MA, *et al*
——. *See* MANN JS, DOUGLAS JG, *et al*
LEKUONA I, CABRERA A, INGUANZO R, CID C, AGOSTI J: Direct communication between the right pulmonary artery and the left atrium, 78
LENNARD-JONES AM. *See* PAVIA D, BATEMAN JRM, *et al*
LENNARD-JONES T. *See* TAYLOR RG, PAVIA D, *et al*
LENNOX SC. *See* MITCHELL IM, SAUNDERS NR, *et al*
Leucocyte count and plasma nicotine concentration in smokers, 407
Leucocytes, polymorphonuclear, elastase and antileucoprotease activity, *in vitro* effect of mercapto-ethanesulphonate, 840
Leukotriene B_4 and B_5, comparative activities in enhancement of complement receptors (CR1 and CR3) in human neutrophils (P), 734
B_4 generation by human neutrophils stimulated by unopsonised zymosan, interleukin-1 augmentation of (P), 733
C_4, prostaglandins and thromboxane, generation by human eosinophils stimulated by calcium ionophore (A23187) and unopsonised zymosan (P), 733
D_4, airway responsiveness to, effect of verapamil *in vitro* and *in vivo*, 12
D_4, bronchoconstriction in asthma induced by, effect of sodium cromoglycate (P), 246
D_4, bronchoconstriction in asthma induced by, effect of verapamil and sodium cromoglycate, 753
D_4, human *in vitro* bronchial smooth muscle responses to, in relation to quantity of muscle (P), 734
inhibitors. *See* Piriprost (U-60, 257)
LEUNG KBP. *See* FLINT KC, LEUNG KBP, *et al*
LEVER AML, MILBURN HJ, GRUNDY JE, PRATT P, GRIFFITHS PD, DU BOIS RM: Local production of alpha interferon in cytomegalovirus pneumonitis (P), 730
LEVISON H. *See* CANNY GJ, MARCOTTE JE, *et al*
LEVY H, KALLENBACH JM, FELDMAN C, PINCUS P, HURWITZ M: Delayed pneumothorax after transbronchial lung biopsy, 647
LEWIS GTR. *See* GOULD GA, ASHWORTH M, *et al*
——. *See* HIGGS CMB, RICHARDSON RB, *et al*
LEWIS P. *See* DAVISON AG, LEWIS P, *et al*
——. *See* RAFFERTY P, HOLGATE ST, *et al*
Leyden, Ernst Victor von (1832–1910), Charcot-Leyden crystals and Curschmann spirals in asthmatic sputum (*Historical review*), 503
LEYS K, MORICE AH, HUGHES A, SCHACHTER M, SEVER PS: Autoradiographic visualisation of VIP receptors in human lung (P), 242
LILLINGTON GA. *See* LOUIE S, LILLINGTON GA
LIM TK, INGRAM RH, JR, PRIDE NB: The effect of volume history on maximal airflow in bronchial asthma during spontaneous and induced airflow obstruction (P), 724
LINDSAY D. *See* HUGHES CF, WAUGH R, *et al*
LINDSAY DC, FREEMAN JG, RECORD CO: Unilateral hyperhidrosis associated with underlying intrathoracic neoplasia, 814
LINDSEY DC, CHIH-HSIUNG W, CROSS CE, KRAMER GC: Distribution of bronchial blood flow during histamine infusion in unanaesthetised sheep (P), 245
LINK H, REINHARD U, BLAUROCK M, OSTENDORF P: Lung function changes after allogeneic bone marrow transplantation, 508
Lipopolysaccharide of *Haemophilus influenzae*, effect on human respiratory epithelium *in vitro* (P), 728
Lipoxygenase inhibitor (AA-861) and thromboxane synthetase inhibitor (OKY-046), effects on bronchial responsiveness to acetycholine in asthma, 955
LIRON M. *See* SCARLAT A, BODNER G, *et al*
LIU FL-W, COHEN RD, DOWNAR E, BUTANY JW, EDELSON JD, REBUCK AS: Amiodarone pulmonary toxicity: functional and ultrastructural evaluation, 100
LLEWELLYN MJ. *See* GAUTAM PC, COULSHED N, *et al*
LLOYD MH. *See* BANNER NR, LLOYD MH, *et al*
Lobectomy and pneumonectomy, pneumopericardium after, 55
LOCKWOOD P. *See* BANNER NR, LLOYD MH, *et al*
Locusts (*S gregaria* and *L migratoria*), allergy to (P), 251
LOFTRUS J. *See* GREENHOUGH A, STOCKS J, *et al*
LOFTUS BG, PRICE JF: Clinical and immunological characteristics of asthma in pre-school children (P), 225
LOPEZ-VIDRIERO MT, PAVIA D, GREENSTONE MA, HENDRY WF, CLARKE SW: Viscoelastic properties of sputum from patients with Young's syndrome (P), 254
——. *See also* AGNEW JE, LOPEZ-VIDRIERO MT, *et al*
——. *See also* CURRIE DC, PAVIA D, *et al*
——. *See also* GEORGE RJD, PAVIA D, *et al*
——. *See also* MILLAR AB, AGNEW JE, *et al*
——. *See also* PAVIA D, AGNEW JE, *et al*
——. *See also* SPITERI MA, PAVIA D, *et al*
——. *See also* TAYLOR RG, PAVIA D, *et al*
LOUIE S, LILLINGTON GA: Low dose methotrexate pneumonitis in rheumatoid arthritis, 703
LOZEWICZ S. *See* ASSOUFI BK, DALLY M, *et al*
LUK A. *See* ANDERSON K, LUK A, *et al*
LUKSZA AR, SMITH P, COAKLEY J, GORDAN IJ, ATHERTON ST: Acute severe asthma treated by mechanical ventilation: 10 years' experience from a district general hospital, 459
——. *See also* TAYLOR KJ, LUKSZA AR
LUND C. *See* SØRENSEN HR, LUND C, *et al*
Lung abscess in cystic fibrosis, case of, 221
amiodarone toxicity in, functional and structural evaluation, 100
and bone marrow transplantation (E), 497
biopsy, transbronchial, delayed pneumothorax after, 2 cases of, 647
biopsy, transvenous, in pig, 964
biopsy, trephine, with high speed air drill, 38 months' experience in developing country (Ethiopia), 804
bullae, large, in sarcoidosis, 3 cases of, 792
cancer, bronchial brushing and bronchial biopsy in, comparison of diagnostic accuracy and cell typing reliability, 475
cancer, diagnosis by CA-50 radioimmunoassay inhibition test (P), 716
cancer presenting with digital ischaemia, case of, 573
cancer, prognosis after surgery with and without preoperative CT scans of thorax, abdomen and head (P), 229
cancer, small cell, chemotherapy for, quality of life during (P), 719
cancer, small cell, detection in pleural effusions with monoclonal antibodies (P), 238
cancer, small cell, gallium scanning in (P), 229
cancer, small cell, short duration combination chemotherapy in treatment of, 688
cancer, small cell, survival after surgery in, 479; *(Letter)*, 896
cancer, transbronchial aspiration of subcarinal lymph nodes in (P), 711
cancer xenografts, human, activity of cytotoxic agents in, effect of interferon (P), 233
cavities as complication of coeliac disease (P), 237
china stone and china clay dusts retained in, mineralogy of, relationship to pathological changes, 190
collagen (*Review article*), 418
disease after exposure to polyvinyl chloride dust, case of, 566
disease, bullous, selection for surgery in, value of computed tomography for, 855
disease, chronic, α_1-antitrypsin gene in, restriction fragment length polymorphism of (P), 719
disease, diffuse, narrow section CT in (P), 717
disease due to *Mycobacterium gordonae*?, 2 cases, 152

disease, "early", detection of, and pathogenesis of chronic airflow obstruction in smokers (E), 81
disease, hypoxic, polycythaemia secondary to, reversal of, calf blood flow and oxygen carriage after, 306
disease, infective, sputum histamine rises in, potential role of *H influenzae* in (P), 241
disease, interstitial, alveolar macrophages in, phenotypic analysis of, 429
disease, interstitial, mast cells of bronchoalveolar lavage fluid in, comparison with transbronchial biopsy sections and ultrastructural appearance (P), 232
disease, interstitial, ventilation and gas exchange during sleep in, 777
disease, obstructive, chronic, and pulmonary vascular disease, pulmonary hypertension due to, effect of prostacyclin (P), 723
disease, obstructive, chronic, nocturnal hypoxaemia and quality of sleep in, 846
disease, obstructive, chronic, oral progesterone treatment in, failure of voluntary hyperventilation to predict response to, 616
disease, obstructive. *See also* Airflow obstruction
disease, occupational, validation of smoking histories in (P), 252
disease, pulmonary inflammation, and cigarette smoking, effect on carcinoembryonic antigen concentrations in serum and secretions, 17
diseases related to humidifier, bronchial challenge tests in (P), 252
dysfunction, in chronic alcoholics, contribution of ethanol and cigarette smoking to, 197
elastin in relation to (*Review article*), 577
emphysematous, bullous, intracavity drainage of (P), 233
farmer's, after *Mycoplasma pneumoniae* infection, 2 cases of, 68
function after bone marrow transplantation, effect of preconditioning regimens (P), 726
function and bronchodilator distribution, effect of particle size of aerosols (P), 721
function and tracheobronchial mucociliary clearance in healthy subjects, effect of selective and non-selective beta blockade, 301
function changes after allogeneic bone marrow transplantation, 508
function in bronchiectasis, effect of short and long term antibiotic response, 798
function in cystic fibrosis, effect of postural drainage with forced expiration technique (P), 236
function in elderly *(Letters)*, 335
function in farmer's lung disease, relationship to radiographic changes and bronchoalveolar lavage fluid lymphocytes, 28
function in hyperthyroidism before and after treatment (P), 243
function in sarcoidosis, rate of improvement during corticosteroid treatment, 473
function, influence of circulating α adrenoceptor agonists in healthy subjects and patients with exercise induced asthma, 552
function laboratories, gas analysis in, accuracy of, 133
function monitor, pocket size (Respiradyne) (P), 243
function of farmers and farmworkers in England and Wales, 117
function studies, number of patients required, 830
gas and tissue volumes, regional, estimation in supine man with computed tomography, 620
gas and tissue volumes, regional, in supine subjects with chronic airflow limitation or fibrosing alveolitis, computed tomography based estimates of, 932
gas diffusion in, effect of airflow limitation (P), 242
human, VIP receptors in, autoradiographic visualisation of (P), 242
imaging studies, ^{123}I-iodoamphetamine for, 801
immunoglobulins in (E), 337
injury, patterns of ^{111}In-neutrophil traffic in (P), 232
leiomyosarcoma of, primary, presenting with persistent pneumothorax, case of, 649
meningioma of, metastatic, case of, 487
migration of ^{111}indium-labelled neutrophils to, in bronchiectasis (P), 256
mucociliary clearance in, effect of 4 weeks' high dose ipratropium bromide treatment, 295
permeability in patients with haematological malignancies treated with cytotoxic drugs (P), 227
permeability in pigeon fanciers (P), 227
rat, effect of monocrotaline ingestion on distribution of protein and angiotensin converting enzyme activity in, 914
secretions in chronic obstructive bronchitis, tissue inhibitor of metalloproteinases and collagenase inhibitory activity in, effect of corticosteroid treatment, 740
tissue, human, mineral fibres from, assessment of (*Review article*), 167
VIP clearance in, 88
volumes, radiographic measurement of, use of different magnification factors for, 158
See also Pulmonary
Lymph node changes, central, and progressive massive fibrosis in coalworkers, 531
nodes in shrinking pleuritis with atelectasis, exogenous particles in *(Letters)*, 655
nodes, subcarinal, transbronchial aspiration of, in carcinoma of lung (P), 711
Lymphadenopathy, mediastinal, tuberculous, treatment of, comparison of RHZ2/RH10 and RHE2/RH10 regimens for (P), 708
Lymphangitis, bilateral, diffuse pulmonary mesothelioma presenting as *(Letters)*, 223
carcinomatosa, chronic pulmonary paracoccidioidomycosis masquerading as, case of, 72
Lymphocyte adrenoceptors and modulation by theophylline (P), 249
and macrophage phenotypes in lesions of sarcoidosis, two pathological processes present? (P), 231
counts, serial, in lung lavage, serum angiotensin converting enzyme measurements, and gallium-67 scans for monitoring of corticosteroid treatment in pulmonary sarcoidosis, evaluation of, 903
Lymphocytes in bronchoalveolar lavage fluid in farmer's lung disease, relationship to radiographic changes and lung function, 28
macrophage abnormality in pulmonary sarcoidosis induced by (P), 728
See also T cells
LYNCH PP. *See* BANHAM SW, MCSHARRY C, *et al*
LYONS DJ, HOWARD SV, MILLEDGE JS, PETERS TJ: Contribution of ethanol and cigarette smoking to pulmonary dysfunction in chronic alcoholics, 197
LYONS J. *See* WAGNER JC, POOLEY FD, *et al*

M

MCALLISTER W. *See* TURNER-WARWICK M, MCALLISTER, W, *et al*
MCCARTHY CF. *See* STEVENS FM, CONNOLLY CE, *et al*
MCCARTHY G. *See* HIGGINS RM, COOKSON WOCM, *et al*
MCCARTNEY AC. *See* WINTER JH, MCCARTNEY AC, *et al*
MCCONNOCHIE K, SIMONATO L, WAGNER JC: Mesothelioma in Cyprus—the role of tremolite (P), 250
MCCRACKEN JS. *See* WOODHEAD MA, MACFARLANE JT, *et al*
MCCREATH GT. *See* SHAND J, MCCREATH GT, *et al*
MACDERMOT J. *See* SYKES DA, WILSON R, *et al*
MCDONALD CF. *See* CROMPTON GK, GRANT IWB, *et al*
MACFARLANE JT. *See* RADVAN J, WOODHEAD MA, *et al*
——. *See* WOODHEAD MA, MACFARLANE JT
——. *See* WOODHEAD MA, MACFARLANE JT, *et al*
MACFARLANE P, MILLER V, COURIEL J: Gastro-oesophageal reflux and childhood asthma: the acid test (*Letter*), 160
MCGAVIN C: Farmer's lung after *Mycoplasma pneumoniae* infection, 68
MCHARDY GJR. *See* SHAUNAK S, FRANCE AJ, *et al*
MCINTYRE C. *See* WHITE RJ, COUTTS I, *et al*
MCIVOR J. *See* WINNING AJ, MCIVOR J, *et al*

MACKAY IS. *See* WILSON R, SWEATMAN MC, *et al*
MACKAY NSD. *See* DORWARD AJ, BANHAM SW, *et al*
MCKENDRICK O. *See* O'HALLORAN SM, GILBERT J, *et al*
MCKILLOP J. *See* BANHAM SW, MCKILLOP J, *et al*
——. *See* MILROY R, SMITH ML, *et al*
MCLEAN A. *See* GOULD GA, MCLEAN A, *et al*
——. *See* LAMB D, MACLEAN A, *et al*
MCLEOD DT, CROUGHAN MJ, AHMAD F, BRETTLE R, CALDER MA: Further studies of the pathogenic mechanisms of *Branhamella catarrhalis:* lack of IgA1 protease production (P), 253
——. *See also* FRANCE AJ, MCLEOD DT, *et al*
MCLEOD J. *See* ANDERSON K, LUK A, *et al*
MCMILLAN JF. *See* POLLOK AJ, GEMMELL CG, *et al*
MCNABB WR. *See* FAIRFAX AJ, MCNABB WR, *et al*
MACNEE W. *See* CONNAUGHTON JJ, MACNEE W, *et al*
——. *See* GOULD GA, MCLEAN A, *et al*
MCNICHOLAS K. *See* SERRA J, SOULEN R, *et al*
MCNICHOLAS WT, COFFEY M, BOYLE T, FITZGERALD MX: Stimulant effect of nasal airflow on ventilation during sleep (P), 243
——, ——, FITZGERALD MX: Ventilation and gas exchange during sleep in patients with interstitial lung disease, 777
MCNICOL MW. *See* TURNER JA MCM, MCNICOL MW, *et al*
Macroglobulinaemia, Waldenström's, with pulmonary infiltrates, bronchoalveolar lavage in case of, 409
Macrophage and lymphocyte phenotypes in lesions of sarcoidosis, two pathological processes present? (P), 231
Macrophages, alveolar, function, alteration of, and pulmonary cellular defence after inhalation injury (P), 728
alveolar, obtained by BAL in pulmonary sarcoidosis, density of HLA-DR antigen on (P), 231
alveolar, phenotypic analysis in normal subjects and in interstitial lung disease, 429
human, from bronchoalveolar lavage fluid, HLA-DR antigens on, 261
lymphocyte induced abnormality in pulmonary sarcoidosis (P), 728
MCSHARRY C. *See* ANDERSON K, MCSHARRY C, *et al*
——. *See* BANHAM SW, MCSHARRY C, *et al*
MACWILLIAM L. *See* STANLEY PJ, WILSON R, *et al*
MAEDA H. *See* SUGIYAMA Y, MAEDA H, *et al*
MAGNUSSEN H, REUSS G, JÖRRES R: Airway response to methacholine during exercise induced refractoriness in asthma, 667
MAHAUTHAMAN R, YOULTEN LJF, SPUR B, CLARK TJH, LEE TH: Prostaglandins, thromboxane and leukotriene C_4 generation by the human eosinophil stimulated by calcium ionophore (A23187) and unopsonised zymosan (P), 733
MAHER O. *See* MITCHELL IM, SAUNDERS NR, *et al*
MAINI RN. *See* SWEATMAN MC, MARKWICK JR, *et al*
Maleic anhydride, occupational asthma due to, bronchial provocation testing and immunological data (P), 251
Malignancies, haematological, lung permeability in patients treated with cytotoxic drugs for (P), 227
MALMBORG A-S. *See* GILLJAM H, MALMBORG A-S, *et al*
Manchester air disaster, pulmonary complications associated with (P), 234
MANN JS, DOUGLAS JG, INGLIS JM, LEITCH AG: Q fever: person to person transmission within a family, 974
——, ROBINSON, SHERIDAN AQ, CLEMENT P, BACH MK, HOLGATE ST: Effect of inhaled Piriprost (U-60, 257), a novel leukotriene inhibitor, on allergen and exercise induced bronchoconstriction in asthma, 746
MARCOTTE JE. *See* CANNY GJ, MARCOTTE JE, *et al*
MARCUSE HR. *See* ZANDWIJK N VAN, ZWIJNENBURG A, *et al*
MARKLAND CG. *See* ROXBURGH JC, MARKLAND CG, *et al*
MARKWICK JR. *See* SWEATMAN MC, MARKWICK JR, *et al*
MARQUIS A. *See* GRAY B, BARNES NC, *et al*
MARTIN G, HUGHES A, MORICE AH, SCHACHTER M, SEVER PS: Potentiating effect of forskolin on isoprenaline in isolated trachea (P), 242
MARTIN JW. *See* SACKS SH, HARRISON M, *et al*
MARTINEZ J. *See* RODRIGUEZ E, MARTINEZ J, *et al*
MARTINEZ-VAZQUEZ JM, RIBERA E, OCAÑA I, SEGURA RM, SERRAT R, SAGRISTA J: Adenosine deaminase activity in tuberculous pericarditis, 888
MARTINSSON A. *See* LARSSON K, MARTINSSON A, *et al*
MASCIE-TAYLOR BH. *See* KNOX AJ, MASCIE-TAYLOR BH, *et al*
MASKELL G. *See* DAVIDSON AC, JONES BJM, *et al*
MASON H. *See* DAVISON AG, FAYERS PM, *et al*
Mast cells and eosinophils in bronchoalveolar lavage in mild asthma, relationship to bronchial hyperreactivity (P), 733
cells, bronchoalveolar, in sarcoidosis, increased numbers and accentuation of mediator release, 94
cells of bronchoalveolar lavage fluid in interstitial lung disease, comparison with transbronchial biopsy sections and ultrastructural appearance (P), 232
MATSUDA M, HORAI T, NAKAMURA S, NISHIO H, SAKUMA T, IKEGAMI H, TATEISHI R: Bronchial brushing and bronchial biopsy: comparison of diagnostic accuracy and cell typing reliability in lung cancer, 475
MATSUDA T. *See* FUJIMURA M, SASAKI F, *et al*
MATSUMIYA N, MAYUMI T, SHIMIZU H, MOTOHARA T: Bronchopleural fistula after pneumonectomy (*Letter*), 896
MATTHEWS AW. *See* PEACOCK AJ, MATTHEWS AW
MATTHEWS HR. *See* BENFIELD G, CULLEN M, *et al*
——. *See* LAMB RK, REDDY A, *et al*
MATTHYS H. *See* COSTABEL U, BROSS KJ, *et al*
MAXWELL DL. *See* NOLOP KB, MAXWELL DL, *et al*
MAY JJ, STALLONES L, DARROW D, PRATT DS: Organic dust toxicity (pulmonary mycotoxicosis) associated with silo unloading, 919
MAYUMI T. *See* MATSUMIYA N, MAYUMI T, *et al*
Meconium ileus equivalent in cystic fibrosis, oral gastrografin in treatment of (P), 733
Mediastinal fibrosis, idiopathic, surgical treatment of 5 cases, 210
lymphadenopathy, tuberculous, treatment of, comparison of RHZ2/RH10 and RHE2/RH10 regimens for (P), 708
Mediastinoscopy, cervical, role in patients with superior vena caval obstruction (P), 712
Mediastinum, posterior, xanthogranulomatous malignant fibrous histiocytoma arising from, case of, 322
Mediator and catecholamine concentrations, circulating, during refractory period in exercise induced asthma (P), 718
MELISSINOS CH. *See* BOUROS DE, GASIS A, *et al*
Meningioma of lung, metastatic, case of, 487
Mercapto-ethanesulphonate, *in vitro effect* on polymorphonuclear leucocyte elastase and antileucoprotease activity, 840
MERDAD A, JEYASINGHAM KJ: Wide surgical resection as the main treatment modality in primary chest wall tumours (P), 713
Mesothelial proliferation, pleurisy, and pleural fibrosis, pathogenesis of (*Review article*), 176
Mesothelioma and mineral fibres (E), 161
in Cyprus, role of tremolite in (P), 250
pulmonary, diffuse, presenting as bilateral lymphangitis (*Leters*), 223
Metalloproteinases. *See* Tissue inhibitor of metalloproteinases
METAXAS N. *See* WINNING AJ, MCIVOR J, *et al*
Methacholine, airway response during exercise induced refractoriness in asthma to, 667
and histamine, nasal response of rhinitic and non-rhinitic subjects to, comparative study, 863
challenge in asthma, arterial hypoxaemia occurring after, effect of nifedipine, 468
inhaled, bronchial reactivity to, prevalence in New Zealand children, 283; (*Letters*), 705
Methotrexate, low dose, pneumonitis in rheumatoid arthritis due to, case of, 703
Methoxamine and phenylephrine, mechanism of action in asthmatic airways (P), 718
Methylprednisolone therapy, intravenous, "pulsed", for refractory sarcoidosis (P), 714
MICHEL O, SERGYSELS R: Acute pulmonary toxoplasmosis with alveolitis of T suppressor lymphocyte type, 972

MIDDLETON WG. *See* DOUGLAS JG, MIDDLETON WG, *et al*
MIER A, BROPHY C, GREEN M: Diaphragm dysfunction associated with brainstem pathology (P), 710
——, ——, MOXHAM J, GREEN M: A new symptom of diaphragm weakness (P), 244
——, ——, ——, ——: Phrenic nerve stimulation (P), 243
——, ——, WASS J, GREEN M: Respiratory muscle function in hyperthyroidism before and after treatment (P), 710
MIFUNE J-I. *See* FUJIMURA M, SASAKI F, *et al*
MILBURN HJ, GROB JP, PRENTICE HG, GRUNDY JE, DU BOIS RM: High dose total body irradiation and subsequent cytomegalovirus pneumonitis in patients receiving bone marrow transplants (P), 730
——, STIRK PR, DAVISON AG, DU BOIS RM: Rapid diagnosis of cytomegalovirus pneumonitis by bronchoalveolar lavage (P), 234
——. *See also* LEVER AML, MILBURN HJ, *et al*
Miliary tuberculosis, sputum-negative, rapid diagnosis with flexible fibreoptic bronchoscope, 681
MILLAR AB, AGNEW JE, NEWMAN SP, LOPEZ-VIDRIERO MT, PAVIA D, CLARKE SW: Comparison of nasal and tracheobronchial clearance by similar techniques in normal subjects, 783
——, FROMSON B, STRICKLAND BA, DENISON DM: Computed tomography based estimates of regional gas and tissue volume of the lung in supine subjects with chronic airflow limitation or fibrosing alveolitis, 932
——. *See also* DENISON DM, MORGAN MDL, *et al*
MILLEDGE JS. *See* LYONS DJ, HOWARD SV, *et al*
——. *See* NASH PE, MILLEDGE JS, *et al*
——. *See* NUNN JF, MILLEDGE JS, *et al*
MILLER MR, SHAW D, HIGENBOTTAM TW: the effect of airflow limitation on gas diffusion in the lungs (P), 242
MILLER R, RUDD R: Prognosis after surgery for lung cancer with and without preoperative CT scans of thorax, abdomen and head (P), 229
MILLER V. *See* MACFARLANE P, MILLER V, *et al*
MILLER WC, HEARD JG, UNGER KM, SUICH DM: Anatomical lung shunting in pulmonary fibrosis, 208
MILROY R, SMITH ML, BANHAM SW, MCKILLOP J: Gallium scanning in small cell lung cancer (P), 229
MINATO N. *See* NATSUAKI M, YOSHIKAWA Y, *et al*
Mineral fibres and mesothelioma (E), 161
fibres from human lung tissue, assessment of (*Review article*), 167
MITCHELL DM, GILDEH P, DIMOND AH, COLLINS JV: Value of serial peak expiratory flow measurements in assessing treatment response in chronic airflow limitation, 606
——, SOLOMON M, TOLFREY S, SHORT M, SPIRO SG: The effect of particle size of bronchodilator aerosols on lung distribution and pulmonary function (P), 721
MITCHELL DN. *See* MUNRO CS, CAMPBELL DA, *et al*
——. *See* WARRENS AN, BARNES PJ, *et al*
——. *See* WILSON R, SWEATMAN MC, *et al*
MITCHELL IM, SAUNDERS NR, MAHER O, LENNOX SC, WALKER DR: Surgical treatment of idiopathic mediastinal fibrosis: report of five cases, 210
Mitral stenosis, long term survival in, preoperative clinical predictors of, analysis of 200 cases up to 27 years after closed mitral valvotomy, 401
stenosis, massive haemoptysis as presenting symptom in case of, 413
valve, bioprosthetic, failure due to attachment of residual chorda, case of, 652
MOGHISSI K, JESSOP T, DENCH M: A new bronchoscopy set for laser therapy, 485
MONCRIEFF CB. *See* WAGNER JC, POOLEY FD, *et al*
MONIE RDH. *See* SHAND J, MCCREATH GT, *et al*
Monoclonal antibodies against epidermal growth factor receptor (P), 238
antibodies, detection of small cell lung carcinoma in pleural effusions with (P), 238
Monocrotaline ingestion, effect on distribution of protein and angiotensin converting enzyme activity in rat lung, 914
MONSO E, VIDAL R, GRACIA X DE, MORAGAS A: Pulmonary toxoplasmoma presenting as obstructive pneumonia, 489
MONTAÑO M. *See* SELMAN M, MONTAÑO M, *et al*
MOORE BP. *See* ASHRAF J, DUSSEK JE, *et al*
MOORE NR, PHILLIPS MS, SHNEERSON JM, FLOWER CDR, DIXON AK: Pleural thickening and skeletal deformity in thoracoplasty—the relationship with ventilatory failure (P), 717
MOORE R. *See* SERRA J, SOULEN R, *et al*
MOORE-GILLON J, GEORGE RJD, GEDDES DM: Perception of dyspnoea during and after exercise (P), 725
MORAGAS A. *See* MONSO E, VIDAL R, *et al*
MORAN F. *See* ANDERSON K, LUK A, *et al*
——. *See* WINTER JH, CARTER R, *et al*
MORCOS SK: Exogenous particles in lymph nodes in patients with shrinking pleuritis with atelectasis (*Letter*), 655
MORELL F, CURULL V, ORRIOLS R, GRACIA J DE: Skin tests in bird breeder's disease, 538
MORGAN A. *See* DAVIS JMG, GYLSETH B, *et al*
MORGAN AD, CONNAUGHTON JJ, CATTERALL JR, SHAPIRO CM, DOUGLAS NJ, FLENLEY DC: Sodium cromoglycate in nocturnal asthma, 39
——. *See also* MORGAN JM, MORGAN AD, *et al*
——. *See also* RUSSELL NJ, CRICHTON NJ, *et al*
MORGAN JM, MORGAN AD, ADDIS B, BRADLEY GW, SPIRO SG: Fatal haemorrhage from mycotic aneurysms of the pulmonary artery, 70
MORGAN M. *See* SIMPSON FG, MORGAN M, *et al*
MORGAN MDL, DENISON DM, STRICKLAND BA: Value of computed tomography for selecting patients with bullous lung disease for surgery, 855
——. *See also* DENISON DM, MORGAN MDL, *et al*
——. *See also* GOLDMAN JM, ROSE LS, *et al*
——. *See also* HODSON ME, WEBBER BA, *et al*
MORICE AH, SNAPE C, EWAN PW: Intranasal salbutamol in perennial rhinitis (P), 247
——. *See also* BARROWCLIFFE MP, MORICE AH, *et al*
——. *See also* LEYS K, MORICE AH, *et al*
——. *See also* MARTIN G, HUGHES A, *et al*
MORIN JF, JEYASINGHAM KJ: Myasthenia gravis—a surgical experience (P), 713
MORRIS DL. *See* UBHI C, MORRIS DL
MORRIS MM. *See* RAMSDALE EH, MORRIS MM, *et al*
MORRIS RW. *See* PEACH H, SHAH D, *et al*
MORRISON DA, GOLDMAN AL: Oral progesterone treatment in chronic obstructive lung disease: failure of voluntary hyperventilation to predict response, 616
MORRISON HM, KRAMPS JA, BURNETT D, DIJKMAN JH, STOCKLEY RA: Anti-elastases in bronchoalveolar lavage fluid from patients with α_1-proteinase inhibitor deficiency or chronic obstructive bronchitis (P), 254
——, ——, DIJKMAN JH, STOCKLEY RA: Comparison of concentrations of two proteinase inhibitors, porcine pancreatic elastase inhibitory capacity, and cell profiles in sequential bronchoalveolar lavage samples, 435
——. *See also* HILL SL, MORRISON HM, *et al*
——. *See also* KALSHEKER NA, HODGSON I, *et al*
——. *See also* STOCKLEY RA, MORRISON HM, *et al*
MORRISON JFJ. *See* SIMPSON FG, MORRISON JFJ, *et al*
MORRITT GN. *See* CORRIS PA, KERTES PJ, *et al*
MORTAGY A. *See* BRITTON JR, MORTAGY A, *et al*
MOSS FM, BOBROW LG, BEVERLEY PCL, SOUHAMI RL: Detection of small cell lung carcinoma in pleural effusions using monoclonal antibodies (P), 238
MOTOHARA T. *See* MATSUMIYA N, MAYUMI T, *et al*
MOXHAM J. *See* JENKINS SC, BARNES NC, *et al*
——. *See* MIER A, BROPHY C, *et al*
Mucociliary clearance and ciliary beat frequency, nasal, effect of cigarette smoking, 519
clearance and functional small airways defence in symptomless cigarette smokers, 524
clearance and upper respiratory tract viral infection (P), 255
clearance in lung, effect of 4 weeks' high dose ipratropium bromide

treatment, 295
clearance, pulmonary, in Kartagener's syndrome, how badly impaired? (P), 255
clearance, tracheobronchial, and lung function in healthy subjects, effect of selective and non-selective beta blockade, 301
'Mucolytic' agents, effect in Young's syndrome (P), 724
MUERS MF. *See* KNOX AJ, MASCIE-TAYLOR BH, *et al*
——. *See* SIMPSON FG, ARNOLD AG, *et al*
MUIR AL. *See* CONNAUGHTON JJ, MACNEE W, *et al*
MUKHERJEE S. *See* CARSWELL F, MUKHERJEE S, *et al*
MULLEY BA. *See* CHRYSTYN H, MULLEY BA, *et al*
MUNRO CS, CAMPBELL DA, MITCHELL DN, DU BOIS RM, COLE PJ, POULTER LW: Lymphocyte and macrophage phenotypes in the lesions of sarcoidosis: are there two pathological processes? (P), 231
MURDOCH R. *See* BELCHER NG, MURDOCH R, *et al*
MURRAY A. *See* GILMARTIN JJ, VEALE D, *et al*
——. *See* KELLY CA, CORRIS PA, *et al*
Myasthenia gravis, surgical experience with (P), 713
Mycobacteria, opportunist, disease due to, true incidence of (P), 709
Mycobacterium bovis, pulmonary tuberculosis due to, 685
gordonae, lung disease due to?, 2 cases, 152
kansasii pulmonary infection, 9 months' rifampicin and ethambutol treatment in, BTS study (P), 709
malmoense infections in Scotland, clinical and radiological features (P), 709
tuberculosis, changes in primary and acquired drug resistance in Blackburn (1960–84), 229
tuberculosis, drug resistance in, survey in native and immigrant groups over 25 years in Blackburn, 946
tuberculosis, pathogenicity during anti-tuberculosis therapy (P), 228
Mycoplasma, legionella and pneumococcal pneumonias, comparative clinical and laboratory features (P), 228
Mycoplasma pneumoniae infection, farmer's lung after, 2 cases of, 68
Mycotic aneurysms of pulmonary artery, fatal haemorrhage from, case of, 70
Mycotoxicosis, pulmonary. *See* Dust toxic syndrome, organic
MYERS MJ. *See* ORPHANIDOU D, HUGHES JMB, *et al*
Myopathy, acute, due to hydrocortisone, in acute severe asthma, case of, 411
Myotonic dystrophy and non-myotonic respiratory muscle weakness, breathing during sleep in (P), 710

N

NAKAMURA S. *See* MATSUDA M, HORAI T, *et al*
NAKATSUMI Y. *See* FUJIMURA M, SASAKI F, *et al*
NAKIB WA. *See* WILSON R, RUTMAN A, *et al*
NARUSE Y. *See* CHINN DJ, NARUSE Y, *et al*
Nasal airflow, stimulant effect on ventilation during sleep (P), 243
allergen, effect of nedocromil sodium (P), 246
and tracheobronchial clearance by similar techniques in normal subjects, comparison of, 783
mucociliary clearance and ciliary beat frequency, effect of cigarette smoking, 519
prong devices conserving oxygen, comparison of 2 systems, and effects of nose and mouth breathing, 808
response of rhinitic and non-rhinitic subjects to histamine and methacholine, comparative study, 863
NASH PE, MILLEDGE JS, PRICE TL: The effect of verapamil on secondary polycythaemia (P), 225
Nasopharynx, tuberculosis of, misdiagnosed as Wegener's granulomatosis, case of, 219
National Health Service staff, pulmonary tuberculosis in (P), 708
NATSUAKI M, YOSHIKAWA Y, ITOH T, MINATO N, YAMADA H: Xanthogranulomatous malignant fibrous histocytoma arising from posterior mediastinum, 322
Nebulised aerosols, distribution of (P), 248
Nebuliser, air driven, salbutamol given at home by, cardiac effects of, 331
compared with Nebuhaler for changes in FEV_1 and disturbances of cardiac rhythm in severe chronic airways obstruction (P), 722
or Nebuhaler for COAD? (P), 722
therapy, domiciliary, with salbutamol, dose-response assessment (P), 247
Nedocromil sodium, effect on nasal allergen (P), 246
sodium, effect on sulphur dioxide induced bronchoconstriction (P), 246
NEEDHAM S. *See* CURRIE DC, NEEDHAM S, *et al*
Needle aspiration, transbronchial, diagnosis and treatment of case of bronchogenic cyst using, 326
Neodymium YAG laser as first line treatment for obstructing tracheal tumours (P), 712
YAG laser photoresection, resuscitative, of tracheal tumour before elective surgery, case of, 812
Neonates, BCG vaccination in, tuberculin sensitivity after (P), 226
Neoplasia, intrathoracic, underlying, unilateral hyperhidrosis associated with, 2 cases of, 814
Neuropathy in COAD patients treated or not treated with almitrine (P), 224
peripheral, with almitrine (P), 723
Neutrophil elastase inhibition, relation to elastase inhibitors of sputum sol phase, 442
Neutrophils, chemotactic activity in acute severe asthma (P), 735
human, complement receptors (CR1 and CR3) in, comparative activities of leukotriene B_4 and B_5 in enhancement of (P), 734
human, stimulated by unopsonised zymosan, leukotriene B_4 generation by, interleukin-1 augmentation of (P), 733
^{111}In-labelled, migration to lungs in bronchiectasis (P), 256
^{111}In-labelled, patterns of traffic in lung injury (P), 232
respiratory burst of, action of *Aspergillus fumigatus* on (P), 256
NEVILLE E. *See* AGIUS RM, GODFREY RC, *et al*
——. *See* CORRIS PA, KERTES PJ, *et al*
NEVIN M, PEPPER JR, WILLIAMS C, VAN BESOUW JP: The place of high frequency jet ventilation in thoracic surgery: an improvement in postoperative recovery (P), 720
New Zealand children, prevalence of bronchial reactivity to inhaled methacholine in, 283: (*Letters*), 705
NEWLAND AC. *See* WALLIS PJW, APPS MCP, *et al*
NEWMAN SP, PELLOW PGD, CLARKE SW: Which nebuliser and compressor should be used for carbenicillin aerosol therapy? (P), 236
——. *See also* MILLAR AB, AGNEW JE, *et al*
——. *See also* TAYLOR RG, PAVIA D, *et al*
——. *See also* WOODMAN G, NEWMAN SP, *et al*
NEWMAN-TAYLOR AJ. *See* AGIUS RM, DAVISON AG, *et al*
——. *See* ASSOUFI BK, DALLY M, *et al*
——. *See* DAVISON AG, FAYERS PM, *et al*
——. *See* DAVISON AG, LEWIS P, *et al*
——. *See* DURHAM SR, DAVIES S, *et al*
——. *See* GRANEEK BJ, DURHAM SR, *et al*
——. *See* GREENSTONE MA, NEWMAN-TAYLOR AJ, *et al*
——. *See* TEE RD, GORDON DJ, *et al*
NICHOLL JF. *See* EVANS TW, WATERHOUSE JC, *et al*
NICHOLL JP. *See* COOPER CB, WATERHOUSE JC, *et al*
NICKELS J. *See* ANTTI-POIKA M, NORDMAN H, *et al*
Nicotine, plasma concentration, and white blood cell count in smokers, 407
Nifedipine, effect on arterial hypoxaemia occurring after methacholine challenge in asthma, 468
NISHIO H. *See* MATSUDA M, HORAI T, *et al*
NOGRADY S: Absence of refractoriness in asthmatic subjects after exercise with warm, humid inspirate (*Letter*), 415
NOLAN MT, FITZGERALD MX: Chronic eosinophilic pneumonia—a long term follow up (P), 715
NOLOP KB, MAXWELL DL, BRAUDE S, ROYSTON D, HUGHES JMB: DTPA clearance is slower when ^{113}indium is the radiolabel (P), 227
NONELL F. *See* RODRIGUEZ E, MARTINEZ J, *et al*
NORDMAN H. *See* ANTTI-POIKA M, NORDMAN H, *et al*
NOTHEN U. *See* GREENOUGH A, STOCKS J, *et al*
Notices, 80, 160, 223, 335, 416, 496, 656, 815, 885, 976

NUNN AJ. *See* DAVISON AG, FAYERS PM, *et al*
——. *See* TEE RD, GORDON DJ, *et al*
NUNN JF, MILLEDGE JS, CHEN D, DORE C: Assessment of fitness for surgery in patients with chronic obstructive disease (P), 720
NYEKO C. *See* GRAY B, BARNES NC, *et al*

O

Oat cell carcinoma of oesophagus, primary, 318
OCAÑA I. *See* MARTINEZ-VAZQUEZ JM, RIBERA E, *et al*
O'CONNOR CM, POWER C, VANBREDA A, ODLUM C, FITZGERALD MX: Fibronectin and collagenase in bronchoalveolar lavage fluid from patients with sarcoidosis (P), 230
Ocular toxicity due to ethambutol (E), 737
ODLUM C. *See* O'CONNOR CM, POWER C, *et al*
O'DOHERTY MJ, VAN DE PETTE J, PAGE CJ, BATEMAN NT: Pulmonary permeability in patients with haematological malignancies treated with cytotoxic drugs (P), 227
O'DRISCOLL BRC, KING M, COCHRANE GM: Should nebulised salbutamol and ipratropium bromide be administered sequentially or as a mixture? (P), 247
Oesophageal intubation for broncho-oesophageal fistula (P), 712
Oesophagoplasty with reversed gastric tube, late complications of, 61
Oesophagus, carcinoma of, oat cell, primary, 318
  stimulation of, effect on asthma in Asian subjects (P), 225
  surgery, gas exchange abnormalities following (P), 230
OGILVIE CM: Regional thoracic medical centres (E), 417
O'HALLORAN SM, GILBERT J, MCKENDRICK O, CARTY H, HEAF D: Oral gastrograffin in the treatment of meconium ileus equivalent in cystic fibrosis (P), 733
O'HICKEY S, CROWNE E, PICKERING CAC: Pulmonary complications associated with the Manchester air disaster (P), 234
Oil mists, occupational asthma due to (P), 250
OKUBANJO AO. *See* OSINOWO O, ADEBO OA, *et al*
O'LAOIDE R. *See* HOWELL F, O'LAOIDE R, *et al*
Oligospermia and bronchiectasis in 2 families (*Letters*), 80
OLLIER S. *See* BLAINEY AD, OLLIER S, *et al*
——. *See* BLAINEY AD, TOPPING MD, *et al*
OLSON LG. *See* CORMICK W, OLSON LG, *et al*
OOSTVEEN ACM. *See* WESTERMANN CJJ, OOSTVEEN ACM, *et al*
OPENSHAW PJM, CANNON MJ, ASKONAS BA: Specificity of murine cytotoxic T-cells to respiratory syncytial virus (P), 730
——, WINTERTON SJ: Late results of plombage (*Letter*), 494
Opioids, endogenous, and exercise induced asthma, 350
O'REILLY JF, GOULD G, KENDRICK AH, LASZLO G: Domiciliary comparison of terbutaline treatment by metered dose inhaler with and without conical spacer in severe and moderately severe chronic asthma, 766
——. *See also* KENDRICK AH, O'REILLY JF, *et al*
O'REILLY L. *See* CLANCY L, KELLY P, *et al*
ORENSTEIN M, WEBBER CA, CASH M, HEURICH AE: Value of bronchoalveolar lavage in the diagnosis of pulmonary infection in acquired immune deficiency syndrome, 345
ORMEROD LP: Comparison of RHZ2/RH10 and RHE2/RH10 regimens in the treatment of tuberculous mediastinal lymphadenopathy (P), 708
——, HARRISON JM, WRIGHT PA: Changes in primary and acquired drug resistance of *Mycobacterium tuberculosis* in Blackburn 1960–84 (P), 229
——, ——, ——: Drug resistance in *Mycobacterium tuberculosis:* a survey over 25 years in Blackburn, 946
ORPHANIDOU D, HUGHES JMB, MYERS MJ, AL-SUHALI A-R, HENDERSON B: Tomography of regional ventilation and perfusion using krypton 81m in normal subjects and asthmatic patients, 542.
ORRIOLS R. *See* MORELL F, CURULL V, *et al*
Oscillation, high frequency, oral, as adjunct to physiotherapy in cystic fibrosis (P), 235
OSINOWO O, ADEBO OA, OKUBANJO AO: Osteomyelitis of the ribs in Ibadan, 58
OSMAN J, DAVIES RJ: Assessing the relevance of skin prick tests (P), 241
OSSELTON JW. *See* VEALE D, COOPER BG, *et al*
OSTENDORF P. *See* LINK H, REINHARD U, *et al*
Osteomyelitis of ribs in Ibadan, 58
OVERBEEK SE. *See* WESTERMANN CJJ, OOSTVEEN ACM, *et al*
Oxygen and carbon dioxide, transcutaneous, changes in response to histamine bronchial challenge (P), 246
  carriage and blood flow, calf, after reversal of polycythaemia secondary to hypoxic lung disease, 306
  comparison of 2 nasal prong systems conserving, and effects of nose and mouth breathing, 808
  inspired, concentration of, effect on effective pulmonary blood flow measured by inert gas rebreathing method in ventilated patients (P), 725
  saturation and sleep in erythrocytosis (P), 711
  supplementary, during exercise in COAD patients, dose response study (P), 725
  therapy, domiciliary, in hypoxic cor pulmonale, survival after (P), 235
  therapy, domiciliary, long term, pulmonary circulation after, pathology and physiology of (P), 716
  therapy in airways obstruction, hypercapnia during, reappraisal of (E), 897
  therapy, portable, via transtracheal catheter during exercise (P), 245
  therapy, short burst, for breathlessness in chronic obstructive airways disease, 611
  therapy, symptomatic, in hypoxic chronic bronchitis (P), 245
  therapy, transtracheal micro-catheters in, staphylococcal infection problems with (P), 235

P

PACKE GE, AYRES JG, CITRON KM, STAFFORTH DE: Large lung bullae in sarcoidosis, 792
PAGE CJ. *See* O'DOHERTY MJ, VAN DE PETTE J, *et al*
PAGE RL. *See* KNOX AJ, WARDMAN AG, *et al*
PAGGIARO PL, INNOCENTI A, BACCI E, ROSSI O, TALINI D: Specific bronchial reactivity to toluene diisocyanate: relationship with baseline clinical findings, 279
Pain, postthoracotomy, role of cryoanalgesia in control of (P), 233
Palatopharyngoplasty in treatment of snoring and obstructive sleep apnoea (P), 719
PALMER JBD, CUSS FMC, WARREN JB, BLANK M, BLOOM SR, BARNES PJ: Effect of infused vasoactive intestinal peptide on airway function in normal subjects, 663
Pancoast's syndrome associated with invasive aspergillosis, case of, 156
Pancreatic elastase, porcine, inhibition of, capacity for, concentrations of proteinase inhibitors (antileucoprotease and α_1 proteinase inhibitor) and cell profiles in sequential bronchoalveolar lavage samples, comparison of, 435
PANTIN CFA, STEAD RJ, HODSON ME, BATTEN JC: Prednisolone in the treatment of airflow obstruction in adults with cystic fibrosis, 34
PAPACOSTA AO. *See* BRITTON JR, BURNEY PGJ, *et al*
——. *See* BURNEY PGJ, BRITTON JR, *et al*
Paracentesis of carcinomatous pleural effusions through fine silastic catheter (P), 711
Paracoccidioidomycosis, pulmonary, chronic, masquerading as lymphangitis carcinomatosa, case of, 72
PARKER RA. *See* SIMONDS AK, PARKER PA, *et al*
PARKER SE, ROLLES CJ, HOLGATE ST: Health care for adult patients with cystic fibrosis in Wessex—the consultant's view (P), 236.
——, ——, ——: Health care for adult patients with cystic fibrosis in Wessex—the patient's view (P), 236
PARKIN J. *See* SHAW RJ, ROWLAND-HILL CA, *et al*
PATEL KR. *See* TITINCHI SJ, CLARK B, *et al*
PAVIA D, AGNEW JE, SUTTON PP, LOPEZ-VIDRIERO MT, CURRIE DC, COLE PJ, CLARKE SW: How badly impaired is the pulmonary mucociliary clearance of patients with Kartagener's syndrome? (P), 255

——, BATEMAN JRM, LENNARD-JONES AM, AGNEW JE, CLARKE SW: Effect of selective and non-selective beta blockade on pulmonary function and tracheobronchial mucociliary clearance in health subjects, 301
——. *See also* AGNEW JE, LOPEZ-VIDRIERO MT, *et al*
——. *See* CLAY MM, PAVIA D, *et al*
——. *See* CURRIE DC, PAVIA D, *et al*
——. *See* GEORGE RJD, PAVIA D, *et al*
——. *See* GREENSTONE MA, CURRIE DC, *et al*
——. *See* LOPEZ-VIDRIERO MT, PAVIA D, *et al*
——. *See* MILLAR AB, AGNEW JE, *et al*
——. *See* SPITERI MA, PAVIA D, *et al*
——. *See* TAYLOR RG, AGNEW JE, *et al*
——. *See* TAYLOR RG, PAVIA D, *et al*
PAYNE-JAMES JJ, WALESBY RK: Symptomatic fibrous dysplasia of the right first rib excised via a posterolateral thoracotomy, 575
PEACH H, SHAH D, MORRIS RW: Validity of smokers' information about present and past cigarette brands—implications for studies of the effects of falling tar yields of cigarettes on health, 203
PEACOCK A, BENSON-MITCHELL R, GODFREY RC: The effect of fibreoptic bronchoscopy on airway physiology (P), 712
PEACOCK AJ, MATTHEWS AW: The effect of captopril on pulmonary haemodynamics and lung function in patients with chronic airflow obstruction (P), 225
PEAKE MD. *See* CHRYSTYN H, MULLEY BA, *et al*
——. *See* SUGGETT AJ, PROCTOR A, *et al*
PEARCE FL. *See* FLINT KC, LEUNG KBP, *et al*
PEARCE P. *See* ANAND IS, HARRIS E, *et al*
PEARSON ADJ. *See* HAMILTON PJ, PEARSON ADJ
PEARSON SB. *See* SIMPSON FG, MORRISON JFJ, *et al*
PELLOW PGD. *See* GREENSTONE MA, CURRIE DC, *et al*
——. *See* NEWMAN SP, PELLOW PGD, *et al*
Pentamethylene diethylene triamine, occupational asthma in bath tub resurfacer due to (P), 251
PEPPER JR. *See* NEVIN M, PEPPER JR, *et al*
Percussion, manual, effect on tracheobronchial clearance in chronic airflow obstruction with excessive tracheobronchial secretion, 448
Perfusion, ventilation and ventilation-perfusion ratios, regional, tomography using krypton 81m of, in normal subjects and asthmatics, 542
Pericarditis, asthma, and eosinophilic pleuropneumonia, combined, without vasculitis, 2 cases of, 571
  tuberculous, adenosine deaminase activity in, 888
PERKS WH. *See* ALLEN MB, WARD AM, *et al*
PERREN T. *See* BENFIELD G, CULLEN M, *et al*
PETERS AM. *See* CURRIE DC, NEEDHAM S, *et al*
PETERS TJ. *See* LYONS DJ, HOWARD SV, *et al*
PETRIE GR. *See* DOUGLAS JG, MIDDLETON WG, *et al*
Phenazine pigments of *Pseudomonas aeruginosa* in sputum in chronic bronchial sepsis, inhibition of human ciliary beat frequency *in vitro* by (P), 729
Phenylephrine and methoxamine, mechanism of action in asthmatic airways (P), 718
PHILLIPS MS, KINNEAR WJM, SHNEERSON JM: Pulmonary tuberculosis treated by thoracoplasty: the outcome after 30 years (P), 719
——. *See also* KINNEAR WJM, PHILLIPS MS, *et al*
——. *See also* MOORE NR, PHILLIPS MS, *et al*
PHILLIPSON EA. *See* STRADLING JR, KOZAR L, *et al*
Pholcodine and salbutamol, effects on citric acid induced cough in normal subjects, 74
Phrenic nerve stimulation (P), 243
Physiotherapy, chest. *See* Chest physiotherapy
PICKERING CAC. *See* CONNELLAN SJ, ROCCHICCIOLI K, *et al*
——. *See* DAVISON AG, FAYERS PM, *et al*
——. *See* HONEYBOURNE D, PICKERING CAC
——. *See* O'HICKEY S, CROWNE E, *et al*
PIERS DA. *See* SCHANS CP VAN DER, PIERS DA, *et al*
Pigeon breeders' disease, avian exposure, and humoral immune response, relationships between, among Scottish pigeon fanciers, 274
  fanciers, lung permeability in (P), 227
PINCHING AJ. *See* SHAW RJ, ROWLAND-HILL CA, *et al*
PINCUS P. *See* LEVY H, KALLENBACH JM, *et al*
Piriprost (U-60, 257), inhaled, effect on allergen and exercise induced bronchoconstriction in asthma, 746
PITT T. *See* WILSON R, PITT T, *et al*
Plasma histamine concentration in acute asthma (P), 241
  nicotine concentration and white blood cell count in smokers, 407
  pharmacokinetics of inhaled sodium cromoglycate, factors affecting (P), 721
Platelet activation during exercise induced asthma, effect of prophylaxis with cromoglycate and salbutamol, 290
  size, effect of hypoxia (P), 725
PLATT H. *See* BURNEY PGJ, BRITTON JR, *et al*
Pleural effusion in Iraq, prospective study of 100 cases, 492
  effusion, tuberculous, occurring during corticosteroid treatment of sarcoidosis, case of, 651
  effusions, carcinomatous, paracentesis through fine silastic catheter (P), 711
  effusions, detection of small cell lung carcinoma with monoclonal antibodies in (P), 238
  thickening and skeletal deformity in thoracoplasty, relationship with ventilatory failure (P), 717
Pleurisy, pleural fibrosis, and mesothelial proliferation, pathogenesis of *(Review article,)*, 176
Pleuritis, shrinking, with atelectasis, exogenous particles in lymph nodes in *(Letters)*, 655
Pleuropneumonia, eosinophilic, asthma, and pericarditis, combined, without vasculitis, 2 cases of, 571
Pleuropulmonary fibrosis induced by bromocriptine, case of, 328
Plombage, late results of *(Letters)*, 494
Pneumococcal, legionella and mycoplasma pneumonias, comparative clinical and laboratory features (P), 228
Pneumonectomy and lobectomy, pneumopericardium after, 55
  bronchopleural fistula after *(Letter)*, 896
Pneumonia, community-acquired, in previously fit adults, *Haemophilus influenzae* as cause of (P), 228
  due to *Haemophilus influenzae* in hospitalised patients (P), 731
  eosinophilic, chronic, long term follow up (P), 715
  in community, incidence, radiology and outcome (P), 714
  obstructive, pulmonary toxoplasmoma presenting as, case of, 489
  radiological clearing after (P), 731
  related to AIDS, comparison of clinical and bronchoscopic diagnosis in (P), 228
  staphylococcal, community acquired, in Trent region (P), 731
Pneumonias, legionella, pneumococcal and mycoplasma, comparative clinical and laboratory features (P), 228
Pneumonitis, cytomegalovirus, after high dose total body irradiation in bone marrow transplant recipients (P), 730
  cytomegalovirus, rapid diagnosis by bronchoalveolar lavage (P), 234
  due to low dose methotrexate in rheumatoid arthritis, case of, 703
  megalovirus, alpha interferon in, local production of (P), 730
Pneumopericardium after pneumonectomy and lobectomy, 55
Pneumothorax, delayed, after transbronchial lung biopsy, 2 cases of, 647
  persistent, primary leiomyosarcoma of lung presenting with, case of, 649
  simple aspiration of (P), 711
  spontaneous, concurrent, in identical twins, 971
  spontaneous, familial, in 2 brothers, with family history, 969
POCOCK S. *See* SPITERI MA, COOK D, *et al*
POLLOK AJ, GEMMELL CG, CLARK CJ, MCMILLAN JF, REID WH, CAMPBELL D: Pulmonary cellular defence: alteration of alveolar macrophage function following inhalation injury (P), 728
Polycythaemia, secondary, effect of verapamil (P), 225
  secondary to hypoxic lung disease, reversal of, calf blood flow and oxygen carriage after, 306
Polyvinyl chloride dust, exposure to, lung disease after, case of, 566

POOLEY FD. *See* WAGNER JC, POOLEY FD
——. *See* WAGNER JC, POOLEY FD, *et al*
POSNER V, COTES JE: Respiratory patients with mobility allowances: what criteria for eligibility? (P), 237
POSTMA DS. *See* SCHANS CP VAN DER, PIERS DA, *et al*
Postural drainage with forced expiration technique, effect on lung function in cystic fibrosis (P), 236
POTGIETER PD. *See* WILLCOX PA, POTGIETER PD, *et al*
POULTER LW, CAMPBELL DA, DU BOIS RM: Lymphocyte induced macrophage abnormality in pulmonary sarcoidosis (P), 728
——. *See also* CAMPBELL DA, DU BOIS RM, *et al*
——. *See also* CAMPBELL DA, POULTER LW, *et al*
——. *See also* MUNRO CS, CAMPBELL DA, *et al*
Pourfour du Petit syndrome, interrupted aortic arch associated with, case of, 217
POWER C. *See* O'CONNOR CM, POWER C, *et al*
POZNIAK AL, SWINBURN CR, SEMPLE SJG, JOHNSON NMCt: A comparison of clinical and bronchoscopic diagnosis in AIDS related pneumonia (P), 228
PRATT DS. *See* MAY JJ, STALLONES L, *et al*
PRATT P. *See* LEVER AML, MILBURN HJ, *et al*
Prednisolone, bronchial reactivity in chronic obstructive airways disease following (P), 240
in treatment of airflow obstruction in adults with cystic fibrosis, 34
oral, intravenous hydrocortisone added to, effect on patients admitted with severe asthma but not in ventilatory failure (P), 248
Pregnancy, asthma in (P), 707
in cystic fibrosis (P), 732
PRENDIVILLE A, GREEN S, SILVERMAN M: Airway response to salbutamol in wheezy infants: evidence for beta-adrenergic responsiveness (P), 240
PRENTICE HG. *See* MILBURN HJ, GROB JP, *et al*
PRESCOTT RJ: The small clinical trial: is there a better way? (E), 822
——. *See also* CAMPBELL IA, HANSFORD M, *et al*
——. *See also* DOUGLAS JG, MIDDLETON WG, *et al*
PRICE JF. *See* GREENOUGH A, STOCKS J, *et al*
——. *See* LOFTUS BG, PRICE JF
PRICE TL. *See* NASH PE, MILLEDGE JS, *et al*
PRIDE NB. *See* COE CI, JOYCE H, *et al*
——. *See* LIM TK, INGRAM RH, JT, *et al*
——. *See* WATSON A, JOYCE H, *et al*
PRINCE KL. *See* RHIND GB, PRINCE KL, *et al*
PRIOR J. *See* SWEATMAN MC, MARKWICK JR, *et al*
PROCTOR A. *See* SUGGETT AJ, JARRETT JA, *et al*
——. *See* SUGGETT AJ, PROCTOR A, *et al*
Progesterone and tamoxifen, pulmonary tuberous sclerosis treated with, 2 cases of, 892
treatment, oral, in chronic obstructive lung disease, failure of voluntary hyperventilation to predict response to, 616
Propranolol, bronchoconstriction induced by, anticholinergic blockade of (P), 718
Prostacyclin, effect on pulmonary hypertension due to pulmonary vascular disease and chronic obstructive lung disease (P), 723
Prostaglandins, thromboxane and leukotriene C_4, generation by human eosinophils stimulated by calcium ionophore (A23187) and unopsonised zymosan (P), 733
Protease, IgA1, production, lack of, and pathogenic mechanisms of *Branhamella catarrhalis* (P), 253
Protein and angiotensin converting enzyme activity, distribution in rat lung, effect of monocrotaline ingestion, 914
Proteinase inhibitors (antileucoprotease and α_1 proteinase inhibitor), concentrations of, porcine pancreatic elastase inhibitory capacity and cell profiles in sequential bronchoalveolar lavage samples, comparison of, 435
inhibitors. *See also* Elastase inhibitors
α_1-Proteinase inhibitor deficiency or chronic obstructive bronchitis, anti-elastases in bronchoalveolar lavage fluid from patients with (P), 254
Proteins, acute phase, in serum in purulent bronchiectasis (P), 254
Protriptyline, effects on sleep related breathing disturbances in restrictive chest wall disease, 586
PROWSE K. *See* ALLEN MB, CHANDRASEKERA C, *et al*
——. *See* ALLEN MB, GROCCOT L, *et al*
——. *See* ALLEN MB, PROWSE K
Pseudomonas aeruginosa phenazine pigments in sputum in chronic bronchial sepsis, inhibition of human ciliary beat frequency *in vitro* by (P), 729
PUGH E. *See* ALLEN MB, PUGH E, *et al*
PUGSLEY A. *See* CLIFFORD RD, PUGSLEY A, *et al*
Pulmonary artery, mycotic aneurysms of, fatal haemorrhage from, case of, 70
artery, right, and left atrium, direct communication between, case of, 78
aspergilloma, preoperative embolisation of bronchial circulation in, case of, 324
blood flow, effective, measured by inert gas rebreathing method in ventilated patients, effect of inspired oxygen concentration (P), 725
cellular defence and alteration of alveolar macrophage function after inhalation injury (P), 728
circulation after long term domiciliary oxygen therapy, pathology and physiology of (P), 716
clearance of ^{99m}Tc DTPA, changes during haemodialysis, 381
complications associated with Manchester air disaster (P), 234
complications of AIDS, review of 90 English cases (P), 730
emphysema, extent as assessed by CT scan in life, not related to pulmonary haemodynamics during rest or exercise (P), 726
fibrosis, anatomical lung shunting in, 208
fibrosis, idiopathic, collagen concentration, biosynthesis and degradation in, 355
haemodynamics of yak, cattle, and cross breeds at high altitude, 696
hypertension due to pulmonary vascular disease and chronic obstructive lung disease, effect of prostacyclin (P), 723
infection, acute exacerbations of, response to salbutamol in adults with cystic fibrosis related to recovery from (P), 732
infection and Kaposi's sarcoma, differentiation by fibreoptic bronchoscopy in AIDS (P), 715
infection in AIDS, diagnosis of, value of bronchoalveolar lavage in, 345
infiltrates, Waldenström's macroglobulinaemia with, bronchoalveolar lavage in case of, 409
involvement in scleroderma, comparison with cryptogenic fibrosing alveolitis (P), 714
lesions, discrete, fine needle aspiration of, interpretation of negative results in, 875
mesothelioma, diffuse, presenting as bilateral lymphangitis *(Letters)*, 223
mucociliary clearance in Kartagener's syndrome, how badly impaired? (P), 255
Mycobacterium kansasii infection, 9 months' rifampicin and ethambutol treatment in, BTS study (P), 709
mycotoxicosis. *See* Dust toxic syndrome, organic
paracoccidioidomycosis, chronic, masquerading as lymphangitis carcinomatosa, case of, 72
sarcoidosis, active, absence of acute phase response in (P), 231
sarcoidosis, corticosteroid treatment in, monitoring of, evaluation of serial lavage lymphocyte counts, serum angiotensin converting enzyme measurements, and gallium-67 scans for, 903
sarcoidosis, density of HLA-DR antigen on alveolar macrophages obtained by BAL in (P), 231
sarcoidosis, lymphocyte induced macrophage abnormality in (P), 728
sequestration, middle lobe, case of, 810
toxoplasmoma presenting as obstructive pneumonia, case of, 489
toxoplasmosis, acute, with alveolitis of T suppressor lymphocyte type, case of, 972
tuberculosis due to *Mycobacterium bovis*, 685
tuberculosis, gallium 67 lung scans in (P), 228

tuberculosis in NHS staff (P), 708
tuberculosis treated by thoracoplasty, outcome after 30 years (P), 719
tuberous sclerosis treated with tamoxifen and progesterone, 2 cases of, 892
veno-occlusive after chemotherapy *(Letters)*, 415
See also Lung
Purulent infection, cilia from sites of, beat frequency of, 453
PURVIS A. *See* SIMPSON FG, ARNOLD AG, *et al*

Q

Q fever (*Coxiella burnetii* infection), person to person transmission within family, 974

R

RADFORD M. *See* CLIFFORD RD, HOLGATE ST, *et al*
——. *See* CLIFFORD RD, PUGSLEY A, *et al*
RADHI JM. *See* LAU YL, RADHI JM, *et al*
Radiographic changes in farmer's lung disease, relationship to lung function and bronchoalveolar lavage fluid lymphocytes, 28
measurement of lung volume, use of different magnification factors for, 158
RADVAN J, WOODHEAD MA, MACFARLANE JT: Community acquired staphylococcal pneumonia in the Trent region (P), 731
RAEBURN D. *See* ROBERTS JA, GIEMBYCZ MA, *et al*
RAFFERTY P, BEASLEY CR, HOLGATE ST: The inhibitory effect of terfenadine on bronchoconstriction induced by adenosine monophosphate and allergen (P), 734
——, HOLGATE ST, LEWIS P, WHEELEY MSTG: Terfenadine as a potent and specific H_1 histamine receptor antagonist for human airways in asthma (P), 247
RAMOS C. *See* SELMAN M, MONTAÑO M, *et al*
RAMSAY AD. *See* GEORGE PJM, GARRETT CPO, *et al*
RAMSDALE EH, MORRIS MM, HARGREAVE FE: Interpretation of the variability of peak flow rates in chronic bronchitis, 771
RASHID A, SENDI A, AL-KADHIMI A, DONNELLY RJ: Concurrent spontaneous pneumothorax in identical twins, 971
REA HH, SCRAGG R, JACKSON R, BEAGLEHOLE R, FENWICK J, SUTHERLAND DC: A case-control study of deaths from asthma, 833
REBUCK AS. *See* LIU FL-W, COHEN RD, *et al*
RECORD CO. *See* LINDSAY DC, FREEMAN JG, *et al*
REDDY A. *See* LAMB RK, REDDY A, *et al*
REDPATH AT. *See* GOULD GA, MCLEAN A, *et al*
REECE IJ. *See* WINTER JH, MCCARTNEY AC, *et al*
REES PJ, KING M, GLEESON MJ, WENGRAF CL: Palatopharyngoplasty in the treatment of snoring and obstructive sleep apnoea (P), 719
——. *See also* BELCHER NG, MURDOCH R, *et al*
——. *See also* BELCHER NG, REES PJ
——. *See also* BELCHER NG, REES PJ, *et al*
Reflux dyspareunia, 215
——, gastro-oesophageal, in childhood asthma, acid test for *(Letter)*, 160
REID WH. *See* POLLOK AJ, GEMMELL CG, *et al*
REINHARD U. *See* LINK H, REINHARD U, *et al*
RENWICK AG. *See* RICHARDS R, RENWICK AG, *et al*
Respiradyne (pocket size lung function monitor) (P), 243
Respiratory burst of neutrophils, action of *Aspergillus fumigatus* on (P), 256
compliance and functional residual capacity in young children (P), 226
diseases and industrial benefits (E), 257; *Erratum*, 496
epithelium, human, effect of *Haemophilus influenzae* polysaccharide *in vitro* (P), 728
health after acute chlorine exposure (P), 249
muscle function in hyperthyroidism before and after treatment (P), 710
muscle weakness, non-myotonic, and myotonic dystrophy, breathing during sleep in (P), 710
patients' eligibility for mobility allowances, what criteria? (P), 237
research funding, improvement of chances for (E), 817
resistance in smokers, frequency dependence of (P), 242
symptom changes and bronchial reactivity changes, relationship between, in community survey (P), 713
symptoms in coffee process workers, relationship to bronchial hyperresponsiveness, atopy and sensitisation to green coffee bean (P), 708
syncytial virus, specificity of murine cytotoxic T-cells to (P), 730
system, examination of, reliability of physical signs in (P), 720
tract infection and atopy, role in autumnal exacerbation of bronchial reactivity in rural population (P), 239
tract, lower, leiomyomas of *(Letter)*, 976
tract, upper, viral infection of, and mucociliary clearance (P), 255
REUSS G. *See* MAGNUSSEN H, REUSS G, *et al*
REYNOLDS JJ. *See* BURNETT D, REYNOLDS JJ, *et al*
Rheumatic heart disease, central cyanosis in patient with, unusual cause of, 333
Rheumatoid arthritis and silicosis, relationship between, in South African gold miners, 596
arthritis, low dose methotrexate pneumonitis in, case of, 703
RHIND GB, PRINCE KL, SCOTT W, FLENLEY DC: Symptomatic oxygen therapy in hypoxic chronic bronchitis (P), 245
——. *See also* CATTERALL JR, RHIND GB, *et al*
——. *See also* CONNAUGHTON JJ, MACNEE W, *et al*
Rhinitis, nasal response to histamine and methacholine of patients with, comparison with non-rhinitic subjects, 863
perennial, intranasal salbutamol in (P), 247
Rib, first, right, symptomatic fibrous dysplasia of, excised via posterolateral thoracotomy, case of, 575
Ribcage and abdominal motion during external negative pressure ventilation using cuirass respirators (P), 710
RIBERA E. *See* MARTINEZ-VAZQUEZ JM, RIBERA E, *et al*
Ribs, osteomyelitis of, in Ibadan, 58
RICHARDS R, RENWICK AG, DICKSON CR, HOLGATE ST: Factors affecting the plasma pharmacokinetics of inhaled sodium cromoglycate (P), 721
RICHARDSON RB. *See* HIGGS CMB, RICHARDSON RB, *et al*
Rifampicin and ethambutol, 9 months' treatment with, in *Mycobacterium kansasii* pulmonary infection, BTS study (P), 709
ROBERTS C. *See* WILKINS EGL, GRIFFITHS RJ, *et al*
ROBERTS CM. *See* ASSOUFI BK, STEAD RJ, *et al*
ROBERTS D. *See* WILSON R, PITT T, *et al*
ROBERTS JA, RODGER IW, THOMSON NC: Effect of verapamil and sodium cromoglycate on leukotriene D_4 induced bronchoconstriction in patients with asthma, 753
——, ——, ——: Human *in vitro* bronchial smooth muscle responses to leukotriene D_4 in relation to the quantity of muscle (P), 734
——, ELLIOT JA, GUNNEBERG A, THOMAS NC: Does hydroxychloroquine have a steroid sparing effect in chronic steroid dependent asthma? (P), 721
——, GIEMBYCZ MA, RAEBURN D, RODGER IW, THOMSON NC: In vitro and in vivo effect of verapamil on human airway responsiveness to leukotriene D_4, 12
——, THOMSON NC: Effect of sodium cromoglycate on leukotriene D_4 induced bronchoconstriction in asthmatic patients (P), 246
ROBERTS KM, LAWFORD PV: Failure of a bioprosthetic mitral valve due to attachment of a residual chorda, 652
ROBERTSON AS, WIELAND GA, BURGE PS: Bronchial challenge tests in humidifier related lung diseases (P), 252
——, ——, ——: Occupational asthma due to oil mists (P), 250
——. *See also* BURGE PS, WIELAND GA, *et al*
——. *See also* GOVE RI, ROBERTSON AS, *et al*
ROBINSON AA. *See* HARRISON BDW, STOKES TC, *et al*
ROBINSON C. *See* MANN JS, ROBINSON C, *et al*
ROBINSON E. *See* CARSWELL F, HEK G, *et al*
ROCA J. *See* BALLESTER E, ROCA J, *et al*

ROCCHICCIOLI K. *See* CONNELLAN SJ, ROCCHICCIOLI K, *et al*
ROCHAT T. *See* GAILLARD RC, BACHMAN M, *et al*
RODGER IW. *See* ROBERTS JA, GIEMBYCZ MA, *et al*
——. *See* ROBERTS JA, RODGER IW, *et al*
RODRIGUEZ E, MARTINEZ J, JAVALOYAS M, NONELL F, TORRES M: Haemothorax in the course of chickenpox, 491
RODRIGUEZ-ROISIN R. *See* BALLESTER E, ROCA J, *et al*
ROLLES CJ. *See* PARKER SE, ROLLES CJ, *et al*
ROSE AG: Pulmonary veno-occlusive disease after chemotherapy *(Letter)*, 416
ROSE DH. *See* WOODHEAD MA, MACFARLANE JT, *et al*
ROSE LS. *See* GOLDMAN JM, ROSE LS, *et al*
ROSIE A. *See* SHAUNAK S, FRANCE AJ, *et al*
ROSS BA. *See* ROXBURGH JC, MARKLAND CG, *et al*
ROSSI O. *See* PAGGIARO PL, INNOCENTI A, *et al*
ROWLAND-HILL CA. *See* SHAW RJ, ROWLAND-HILL CA, *et al*
ROXBURGH JC, MARKLAND CG, ROSS BA, KERR WF: The role of cryoanalgesia in control of postthoracotomy pain (P), 233
ROYSTON D. *See* NOLOP KB, MAXWELL DL, , *et al*
RUCKLEY VA. *See* SEATON A, RUCKLEY VA, *et al*
RUDD RM. *See* MILLER R, RUDD RM
——. *See* WINTER RJD, RUDD RM, *et al*
RUSSELL NJ, CRICHTON NJ, EMERSON PA, MORGAN AD: Quantitative assessment of the value of spirometry, 360
RUTMAN A. *See* BARKER A, RUTMAN A, *et al*
——. *See* WILSON R, PITT T, *et al*
——. *See* WILSON R, RUTMAN A, *et al*
——. *See* WILSON R, SYKES DA, *et al*

S

SABANATHAN S, GRAHAM GP, SALAMA FD: Primary oat cell carcinoma of the oesophagus, 318
SACKS SH, HARRISON M, BISCHLER PJE, MARTIN JW, WATKINS J, GUNNING A: Metallurgical analysis of failed Björk-Shiley cardiac valve prostheses, 142
SAGRISTA J. *See* MARTINEZ-VAZQUEZ JM, RIBERA E, *et al*
SAKULA A: Charcot-Leyden crystals and Curschmann spirals in asthmatic sputum *(Historical review)*, 503
SAKUMA T. *See* MATSUDA M, HORAI T, *et al*
SALAMA FD. *See* SABANATHAN S, GRAHAM GP, *et al*
Salbutamol, airway response to, in wheezy infants, evidence for beta-adrenergic responsiveness (P), 240
and cromoglycate prophylaxis, effect on platelet activation during exercise induced asthma, 290
and ipratropium bromide, nebulised, to be used sequentially or as mixture? (P), 247
and pholcodine, effects on citric acid induced cough in normal subjects, 74
given by air driven nebuliser at home, cardiac effects of, 331
intranasal, in perennial rhinitis (P), 247
nebuliser therapy, domiciliary, dose-response assessment (P), 247
occupational asthma due to (P), 250
response to, in adults with cystic fibrosis, related to recovery from acute exacerbations of pulmonary infection (P), 732
Saline and terbutaline, nebulised, as adjunct to chest physiotherapy, assessment of (P), 235
Salter, Henry Hyde *(Letter)*, 416
SÁNCHEZ-ORTEGA JM. *See* SITGES AC, SÁNCHEZ-ORTEGA JM, *et al*
SANG CTM. *See* WALKER WS, SANG CTM
Sarcoidosis, bronchoalveolar mast cells in, increased numbers and accentuation of mediator release, 94
commoner in non-smokers?, 787
fibronectin and collagenase in bronchoalveolar lavage fluid from patients with (P), 230
in childhood, adenoidal tissue as aid to diagnosis of, 2 cases, 66
large lung bullae in, 3 cases of, 792
lesions of, lymphocyte and macrophage phenotypes in, two pathological processes present? (P), 231
lung function in, rate of improvement during corticosteroid treatment, 473
pulmonary, active, absence of acute phase response in (P), 231
pulmonary, corticosteroid treatment in, monitoring of, evaluation of serial lavage lymphocyte counts, serum angiotensin converting enzyme measurements, and gallium-67 scans for, 903
pulmonary, density of HLA-DR antigen on alveolar macrophages obtained by BAL in (P), 231
pulmonary, lymphocyte induced macrophage abnormality in (P), 728
refractory, "pulsed" intravenous methylprednisolone therapy for (P), 714
relationship between changed alveolar-capillary permeability and serum angiotensin converting enzyme activity in, 629
tuberculous pleural effusion occurring during corticosteroid treatment in, case of, 651
Sarcoma, Kaposi's, and pulmonary infection, differentiation by fibreoptic bronchoscopy in AIDS (P), 715
SASAKI F. *See* FUJIMURA M, SASAKI F, *et al*
SAUNDERS NA. *See* CORMICK W, OLSON LG, *et al*
SAUNDERS NR. *See* MITCHELL IM, SAUNDERS NR, *et al*
SAYNOR R. *See* YEO H, DOYLE T, *et al*
SCARLAT A, BODNER G, LIRON M: Massive haemoptysis as the presenting symptom in mitral stenosis, 413
SCHACHTER M. *See* LEYS K, MORICE AH, *et al*
——. *See* MARTIN G, HUGHES A, *et al*
SCHANS CP VAN DER, PIERS DA, POSTMA DS: Effect of manual percussion on tracheobronchial clearance in patients with chronic airflow obstruction and excessive tracheobronchial secretion, 448
Schistosomiasis, aortic aneurysm caused by, case of, 890
Schoolchildren, bronchial hyperresponsiveness symptoms in (P), 735
Schoolteachers, primary, role in supervision of childhood asthma (P), 707
SCHWARTZ AR, FISHMAN EK, WANG KP: Diagnosis and treatment of a bronchogenic cyst using transbronchial needle aspiration, 326
Scleroderma, pulmonary involvement in, comparison with cryptogenic fibrosing alveolitis (P), 714
Sclerosis, tuberous, pulmonary, treated with tamoxifen and progesterone, 2 cases of, 892
Scotland, *Mycobacterium malmoense* infections in, clinical and radiological features (P), 709
SCOTT M. *See* DAVISON AG, FAYERS PM, *et al*
SCOTT W. *See* DOWNING I, SCOTT W, *et al*
——. *See* RHIND GB, PRINCE KL, *et al*
SCRAGG R. *See* REA HH, SCRAGG R, *et al*
SEAL RME, COCKCROFT A, KUNG I, WAGNER JC: Central lymph node changes and progressive massive fibrosis in coalworkers, 531
SEARS MR: Prevalence of bronchial reactivity to inhaled methacholine in New Zealand children *(Letter)*, 705
——, JONES DT, HOLDAWAY MD, HEWITT CJ, FLANNERY EM, HERBISON GP, SILVA PA: Prevalence of bronchial reactivity to inhaled methacholine in New Zealand children, 283
SEATON A, RUCKLEY VA, ADDISON J, BROWN WR: Silicosis in barium miners, 591
——. *See also* FRANCE AJ, MCLEOD DT, *et al*
SEED WA. *See* WINNING AJ, MCIVOR J, *et al*
SEGURA RM. *See* MARTINEZ-VAZQUEZ JM, RIBERA E, *et al*
SELMAN M, MONTAÑO M, RAMOS C, CHAPELA R: Concentration, biosynthesis and degradation of collagen in idiopathic pulmonary fibrosis, 355
SEMPLE SJG. *See* POZNIAK AL, SWINBURN CR, *et al*
SENDI A. *See* RASHID A, SENDI A, *et al*
Sepsis, bronchial, chronic, cilioinhibitory factors in sputum in (P), 253
SERGYSELS R. *See* MICHEL O, SERGYSELS R
SERRA J, SOULEN R, MOORE R, MCNICHOLAS K: Interrupted aortic arch associated with Pourfour du Petit syndrome, 217
SERRAT R. *See* MARTINEZ-VAZQUEZ JM, RIBERA E, *et al*
Serum acute phase proteins in purulent bronchiectasis (P), 254
angiotensin converting enzyme activity and changed alveolar-

capillary permeability in sarcoidosis, relationship between, 629
angiotensin converting enzyme measurements, serial lavage lymphocyte counts, and gallium-67 scans for monitoring of corticosteroid treatment in pulmonary sarcoidosis, evaluation of, 903
theophylline concentration, measurement on admission before intravenous aminophylline, essential? (P), 248
theophylline concentration on admission, knowledge of, effect on calculated dose of intravenous aminophylline in patients already taking oral theophylline, 759
SETHI TJ. *See* ARM JP, SETHI TJ, *et al*
SETHIA B. *See* ALLAN A, SETHIA B, *et al*
SEVER PS. *See* BARROWCLIFFE MP, MORICE AH, *et al*
——. *See* LEYS K, MORICE AH, *et al*
——. *See* MARTIN G, HUGHES A, *et al*
——. *See* WINTER RJD, RUDD RM, *et al*
SHAH D. *See* PEACH H, SHAH D, *et al*
SHALE DJ, WISEMAN MS, COOKSON WOCM: Effect of monocrotaline ingestion on the distribution of protein and angiotensin converting enzyme activity in the rat lung, 914
SHAND J, MCCREATH GT, MONIE RDH: Paracentesis of carcinomatous pleural effusions through a fine silastic catheter (P), 711
SHAPIRO CM. *See* CATTERALL JR, RHIND GB, *et al*
——. *See* MORGAN AD, CONNAUGHTON JJ, *et al*
SHAUNAK S, FRANCE AJ, ROSIE A, MCHARDY GJR, SUDLOW MF: Should serial records of peak expiratory flow be plotted on a logarithmic scale? (P), 233
SHAW D. *See* MILLER MR, SHAW D, *et al*
SHAW JC. *See* HILL SL, SHAW JC, *et al*
——. *See* STOCKLEY RA, SHAW JC, *et al*
SHAW RJ, ROWLAND-HILL CA, PARKIN J, FOSTER S, KEAL EE, PINCHING AJ: Pulmonary complications of AIDS: a review of 90 English cases (P), 730
SHEERS G. *See* WAGNER JC, POOLEY FD, *et al*
SHEINMAN BD, DEVALIA JL, CROOK SJ, DAVIES RJ: Histamine in the sputum in infective lung disease: the potential role of *Haemophilus influenzae* (P), 241
SHEN AS. *See* HASLETT C, SHEN AS, *et al*
SHERIDAN AQ. *See* MANN JS, ROBINSON C, *et al*
SHIMIZU H. *See* MATSUMIYA N, MAYUMI T, *et al*
SHNEERSON JM: Non-respiratory symptoms of acute asthma, 701
——. *See also* KINNEAR WJM, PHILLIPS MS, *et al*
——. *See also* KINNEAR WJM, SHNEERSON JM
——. *See also* LARGE SR, SHNEERSON JM, *et al*
——. *See also* MOORE NR, PHILLIPS MS, *et al*
——. *See also* PHILLIPS MS, KINNEAR WJM, *et al*
SHORT M. *See* MITCHELL DM, SOLOMON M, *et al*
SHUSTER S: Comparative trial of two non-sedative H_1 anti-histamines, terfenadine and astemizole, for hay fever *(Letters)*, 654; 976
SIBERT JR. *See* WILLIAMS H, VERRIER JONES ER, *et al*
Silicosis and rheumatoid arthritis, relationship between, in South African gold miners, 596
in barium miners, 591
SILLETT RW. *See* TURNER JA MCM, MCNICOL MW, *et al*
Silo unloading, organic dust toxic syndrome (pulmonary mycotoxicosis) associated with, 919
SILVA PA. *See* SEARS MR, JONES DT, *et al*
SILVER JR. *See* GOLDMAN JM, ROSE LS, *et al*
——. *See* GOLDMAN JM, WILLIAMS SJ, *et al*
SILVERMAN M. *See* PRENDIVILLE A, GREEN S, *et al*
——. *See* WILSON NM, CHUDRY N, *et al*
——. *See* WILSON NM, SILVERMAN M
SIMONATO L. *See* MCCONNOCHIE K, SIMONATO L, *et al*
SIMONDS AK, PARKER RA, BRANTHWAITE MA: Effects of protriptyline on sleep related disturbances of breathing in restrictive chest wall disease, 586
——, ——, ——: Intermittent positive pressure hyperinflation in restrictive chest wall disease (P), 244
SIMPSON FG, ARNOLD AG, PURVIS A, BELFIELD PW, MUERS MF, COOKE NJ: Postal survey of bronchoscopic practice by physicians in the United Kingdom, 311
——, MORGAN M, COOKE NJ: Pancoast's syndrome associated with invasive aspergillosis, 156
——, MORRISON JFJ, COOKE NJ, PEARSON SB: General practitioner referrals for static miniature chest radiography—indications and diagnostic yield (P), 717
SITGES AC, SÁNCHEZ-ORTEGA JM, SITGES AS: Late complications of reversed gastric tube oesophagoplasty, 61
SITGES AS. *See* SITGES AC, SÁNCHEZ-ORTEGA JM, *et al*
Skeletal deformity and pleural thickening in thoracoplasty, relationship with ventilatory failure (P), 717
Skin prick tests, relevance of, assessment of (P), 241
tests in bird breeder's disease, 538
SKINNER C. *See* WIGGINS J, SKINNER C
Sleep and oxygen saturation in erythrocytosis (P), 711
and wakefulness, steady state responses to hypercapnia and added deadspace in dogs during (P), 724
apnoea, obstructive, and snoring, palatopharyngoplasty in treatment of (P), 719
breathing disturbances in restrictive chest wall disease related to, effects of protriptyline, 586
breathing during, in myotonic dystrophy and non-myotonic respiratory muscle weakness (P), 710
deprivation, effect on overnight bronchoconstriction in nocturnal asthma, 676
quality of, and nocturnal hypoxaemia in chronic obstructive lung disease, 846
ventilation and gas exchange in interstitial lung disease during, 777
ventilation during, stimulant effect of nasal airflow (P), 243
SLUIS-CREMER GK, HESSEL PA, HNIZDO E, CHURCHILL AR: Relationship between silicosis and rheumatoid arthritis, 596
Small-cell bronchial carcinoma, operable, intensive chemotherapy plus adjuvant surgery in, phase II study (P), 230
carcinoma of lung, chemotherapy for, quality of life during (P), 719
carcinoma of lung, detection in pleural effusions with monoclonal antibodies (P), 238
carcinoma of lung, gallium scanning in (P), 229
carcinoma of lung, short duration combination chemotherapy in treatment of, 688
carcinoma of lung, survival after surgery in, 479; *(Letter)*, 896
SMITH GH. *See* YEO H, DOYLE T, *et al*
SMITH MJ, HODSON ME: Twice daily beclomethasone dipropionate administered with a concentrated aerosol inhaler: efficacy and patient compliance, 960
SMITH ML. *See* MILROY R, SMITH ML, *et al*
SMITH NJ. *See* DAVISON AG, FAYERS PM, *et al*
SMITH P. *See* LUKSZA AR, SMITH P, *et al*
SMITH RE. *See* BLAINEY AD, OLLIER S, *et al*
SMITH SR. *See* HILL SL, SHAW JC, *et al*
Smoke inhalation injury, pulmonary cellular defence and alteration of alveolar macrophage function after (P), 728
Smokers and non-smokers, distribution of carboxyhaemoglobin concentrations in, 25
and non-smokers, sarcoidosis commoner in latter?, 787
and non-smokers, young, respiratory epithelial permeability, bronchial reactivity, and small airway tests in (P), 226
attending for chest radiography, effect of "stop smoking" booklet, study of, 369
chronic airflow obstruction in, pathogenesis of, and detection of "early" lung disease (E), 81
cigarette, information about brands from, validity of, and implications for studies of effects of falling tar yields, 203
cigarette, symptomless, functional small airways defence and mucociliary clearance in, 524
emphysema in, size of distal airspaces defining, estimation by quantitative CT scan and CO transfer (P), 717
plasma nicotine concentration and white blood cell count in, 407
respiratory resistance in, frequency dependence of (P), 242
response and acclimatisation to low nicotine, low tar cigarettes, puff and inhaled smoke volume measurements (P), 726

Smoking and blood basophils *(Letter)*, 335
assessment, low cost carbon monoxide monitors in, 886
cigarette, and ethanol, contribution to pulmonary dysfunction in chronic alcoholics, 197
cigarette, effect on nasal mucociliary clearance and ciliary beat frequency, 519
cigarette, effect on prevalence of extrinsic allergic alveolitis (P), 252
cigarette, emphysema in byssinosis due to, physiological evidence, 6
cigarette, pulmonary inflammation, and lung disease, effect on carcinoembryonic antigen concentrations in serum and secretions, 17
cigarette, studies of, importance of time course of end expired carbon monoxide concentration in (P), 727
habit, influence on carbon monoxide transfer coefficient changes over 10 years in middle aged men (P), 726
histories, validation in study of occupational lung disease (P), 252
Smooth muscle, bronchial, human, *in vitro* responses to leukotriene D_4 in relation to quantity of muscle (P), 734
SMYLLIE H. *See* SUGGETT AJ, PROCTOR A, *et al*
SMYTH JF. *See* FERGUSSON RJ, ANDERSON LE, *et al*
——. *See* FERGUSSON RJ, CARMICHAEL J, *et al*
SNAPE C. *See* MORICE AH, SNAPE C, *et al*
Snoring and obstructive sleep apnoea, palatopharyngoplasty in treatment of (P), 719
SO SY. *See* LEE PK, SO SY, *et al*
Sodium excretion, 24 hour, relationship to bronchial response to inhaled histamine (P), 240
Sodium cromoglycate and salbutamol prophylaxis, effect on platelet activation during exercise induced asthma, 290
cromoglycate and verapamil, effect on leukotriene D_4 induced bronchoconstriction in asthma, 753
cromoglycate, effect on leukotriene D_4 induced bronchoconstriction in asthma (P), 246
cromoglycate in nocturnal asthma, 39
cromoglycate, inhaled, plasma pharmacokinetics of, factors affecting (P), 721
cromoglycate pretreatment and clearance of ^{99m}Tc-DTPA in "fog" induced bronchoconstriction (P), 227
SOLOMON M. *See* MITCHELL DM, SOLOMON M, *et al*
SOLOMONS K: Diffuse pulmonary mesothelioma presenting as bilateral lymphangitis *(Letter)*, 223
SØRENSEN HR, LUND C, ALSTRUP P: Survival in small cell lung cancinoma after surgery, 479
SOUHAMI RH. *See* GEDDES DM, SPIRO SG, *et al*
SOUHAMI RL. *See* MOSS FM, BOBROW LG, *et al*
SOUKOP M. *See* DORWARD AJ, BANHAM SW, *et al*
SOULEN R. *See* SERRA J, SOULEN R, *et al*
SPENCER A. *See* JOHNSON CE, BELFIELD PW, *et al*
SPIRO SG. *See* EFTHIMIOU J, FLEMING J, *et al*
——. *See* FAIRFAX AJ, MCNABB WR, *et al*
——. *See* GEDDES DM, SPIRO SG , *et al*
——. *See* MITCHELL DM, SOLOMON M, *et al*
——. *See* MORGAN JM, MORGAN AD, *et al*
Spirometry, value of, quantitative assessment of, 360
SPITERI MA, COOK D, POCOCK S, CLARKE SW: The reliability of physical signs in examination of the respiratory system (P), 720
——, PAVIA D, LOPEZ-VIDRIERO MT, AGNEW JE, CLARKE SW: Is tracheobronchial clearance affected by temazepam? (P), 727
SPUR B. *See* MAHAUTHAMAN R, YOULTEN LJF, *et al*
Sputum and contamination free endobronchial samples from patients with cystic fibrosis, conformity of bacterial growth in, 641
asthmatic, Charcot-Leyden crystals and Curschmann spirals in *(Historical review)*, 503
histamine rises in infective lung disease, potential role of *H influenzae* in (P), 241
in chronic bronchial sepsis, cilioinhibitory factors in (P), 253
in Young's syndrome, viscoelastic properties of (P), 254
negative, miliary tuberculosis with, rapid diagnosis with flexible fibreoptic bronchoscope, 681
Pseudomonas aeruginosa phenazine pigments in chronic bronchial sepsis, inhibition of human ciliary beat frequency *in vitro* by (P), 729
purulent, daily production of, without bronchiectasis (P), 720
purulent, elastolytic activity in, quantitation of, more sensitive method for (P), 729
sol phase, elastase inhibitors of (α_1 proteinase inhibitor, anti-leucoprotease, and α_2 macroglobulin), variability, relationship to neutrophil elastase inhibition, and effect of corticosteroid treatment, 442
STABLEFORTH DE. *See* PACKE GE, AYRES JG, *et al*
——. *See* WIGGINS J, ARBAB OA, *et al*
STACK BHR. *See* DORWARD AJ, BANHAM SW, *et al*
STALLONES L. *See* MAY JJ, STALLONES L, *et al*
STANLEY PJ, WILSON R, GREENSTONE MA, MACWILLIAM L, COLE PJ: Effect of cigarette smoking on nasal mucociliary clearance and ciliary beat frequency, 519
Staphylococcal infection of left ventricular aneurysm, case of, 154
infection problems with transtracheal micro-catheters in oxygen therapy (P), 235
pneumonia, community acquired, in Trent region (P), 731
STARCHER BC: Elastin and the lung *(Review article)*, 577
STARKEY IR, KAPLAN DK, THORPE JAC: Staphylococcal infection of a left ventricular aneurysm, 154
Statistics and small clinical trials (E), 822
STEAD RJ, DUNCAN FR, DAVIDSON TI, HODSON ME, BATTEN JC: Use of totally implantable system for venous access in cystic fibrosis (P), 732
——, HODSON ME, BATTEN JC: Pregnancy in cystic fibrosis (P), 732
——. *See also* ASSOUFI BK, STEAD RJ, *et al*
——. *See also* PANTIN CFA, STEAD RJ, *et al*
STEIN R. *See* HERSHMAN MJ, HABIB NA, *et al*
STEINFORT C, WILSON R, SYKES DA, COLE PJ: Effect of *Streptococcus pneumoniae* on human ciliary function *in vitro* (P), 253
——. *See also* SYKES DA, WILSON R, *et al*
Sternomastoid muscle fatigue, effect of aminophylline, 122
STEVENS FM, CONNOLLY CE, MCCARTHY CF, HITCHCOCK H: Lung cavities: a complication of coeliac disease (P), 237
STEWART IC. *See* CATTERALL JR, RHIND GB, *et al*
——. *See* FRANCE AJ, STEWART IC, *et al*
STIRK PR. *See* MILBURN HJ, STIRK PR, *et al*
STOCKLEY RA, MORRISON HM, KRAMPS JA, DIJKMAN JH, BURNETT D: Elastase inhibitors of sputum sol phase: variability, relationship to neutrophil elastase inhibition, and effect of corticosteroid treatment, 442
——, SHAW JC, WHITFIELD AGW, WHITEHEAD TP, CLARKE CA, BURNETT D: Effect of cigarette smoking, pulmonary inflammation, and lung disease on concentrations of carcinoembryonic antigen in serum and secretions, 17
——. *See also* BURNETT D, CROCKER J, *et al*
——. *See also* BURNETT D, REYNOLDS JJ, *et al*
——. *See also* CURRIE DC, AFFORD SA, *et al*
——. *See also* HILL SL, MORRISON HM, *et al*
——. *See also* HILL SL, SHAW JC, *et al*
——. *See also* HILL SL, STOCKLEY RA
——. *See also* KALSHEKER NA, HODGSON I, *et al*
——. *See also* MORRISON HM, KRAMPS JA, *et al*
STOCKS J. *See* GREENOUGH A, STOCKS J, *et al*
STOKES TC. *See* HARRISON BDW, STOKES TC, *et al*
STOLK J, KRAMPS JA, DIJKMAN JH: *In vitro* effect of a mucolytic thiol agent on the activity of polymorphonuclear leucocyte elastase and antileucoprotease, 840
STONE TN. *See* VEALE D, COOPER BG, *et al*
Storage mites, specific IgE to, in Essex farmworkers (P), 251
STOVIN PGI. *See* HAKIM M, STOVIN PGI, *et al*
——. *See* LARGE SR, SHNEERSON JM, *et al*
STRADLING JR: Hypercapnia during oxygen therapy in airways obstruction: a reappraisal (E), 897
——, KOZAR L, ANDREY S, PHILLIPSON EA: Steady state responses to

hypercapnia and added deadspace in awake and sleeping dogs (P), 724
STRANDVIK B. *See* GILLJAM H, MALMBORG A-S, *et al*
Streptococcus pneumoniae, effect on human ciliary function *in vitro* (P), 253
STRETTON TB. *See* LEE WR, STRETTON TB
STRICKLAND BA: Narrow section computed tomography in diffuse lung disease (P), 717
——. *See also* MILLAR AB, FROMSON B, *et al*
——. *See also* MORGAN MDL, DENISON DM, *et al*
STRUVE-CHRISTENSEN E. *See* BRANDENHOFF P, HØIER-MADSEN K , *et al*
STUART N. *See* BENFIELD G, CULLEN M, *et al*
STURRIDGE MF. *See* WILSON APR, TREASURE T, *et al*
SUDLOW MF. *See* SHAUNAK S, FRANCE AJ, *et al*
SUGGETT AJ, JARRETT JA, PROCTOR A, HOWARD P: Neuropathy in patients with COAD and in those on almitrine (P), 224
——, PROCTOR A, SMYLLIE H, PEAKE MD, CAYTON RM, HOWARD P: Which patients benefit from long term almitrine? (P), 224
——. *See also* COOPER CB, WATERHOUSE JC, *et al*
SUGIYAMA Y, MAEDA H, YOTSUMOTO H, TAKAKU F: Familial spontaneous pneumothorax, 969
SUICH DM. *See* MILLER WC, HEARD JG, *et al*
Sulphur dioxide, bronchoconstriction induced by, effect of nedocromil sodium (P), 246
SUMMER WR. *See* HERNANDEZ OG, HAPONIK EF, *et al*
SUTEDJA T, APPERLEY JF, JONES L, KENNEDY HG, HOPPER L, GOLDMAN JM, HUGHES JMB: Effect of preconditioning regimens on pulmonary function following bone marrow transplantation (P), 726
SUTHERLAND DC. *See* REA HH, SCRAGG R, *et al*
SUTTON PP, GEMMELL HG, DAVIDSON J, LAWTIE N, LEGGE JS, FRIEND JAR: An assessment of nebulised saline and terbutaline as an adjunct to chest physiotherapy (P), 235
——. *See also* PAVIA D, AGNEW JE, *et al*
SWEATMAN MC, MARKWICK JR, CHARLES PJ, JONES SE, PRIOR J, MAINI RN, TURNER-WARWICK M: Histocompatibility antigens in adult obliterative bronchiolitis (P), 237
——. *See also* WILSON R, SWEATMAN MC, *et al*
SWINBURN CR. *See* POZNIAK AL, SWINBURN CR, *et al*
SYKES DA, WILSON R, COLE PJ: Action of *Aspergillus fumigatus* on the respiratory burst of neutrophils (P), 256
——, ——, CURRIE DC, STEINFORT C, COLE PJ: Cilioinhibitory factors in the sputum of patients with chronic bronchial sepsis (P), 253
——, ——, WATSON D, TAYLOR G, MACDERMOT J, COLE PJ: *Pseudomonas aeruginosa* phenazine pigments in the sputum in chronic bronchial sepsis inhibit human ciliary beat frequency *in vitro* (P), 729
——. *See also* STEINFORT C, WILSON R, *et al*
——. *See also* WILSON R, SYKES DA, *et al*

T

T cells, cytotoxic, murine, specificity to respiratory syncytial virus (P), 730
cells, function, inhibition by bronchoalveolar lavage fluid (P), 231
TAGA K. *See* FUJIMURA M, SASAKI F, *et al*
TAKAHASHI Y. *See* FUJIMURA M, SASAKI F, *et al*
TAKAKU F. *See* SUGIYAMA Y, MAEDA H, *et al*
TALINI D. *See* PAGGIARO PL, INNOCENTI A, *et al*
TALLIS RC. *See* GAUTAM PC, COULSHED N, *et al*
Tamoxifen and progesterone, pulmonary tuberous sclerosis treated with, 2 cases of, 892
TANAKA T. *See* FUJIMURA M, SASAKI F, *et al*
TARDIF A. *See* CORMIER Y, BÉLANGER J, *et al*
TATEISHI R. *See* MATSUDA M, HORAI T, *et al*
TATTERSFIELD AE. *See* BRITTON JR, BURNEY PGJ, *et al*
——. *See* BRITTON JR, MORTAGY A, *et al*
——. *See* BURNEY PGJ, BRITTON JR, *et al*
——. *See* CROSSLEY J, BRITTON JR, *et al*
——. *See* GARRETT H, BRITTON JR, *et al*
——. *See* GARRETT H, VATHENEN S, *et al*
——. *See* HADFIELD JW, TATTERSFIELD AE
——. *See* HILL RA, TATTERSFIELD AE
TAYLOR G. *See* BARKER A, RUTMAN A, *et al*
——. *See* SYKES DA, WILSON R, *et al*
TAYLOR KJ, LUKSZA AR: Peripheral blood eosinophil counts and bronchial reactivity (P), 241
TAYLOR RG, AGNEW JE, FRANCIS RA, PAVIA D, CLARKE SW: Respiratory epithelial permeability, bronchial reactivity, and small airway tests in young smokers and non-smokers (P), 226
——, PAVIA D, AGNEW JE, LOPEZ-VIDRIERO MT, NEWMAN SP, LENNARD-JONES T, CLARKE SW: Effect of four weeks' high dose ipratropium bromide treatment on lung mucociliary clearance, 295
——, WOODMAN G, CLARKE SW: Plasma nicotine concentration and the white blood cell count in smokers, 407
——. *See also* WINTONIUK DM, WOODMAN G, *et al*
TEE RD, GORDON DJ, HAWKINS R, LACEY J, NUNN AJ, VENABLES KM: Allergy to locusts *S gregaria* and *L migratoria* (P), 251
——. *See also* GRANEEK BJ, DURHAM SR, *et al*
TEKLU B: Lung biopsy with the high speed drill in a developing country, 804
TELFER ABM. *See* WINTER JH, MCCARTNEY AC, *et al*
Temazepam, tracheobronchial clearance affected by? (P), 727
Terbutaline and saline, nebulised, as adjunct to chest physiotherapy, assessment of (P), 235
nebulised, bronchodilatation in asthma with, effect of aerosol particle size, 364
treatment by metered dose inhaler with and without conical spacer, domiciliary comparison in severe and moderately severe chronic asthma, 766
Terfenadine and astemizole as non-sedative H_1 antihistamines for hay fever, comparative trial of *(Letters)*, 654, 976
as H_1 histamine receptor antagonist for airways in asthma (P), 247
inhibitory effect on bronchoconstriction induced by adenosine monophosphate and allergen (P), 734
Tetraplegia, abdominal wall compliance measurement in patients with, 513
breathing in, effect of abdominal binders (P), 244; 940
THATCHER N. *See* CERNY T, BARNES D, *et al*
——. *See* HASLETON PS, GOMM S, *et al*
Theophylline, effects on cardiac rhythm in hypoxaemic chronic airways obstruction (P), 722
modulation of lymphocyte adrenoceptors (P), 249
oral, acute effects on trapped gas volume in chronic bronchitis (P), 722
serum concentration, measurement on admission before intravenous aminophylline, essential? (P), 248
Thiol compounds, mucolytic. *See* Mercapto-ethanesulphonate
THOMAS GO. *See* CITRON KM, THOMAS GO
THOMPSON SJ. *See* CARSWELL F, THOMPSON SJ
THOMSON NC. *See* BERKIN KE, WALKER G, *et al*
——. *See* ROBERTS JA, ELLIOT JA, *et al*
——. *See* ROBERTS JA, GIEMBYCZ MA, *et al*
——. *See* ROBERTS JA, RODGER IW, *et al*
——. *See* ROBERTS JA, THOMSON NC
THOMSON SA. *See* CROMPTON GK, GRANT IWB, *et al*
Thoracic medical centres, regional (E), 417
medical centres, regional, special functions of (BTS Subcommittee report), 496
Thoracoplasty, inspiratory muscle function after (P), 244
pleural thickening and skeletal deformity in, relationship with ventilatory failure (P), 717
pulmonary tuberculosis treated by, outcome after 30 years (P), 719
Thoractomy, lateral, use in revisional coronary artery surgery to avoid injury to patent anterior grafts, 692
pain after, role of cryoanalgesia in control of (P), 233
posterolateral, symptomatic fibrous dysplasia of right first rib excised via, case of, 575

Thorax, editing of, 5
THORPE JAC. *See* STARKEY IR, KAPLAN DK, *et al*
Thromboxane, prostaglandins and leukotriene C_4, generation by human eosinophils stimulated by calcium ionophore (A23187) and unopsonised zymosan (P), 733
Thromboxane synthetase inhibitor (OKY-046) and lipoxygenase inhibitor (AA-861), effects on bronchial responsiveness to acetylcholine in asthma, 955
Thymus, surgical pathology of, 20 years' experience, 51; *Errata*, 706
TIMBURY MC. *See* WINTER JH, MCCARTNEY AC, *et al*
Tissue inhibitor of metalloproteinases and collagenase inhibitory activity in lung secretions in chronic obstructive bronchitis, effect of corticosteroid treatment, 740
TITINCHI SJ, CLARK B, PATEL KR: Lymphocyte adrenoceptors and their modulation by theophylline (P), 249
TOBIAS J. *See* GEDDES DM, SPIRO SG, *et al*
TOLFREY S. *See* MITCHELL DM, SOLOMON M, *et al*
Toluene diisocyanate, specific bronchial reactivity to, relationship with baseline clinical findings, 279
Tomography, computed. *See* Computed tomography
using trypton 81m of regional ventilation, perfusion and ventilation-perfusion ratios in normal subjects and asthmatics, 542
TOPPING M. *See* GRANEEK BJ, DURHAM SR, *et al*
TOPPING MD. *See* BLAINEY AD, TOPPING MD, *et al*
TORRES M. *See* RODRIGUEZ E, MARTINEZ J, *et al*
Toxoplasmoma, pulmonary, presenting as obstructive pneumonia, case of, 489
Toxoplasmosis, pulmonary, acute, with alveolitis of T suppressor lymphocyte type, case of, 972
Trachea, epithelium, ciliated, ferret, effect of bacterial products (P), 729
isolated, potentiating effect of forskolin on isoprenaline in (P), 242
permeability, increased in sensitised rats after aerosol challenge (P), 736
tumour of, resuscitative Nd YAG laser photoresection before elective surgery, case of, 812
tumours of, obstructing, Nd YAG laser as first line treatment for (P), 712
Tracheobronchial and nasal clearance by similar techniques in normal subjects, comparison of, 783
clearance, affected by temazepam? (P), 727
clearance in bronchiectasis (P), 255
clearance in chronic airflow obstruction with excessive tracheobronchial secretion, effect of manual percussion, 448
clearance, reproducibility of, measured by radioaerosol technique (P), 255
mucociliary clearance in healthy subjects, effect of selective and non-selective beta blockage, 301
Tracheo-oesophageal fistula, recurrence 32 years after primary repair, case of, 76
Transbronchial needle aspiration, diagnosis and treatment of case of bronchogenic cyst using, 326
Transplantation, bone marrow, allogeneic, lung function changes after, 508
bone marrow, and lung (E), 497
bone marrow, lung function after, effect of preconditioning regimens (P), 726
heart-lung, distant organ procurement for, single flush preservation technique for (P), 713
Transplants, bone marrow, high dose total body irradiation and subsequent cytomegalovirus pneumonitis in recipients of (P), 730
Transtracheal catheter in portable oxygen therapy during exercise (P), 245
micro-catheters in oxygen therapy, staphylococcal infection problems with (P), 235
TREACHER DF, COWELL TK, BRADLEY RD: Effect of inspired oxygen concentration on effective pulmonary blood flow measured by an inert gas rebreathing method in ventilated patients (P), 725
TREASURE T. *See* WILSON APR, TREASURE T, *et al*
Tremolite, role in mesothelioma in Cyprus (P), 250
Trephine lung biopsy with high speed air drill, 38 months' experience in developing country (Ethiopia), 804
Trials, clinical, in acute severe asthma, importance of type II errors in, 824
clinical, small, limitations and alternatives (E), 822
TROTMAN DM. *See* EDWARDS JH, TROTMAN DM
Tuberculin sensitivity after neonatal BCG (P), 226
Tuberculosis, bacteriologically proved cases of, mortality in single hospital unit 1973–1984 (P), 709
miliary, sputum-negative, rapid diagnosis with flexible fibreoptic bronchoscope, 681
of nasopharynx misdiagnosed as Wegener's granulomatosis, case of, 219
pathogenicity of *Mycobacterium tuberculosis* during therapy against (P), 228
pulmonary, due to *Mycobacterium bovis*, 685
pulmonary, gallium 67 lung scans in (P), 228
pulmonary, in NHS staff (P), 708
pulmonary, treated by thoracoplasty, outcome after 30 years (P), 719
See also Mycobacterium tuberculosis
Tuberculous mediastinal lymphadenopathy, treatment of, comparison of RHZ2/RH10 and RHE2/RH10 regimens for (P), 708
pericarditis, adenosine deaminase activity in, 888
pleural effusion occurring during corticosteroid treatment of sarcoidosis, case of, 651
Tumour, granular cell, of bronchus, bronchoscopic and clinical features, with 2 cases, 927
tracheal, obstructing, Nd YAG laser as first line treatment for (P), 712
tracheal, resuscitative Nd YAG laser photoresection before elective surgery, case of, 812
xenografts, human, growing in immunodeficient mice as model for assessment of chemotherapeutic agents in bronchial carcinoma, 376
Tumours of chest wall, primary, wide surgical resection as main treatment modality in (P), 713
TURNER JA MCM, MCNICOL MW, SILLETT RW: Distribution of carboxyhaemoglobin concentrations in smokers and non-smokers, 25
TURNER MA. *See* ALLAN A, SETHIA B, *et al*
TURNER-WARWICK M: Improving the chances of successful research funding (E), 817
——, MCALLISTER W, LAWRENCE R, BRITTEN A, HASLAM PL: Corticosteroid treatment in pulmonary sarcoidosis: do serial lavage lymphyocyte counts, serum angiotensin converting enzyme measurements, and gallium-67 scans help management?, 903
——. *See also* ALTON EW, JOHNSON M, *et al*
——. *See also* ALTON EW, KWAN S, *et al*
——. *See also* BOWLER S, WOODCOCK A, *et al*
——. *See also* SWEATMAN MC, MARKWICK JR, *et al*
TWENTYMAN OP, HOLGATE ST, HOWARTH P: The effect of H_1-receptor blockade on exercise induced asthma (P), 735
TYRELL D. *See* WILSON R, RUTMAN A, *et al*

U

UBHI C, MORRIS DL: New complication associated with the Angelchik prosthesis *(Letter)*, 655
Ultrasonically nebulized distilled water ("fog"), bronchoconstriction induced by, sodium cromoglycate pretreatment and clearance of ^{99m}Tc-DTPA in (P), 227
UNGER KM. *See* MILLER WC, HEARD JG, *et al*

V

Valve prostheses, Björk-Shiley, failed, metallurgical analysis of, 142
VAN BESOUW JP. *See* NEVIN M, PEPPER JR, *et al*

VANBREDA A. *See* O'CONNOR CM, POWER C, *et al*
VAN DE PETTE J. *See* O'DOHERTY MJ, VAN DE PETTE J, *et al*
VANKER EA: Aortic aneurysm caused by schistosomiasis, 890
VARGAS E. *See* GAUTAM PC, COULSHED N, *et al*
Vasculitis, combined asthma, eosinophilic pleuropneumonia, and pericarditis, without, 2 cases of, 571
Vasoactive intestinal peptide. *See* VIP
VATHENEN S. *See* GARRETT H, VATHENEN S, *et al*
VAUGHAN DA. *See* HARRISON BDW, STOKES TC, *et al*
VEALE D, COOPER BG, GILMARTIN JJ, GRIFFITHS CG, HUDGSON P, OSSELTON JW, STONE TN, WALLS TJ, GIBSON GJ: Breathing during sleep in patients with myotonic dystrophy and non-myotonic respiratory muscle weakness (P), 710
——. *See also* GILMARTIN JJ, VEALE D, *et al*
Vena cava, superior, obstruction of, role of cervical mediastinoscopy in patients with (P), 712
VENABLES KM. *See* DAVISON AG, FAYERS PM, *et al*
——. *See* DURHAM SR, DAVIES S, *et al*
——. *See* TEE RD, GORDON DJ, *et al*
VENN GE, WILLIAMS PR, GOLDSTRAW P: Intracavity drainage of bullous emphysematous lung (P), 233
Venous access in cystic fibrosis, use of totally implantable system for (P), 732
Ventilation and gas exchange during sleep in interstitial lung disease, 777
during sleep, stimulant effect of nasal airflow (P), 243
external negative pressure, using cuirass respirators, ribcage and abdominal motion during (P), 710
jet, high frequency, in thoracic surgery, improvement in post-operative recovery with (P), 720
mechanical, in severe acute asthma, experience of (1973–85), 464
mechanical (intermittent positive pressure), in treatment of acute severe asthma, 10 years' experience (1974–83) from district general hospital, 459
perfusion and ventilation-perfusion ratios, regional, tomography using krypton 81m of, in normal subjects and asthmatics, 542
See also Oscillation
Ventilatory failure, relationship with pleural thickening and skeletal deformity in thoracoplasty (P), 717
Ventricle, left, aneurysm of, staphylococcal infection of, case of, 154
Verapamil and sodium cromoglycate, effect on leukotriene D_4 induced bronchoconstriction in asthma, 753
effect on airway responsiveness to leukotriene D_4 *in vitro* and *in vivo*, 12
effect on secondary polycythaemia (P), 225
VERHEIJEN-BREEMHAAR D. *See* WESTERMANN CJJ, OOSTVEEN ACM, *et al*
VERRIER JONES ER. *See* WILLIAMS H, VERRIER JONES ER, *et al*
VESEY C. *See* JARVIS MJ, BELCHER M, *et al*
VIDAL R. *See* MONSÓ E, VIDAL R, *et al*
VILJANEN A. *See* ANTTI-POIKA M, NORDMAN H, *et al*
VIP, infused, effect on airway function in normal subjects, 663
pulmonary clearance of, 88
receptors in human lung, autoradiographic visualisation of (P), 242

W

WAGENAAR SJ SC. *See* AUMANN JLTM, BOSCH JMM VAN DEN, *et al*
——. *See* BOSCH JMM VAN DEN, WAGENAAR SJ SC, *et al*
——. *See* WESTERMANN CJJ, OOSTVEEN ACM, *et al*
WAGNER JC, POOLEY FD: Mineral fibres and mesothelioma (E), 161
——, ——, GIBBS A, LYONS J, SHEERS G, MONCRIEFF CB: Inhalation of china stone and china clay dusts: relationship between the mineralogy of dust retained in the lungs and pathological changes, 190
——. *See also* MCCONNOCHIE K, SIMONATO L, *et al*
——. *See also* SEAL RME, COCKCROFT A, *et al*
Waldenström's macroglobulinaemia with pulmonary infiltrates, bronchoalveolar lavage in case of, 409
WALESBY RK. *See* PAYNE-JAMES JJ, WALESBY RK, *et al*
WALKER DR. *See* MITCHELL IM, SAUNDERS NR, *et al*
WALKER G. *See* BERKIN KE, WALKER G, *et al*
WALKER WS, SANG CTM: Avoidance of patent anterior grafts at revisional coronary artery surgery: use of a lateral thoracotomy approach, 692
Walking tests in chronic bronchitis, comparison of 6 and 12 minute walk distance with 100 metre walk times (P), 245
WALLIS PJW, APPS MCP, NEWLAND AC, EMPEY DW: Calf blood flow and oxygen carriage after reversal of polycythaemia secondary to hypoxic lung disease, 306
WALLS TJ. *See* VEALE D, COOPER BG, *et al*
WALLWORK J. *See* HAKIM M, STOVIN PGI, *et al*
——. *See* JONES DK, CAVAROCCHI N, *et al*
——. *See* LARGE SR, SHNEERSON JM, *et al*
WALPORT MJ. *See* ARM JP, SETHI TJ, *et al*
WALTER A. *See* WALTER S, WALTER A
WALTER S, WALTER A: Smoking and blood basophils *(Letter)*, 335
WALTERS EH. *See* KELLY CA, WARD C, *et al*
WANG KP. *See* SCHWARTZ AR, FISHMAN EK, *et al*
WARD AM. *See* ALLEN MB, WARD AM, *et al*
WARD C. *See* KELLY CA, WARD C, *et al*
WARD FG: Industrial benefits and respiratory diseases (E), 257; *Erratum*, 496
WARD MJ: Analysis of the power of asthma trials (P), 248
——: Clinical trials in acute severe asthma: are type II errors important?, 824
WARD RV. *See* BURNETT D, REYNOLDS JJ, *et al*
WARDLAW AJ, DUNNETTE S, GLEICH CJ, COLLINS JV, KAY AB: Eosinophils and mast cells in bronchoalveolar lavage in mild asthma: relationship to bronchial hyperreactivity (P), 733
WARDMAN AG. *See* KNOX AJ, WARDMAN AG, *et al*
WARREN JB. *See* PALMER JBD, CUSS FMC, *et al*
WARREN PM. *See* GOULD GA, MCLEAN A, *et al*
WARREN PW. *See* FILUK RB, WARREN PW
WARRENS AN, BARNES PJ, COLE PJ, MITCHELL DN: "Pulsed" intravenous methylprednisolone therapy for refractory sarcoidosis (P), 714
WASS J. *See* MIER A, BROPHY C, *et al*
Water, distilled, ultrasonically nebulized ("fog"), bronchoconstriction induced by, sodium cromoglycate pretreatment and clearance of ^{99m}Tc-DTPA in (P), 227
WATERHOUSE JC. *See* COOPER CB, WATERHOUSE JC, *et al*
——. *See* EVANS TW, WATERHOUSE JC, *et al*
WATHEN CG. *See* FRANCE AJ, STEWART IC, *et al*
WATKINS GL. *See* KALSHEKER NA, HODGSON I, *et al*
WATKINS J. *See* SACKS SH, HARRISON M, *et al*
WATSON A, JOYCE H, HOPPER L, PRIDE NB: Influence of smoking habit on changes in carbon monoxide transfer coefficient over ten years in middle aged men (P), 726
——. *See also* COE CI, JOYCE H, *et al*
WATSON D. *See* BENFIELD G, CULLEN M, *et al*
——. *See* SYKES DA, WILSON R, *et al*
WAUGH R. *See* HUGHES CF, WAUGH R, *et al*
WEBB JN. *See* CAPEWELL SJ, WEBB JN, *et al*
WEBBER BA. *See* HODSON ME, WEBBER BA, *et al*
——. *See* HOFMEYR JL, WEBBER BA, *et al*
WEBBER CA. *See* ORENSTEIN M, WEBBER CA, *et al*
WEDZICHA JA, COTTER FE, EMPEY DW: Effect of hypoxia on platelet size (P), 725
Wegener's granulomatosis, tuberculosis of nasopharynx misdiagnosed as, case of, 219
WEILL H, JONES RN, HUGHES J, GLINDMEYER HW: Respiratory health following acute chlorine exposure (P), 249
WEIR D. *See* BURGE PS, WIELAND GA, *et al*
WENGRAF CL. *See* REES PJ, KING M, *et al*
WESTERMANN CJJ, OOSTVEEN ACM, WAGENAAR SJ SC, HILVERING C, OVERBEEK SE, VERHEIJEN-BREEMHAAR D, CORRIN B: Pulmonary tuberous sclerosis treated with tamoxifen and progesterone, 892
——. *See also* BOSCH JMM VAN DEN, WAGENAAR SJ SC, *et al*
WHEELEY MSTG. *See* RAFFERTY P, HOLGATE ST, *et al*
Wheezy infants, airway response to salbutamol in, evidence for beta-

adrenergic responsiveness (P), 240
WHITE JP. *See* KALSHEKER NA, HODGSON I, *et al*
WHITE RJ, COUTTS I, GIBBS C, MCINTYRE C: Asthma in pregnancy (P), 707
White cell(s). *See* Leucocyte(s)
WHITEHEAD TP. *See* STOCKLEY RA, SHAW JC, *et al*
WHITFIELD AGW. *See* STOCKLEY RA, SHAW JC, *et al*
WHYTE KF. *See* BIERNACKI W, WHYTE KF, *et al*
——. *See* CATTERALL JR, RHIND GB, *et al*
WIELAND GA. *See* BURGE PS, WIELAND GA, *et al*
——. *See* GOVE RI, ROBERTSON AS, *et al*
——. *See* ROBERTSON AS, WIELAND GA, *et al*
WIGGINS J, ARBAB OA, STABLEFORTH DE, AYRES JG: Intravenous aminophylline in patients already taking oral theophylline: effect on calculated dose of knowledge of serum theophylline concentration on admission, 759
——, ——, ——, ——: Measurement of serum theophylline concentration on admission to hospital before administration of intravenous aminophylline: is it essential? (P), 248
——, SKINNER C: Bromocriptine induced pleuropulmonary fibrosis, 328
WIGHTMAN AJ. *See* FRANCE AJ, STEWART IC, *et al*
WILKINS EGL, GRIFFITHS RJ, ROBERTS C: Pulmonary tuberculosis due to *Mycobacterium bovis*, 685
WILKINSON M, LANGHORNE CA, HEATH D, BARER GR, HOWARD P: Pathology and physiology of the pulmonary circulation after long term domiciliary oxygen therapy (P), 716
WILLCOX PA, POTGIETER PD, BATEMAN ED, BENATAR SR: Rapid diagnosis of sputum negative miliary tuberculosis using the flexible fibreoptic bronchoscope, 681
WILLIAMS AJ. *See* CHURCH SE, FINN R, *et al*
——. *See* CHURCH SE, WILLIAMS AJ
WILLIAMS C. *See* NEVIN M, PEPPER JR, *et al*
WILLIAMS H, VERRIER JONES ER, SIBERT JR: Twice daily versus four times daily treatment with beclomethasone dipropionate in the control of mild childhood asthma, 602
WILLIAMS MH. *See* GOLDSTEIN DS, WILLIAMS MH
WILLIAMS PR. *See* VENN GE, WILLIAMS PR, *et al*
WILLIAMS R. *See* JENKINS PA, WILLIAMS R
WILLIAMS SJ. *See* GOLDMAN JM, ROSE LS, *et al*
——. *See* GOLDMAN JM, WILLIAMS SJ, *et al*
WILSON APR, TREASURE T, STURRIDGE MF, GRÜNEBERG RN: Antibiotic prophylaxis in cardiothoracic surgery in the United Kingdom: current practice, 396; *(Letter)*, 816
WILSON NM, CHUDRY N, SILVERMAN M: Effect of oesophageal stimulation on asthma in Asian subjects (P), 225
——, SILVERMAN M: Gastro-oesophageal reflux and childhood asthma: the acid test *(Letter)*, 160
WILSON R, PITT T, RUTMAN A, ROBERTS D, COLE PJ: A heat stable factor produced by *Haemophilus influenzae* which slows and disorganises the beating of human cilia *in vitro* (P), 253
——, RUTMAN A, HIGGINS P, NAKIB WA, TYRELL D, COLE PJ: Upper respiratory tract viral infection and mucociliary clearance (P), 255
——, SWEATMAN MC, MACKAY IS, MITCHELL DN: Adenoidal tissue as an aid to the diagnosis of sarcoidosis in childhood, 66
——, SYKES DA, CURRIE DC, COLE PJ: Beat frequency of cilia from sites of purulent infection, 453
——, ——, RUTMAN A, ZAMZE S, COLE PJ: The effect of *Haemophilus influenzae* lipopolysaccharide on human respiratory epithelium *in vitro* (P), 728
——. *See also* BARKER A, RUTMAN A, *et al*
——. *See also* STANLEY PJ, WILSON R, *et al*
——. *See also* STEINFORT C, WILSON R, *et al*
——. *See also* SYKES DA, WILSON R, *et al*
WILSON RSE. *See* ALLEN MB, PUGH E, *et al*
WINNING AJ, MCIVOR J, SEED WA, HUSAIN OAN, METAXAS N: Interpretation of negative results in fine needle aspiration of discrete pulmonary lesions, 875
WINTER JH, CARTER R, MORAN F: Bronchial reactivity following prednisolone in chronic obstructive airways disease (P), 240
——, MCCARTNEY AC, FALLON RJ, TELFER ABM, DRURY JK, REECE IJ, TIMBURY MC: Outbreak of legionnaires' disease at Glasgow Royal Infirmary: early containment by rapid diagnosis (P), 731
WINTER RJD, RUDD RM, SEVER PS, DICKINSON KEJ: The effect of isoprenaline on β-adrenoceptor number in peripheral tissue following chronic hypoxia in rats (P), 249
WINTERTON SJ. *See* OPENSHAW PJM, WINTERTON SJ
WINTONIUK DM, WOODMAN G, TAYLOR RG, CLARKE SW: Time course of end expired carbon monoxide concentration is important in studies of cigarette smoking (P), 727
WISEMAN MS. *See* SHALE DJ, WISEMAN MS, *et al*
WOOD CB. *See* HERSHMAN MJ, HABIB NA, *et al*
WOODCOCK A. *See* BOWLER S, WOODCOCK A, *et al*
WOODHEAD MA, MACFARLANE JT: Comparative clinical and laboratory features of legionella, pneumococcal and mycoplasma pneumonias (P), 228
——, ——: *Haemophilus influenzae:* a neglected cause of community acquired pneumonia in previously fit adults? (P), 228
——, ——: Legionnaires' disease: a review of 79 community acquired cases in Nottingham, 635
——, ——, MCCRACKEN JS, ROSE DH, FINCH RG: Pneumonia in the community: incidence, radiology and outcome (P), 714
——. *See also* RADVAN J, WOODHEAD MA, *et al*
WOODMAN G, NEWMAN SP, CLARKE SW: Response and acclimatisation of smokers to low nicotine, low tar cigarettes: puff and inhaled smoke volume measurements (P), 726
——. *See also* GEORGE RJD, PAVIA D, *et al*
——. *See also* TAYLOR RG, WOODMAN G, *et al*
——. *See also* WINTONIUK DM, WOODMAN G, *et al*
WOODROFFE C. *See* BENFIELD G, CULLEN M, *et al*
WORTHEN GS. *See* HASLETT C, SHEN AS, *et al*
WRIGHT PA. *See* ORMEROD LP, HARRISON JM, *et al*

Y

YAMADA H. *See* NATSUAKI M, YOSHIKAWA Y, *et al*
YEO H, DOYLE T, SAYNOR R, SMITH GH: Chalk in the prime, 148
YOSHIKAWA Y. *See* NATSUAKI M, YOSHIKAWA Y, *et al*
YOTSUMOTO H. *See* SUGIYAMA Y, MAEDA H, *et al*
YOULTEN LJF. *See* MAHAUTHAMAN R, YOULTEN LJF, *et al*
Young's syndrome, effect of "mucolytic" agents (P), 724
syndrome, sputum in, viscoelastic properties of (P), 254

Z

ZAMZE S. *See* WILSON R, SYKES DA, *et al*
ZANDWIJK N VAN, ZWIJNENBURG A, HOEFNAGEL CA, MARCUSE HR: *N*-isopropyl-*p*[^{123}I]iodoamphetamine, a new agent for lung imaging studies, 801
ZWIJNENBURG A. *See* ZANDWIJK N VAN, ZWIJNENBURG A, *et al*
Zymosan, unopsonised, and calcium ionophore (A23187), human eosinophils stimulated by, generation of prostaglandins, thromboxane and leukotriene C_4 by (P), 733
unopsonised, human neutrophils stimulated by, leukotriene B_4 generation by, interleukin-1 augmentation of (P), 733